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ABSTRACT 
Chlamydia is responsible for a wide range of diseases with enormous global 
economic and health burden. As the majority of chlamydial infections are 
asymptomatic, a vaccine has greatest potential to reduce infection and disease 
prevalence. Protective immunity against Chlamydia requires the induction of a 
mucosal immune response, ideally, at the multiple sites in the body where an 
infection can be established. Mucosal immunity is most effectively stimulated by 
targeting vaccination to the epithelium, which is best accomplished by direct vaccine 
application to mucosal surfaces rather than by injection. The efficacy of needle-free 
vaccines however is reliant on a powerful adjuvant to overcome mucosal tolerance. 
As very few adjuvants have proven able to elicit mucosal immunity without harmful 
side effects, there is a need to develop non-toxic adjuvants or safer ways to 
administered pre-existing toxic adjuvants.  
In the present study we investigated the novel non-toxic mucosal adjuvant CTA1-
DD. The immunogenicity of CTA1-DD was compared to our “gold-standard” 
mucosal adjuvant combination of cholera toxin (CT) and cytosine-phosphate-
guanosine oligodeoxynucleotide (CpG-ODN). We also utilised different needle-free 
immunisation routes, intranasal (IN), sublingual (SL) and transcutaneous (TC), to 
stimulate the induction of immunity at multiple mucosal surfaces in the body where 
Chlamydia are known to infect. Moreover, administering each adjuvant by different 
routes may also limit the toxicity of the CT/CpG adjuvant, currently restricted from 
use in humans. Mice were immunised with either adjuvant together with the 
chlamydial major outer membrane protein (MOMP) to evaluate vaccine safety and 
quantify the induction of antigen-specific mucosal immune responses. The level of 
protection against infection and disease was also assessed in vaccinated animals 
following a live genital or respiratory tract infectious challenge.  
The non-toxic CTA1-DD was found to be safe and immunogenic when delivered via 
the IN route in mice, inducing a comparable mucosal response and level of protective 
immunity against chlamydial challenge to its toxic CT/CpG counterpart administered 
by the same route. The utilisation of different routes of immunisation strongly 
influenced the distribution of antigen-specific responses to distant mucosal surfaces 
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and also abrogated the toxicity of CT/CpG. The CT/CpG-adjuvanted vaccine was 
safe when administered by the SL and TC routes and conferred partial immunity 
against infection and pathology in both challenge models. This protection was 
attributed to the induction of antigen-specific pro-inflammatory cellular responses in 
the lymph nodes regional to the site of infection and rather than in the spleen. 
Development of non-toxic adjuvants and effective ways to reduce the side effects of 
toxic adjuvants has profound implications for vaccine development, particularly 
against mucosal pathogens like Chlamydia. Interestingly, we also identified two 
contrasting vaccines in both infection models capable of preventing infection or 
pathology exclusively. This indicated that the development of pathology following 
an infection of vaccinated animals was independent of bacterial load and was instead 
the result of immunopathology, potentially driven by the adaptive immune response 
generated following immunisation. While both vaccines expressed high levels of 
interleukin (IL)-17 cytokines, the pathology protected group displayed significantly 
reduced expression of corresponding IL-17 receptors and hence an inhibition of 
signalling. This indicated that the balance of IL-17-mediated responses defines the 
degree of protection against infection and tissue damage generated following 
vaccination. This study has enabled us to better understand the immune basis of 
pathology and protection, necessary to design more effective vaccines. 
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DESCRIPTION OF SCIENTIFIC PROBLEM 
Chlamydia trachomatis is responsible for greater than 92 million new sexually 
transmitted infections (STIs) annually (WHO, 2012). In Australia, notification of C. 
trachomatis increased by 19% from 2009 to 2010, increasing to 74,000 new 
infections (ABS, 2012). Chronic chlamydial genital tract infections can lead to pelvic 
inflammatory disease (PID) and infertility in up to 40% of cases (WHO, 2007). The 
burden of caring for and treating patients with Chlamydia-related fertility 
complications costs billions of dollars each year worldwide (WHO, 2012). 
Serological evidence suggests that virtually everyone will contract a C. pneumoniae 
respiratory tract infection at one point in their lifetime (Grayston, 2000). Moreover, it 
is reported that 75% of first infections occur in early life between the ages of 5 – 14 
years (Aldous et al., 1992; Miyashita, 2006). C. pneumoniae has been associated 
with the exacerbation of cardiovascular disease (CVD), asthma, chronic obstructive 
pulmonary disease (COPD), multiple sclerosis (MS), Alzheimer’s disease and 
reactive arthritis (Kuo et al., 1993; Clementsen et al., 2002; Bachmaier and 
Penninger, 2005), the majority of which have multi-billion dollar healthcare 
expenditures and are leading causes of morbidity and mortality in most nations.  
Therefore, Chlamydia presents a significant health burden in the community and the 
rapidly increasing prevalence calls for effective and immediate intervention to 
eradicate a growing global pandemic. Confounding the matter of infection control, 
between 50 – 90% of acute Chlamydia infections are asymptomatic (Stamm and 
Holmes, 1990; Grayston, 2000) and methods of screening and treating Chlamydia 
infections have largely proven ineffective at reducing infection prevalence long-term 
(Brunham et al., 2005). Consequently, development of a vaccine is the only viable 
alternative. 
Chlamydia is a pathogen that infects through and predominantly resides in the 
mucosal epithelium. To prevent the establishment of an infection requires the 
induction and maintenance of a mucosal immune response at the anatomical portal of 
entry of the invading pathogen (Igietseme and Rank, 1991). Vaccines targeted to the 
epithelium, without the necessity for needles, elicit mucosal immunity by stimulating 
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innate cell populations preconditioned to generate immune responses at mucosal 
surfaces (Brokstad et al., 2002; Holmgren and Czerkinsky, 2005). Moreover, 
mucosal immunity can be induced at multiple sites in the body, like the genital and 
respiratory mucosa, simultaneously by utilising the correct route of immunisation. 
The mucosal epithelium is constantly bombarded with foreign material like food, 
dust and microbes. Suppression of immune responses to innocuous exogenous 
antigens is a characteristic of the epithelium and crucial to avoid unnecessary 
inflammation and tissue damage. As tolerance is the default response to mucosal 
antigen exposure, any vaccine administered to the epithelium must overcome this in 
order to elicit robust and long-lived mucosal immunity. Unfortunately, a major 
obstacle to the development of an effective vaccine for Chlamydia and other mucosal 
pathogens is the lack potent adjuvants proven to elicit good responses at mucosal 
surfaces. 
Whilst the push for research and development of new mucosal adjuvants is greater 
than ever, vaccine safety cannot be compromised. In 2001, Nasalflu® was withdrawn 
from the market due to facial paresis (Bell’s palsy) in some recipients. This was later 
found to be due to caused by an incompatibility between the enterotoxic adjuvant (a 
bacterial toxin derived from Escherichia coli, heat-labile toxin [LT]) and the nasal 
route of administration (Mutsch et al., 2004). Interestingly, the same adjuvant 
applied topically can be equally immunogenic without the inherent toxicity 
(McKenzie et al., 2007; Frech et al., 2008). This shows that utilising different routes 
of immunisation can limit the toxicity associated with certain adjuvants like LT, CT 
and CpG (Heikenwalder et al., 2004; Klinman et al., 2007; DeFrancesco, 2008; 
Lewis et al., 2009), while still harnessing their adjuvanticity. Alternatively, 
detoxification of the enterotoxins (eg. CT), by removing the toxicity while retaining 
the adjuvant properties, is a growing area of research. This is because the nasal route 
is still of particular interest for human vaccines designed to protect against mucosal 
pathogens (Kiyono and Fukuyama, 2004; Brandtzaeg, 2009). The adjuvant CTA1-
DD, a non-toxic derivation of CT, has been shown to be equally immunogenic as the 
native CT holotoxin, but devoid of the toxicity commonly associated with the 
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administration of enterotoxic adjuvants by the nasal route (Eriksson et al., 2004; 
Sundling et al., 2008). 
HYPOTHESIS 
Our hypothesis was that utilising different mucosal immunisation routes and novel 
non-toxic mucosal adjuvants will elicit simultaneous protection against Chlamydia 
genital and respiratory tract infections, without any harmful side effects.  
SIGNIFICANCE 
Eradication of infection and Chlamydia-related disease by vaccination has obvious 
economic and global health ramifications. Development of non-toxic adjuvants or 
effective ways to reduce the side effects of toxic adjuvants has profound implication 
for vaccine development, particularly against mucosal pathogens. Improving needle-
free vaccine delivery would also be most beneficial in the developing world, as it is 
safer and more cost-effective than injectable vaccines, does not require trained 
personnel, facilitates rapid immunisation of large populations and enhances the 
population compliance critical for herd immunity (Glenn et al., 2003; Giudice and 
Campbell, 2006). 
OBJECTIVE 
Immunise mice with two different vaccines (MOMP plus CTA1-DD and MOMP 
plus CT/CpG) delivered by three different needle-free routes (IN, SL and TC). 
Assess vaccine safety and the induction of mucosal responses (Chapter 4) and 
immunity against respiratory (Chapter 5) and genital tract (Chapter 6) challenges 
with C. muridarum. 
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AIMS 
1. Quantify systemic and mucosal immune responses in the genital and 
respiratory tracts following immunisation via IN, SL and TC routes with the 
MOMP plus CTA1-DD or CT/CpG (Chapter 4). 
2. Assess the level of protective immunity against a respiratory tract infection 
and associated disease following immunisation via IN, SL and TC routes with 
the MOMP plus CTA1-DD or CT/CpG (Chapter 5). 
3. Assess the level of protective immunity against a genital tract infection and 
associated disease following immunisation via IN, SL and TC routes with the 
MOMP plus CTA1-DD or CT/CpG (Chapter 6). 
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CHLAMYDIA  
Chlamydiae are Gram negative obligate intracellular pathogens with a unique 
biphasic lifecycle, characterised by two functionally and morphologically distinct 
forms, i.e. the inert infectious extracellular elementary body (EB) and the 
metabolically active non-infectious intracellular reticulate body (RB) (Moulder, 
1991). The chlamydial lifecycle begins with an initial reversible electrostatic 
attachment of the EB to the host cell, followed by a secondary irreversible receptor-
mediated binding during which the cytoskeleton is reorganised beneath the EB, 
culminating in internalisation and formation of an inclusion (Figure 2.1) (Betts et al., 
2009). Avoiding lysosomal fusion by subverting the endocytic pathway, the EB 
differentiates into the productive RB form, replicates by binary fission and de-
differentiates back into the EB form, all inside the membrane-bound inclusion. At 
this point, progenies are released by extrusion and/or cytolysis to re-infect new cells 
or host (Hybiske and Stephens, 2008). An additional viable but non-cultivatable 
state, termed an aberrant body due to their appearance, has also been identified in 
vitro. Inducers of the aberrant phenotype include antibiotic treatment, interferon 
(IFN)-γ , amino acid starvation, iron deprivation, host cell differentiation state and 
co-infection with herpes simplex virus (HSV) (Hogan et al., 2004; Wyrick, 2010). In 
vitro, aberrant bodies have been shown to lay dormant for up to 9 months  and are 
capable of reverting to back to infectious EBs after the removal of the metabolic 
stress (Hogan et al., 2004). Although this persistent phenotype has never been 
definitively proven to exist in vivo (Wyrick, 2010), it is thought to have links with 
infection re-emergence, chronic infection, and disease in humans (Richmond et al., 
1972; Hogan et al., 2004).  
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Figure 2.1: Simplified developmental cycle of Chlamydia.  
(1) A chlamydial EB attaches to the host cell surface, (2) is internalised and forms an 
intracellular inclusion. (3) The EB differentiates into the divisible RB and (4) undergoes 
numerous rounds of replication. Following binary fission, (5) RBs begin to de-
differentiate back into infectious EBs. (4b) Metabolic stress on the inclusion can induce 
a persistent phenotype characterised by the appearance of large aberrant chlamydial 
bodies. Following the alleviation of chlamydial growth stress, normal replication 
resumes. Replication is complete when infectious EB particles are released by cytolysis 
or (6) extrusion (Brunham and Rey-Ladino, 2005). 
TRANSMISSION, PREVALENCE AND ASSOCIATED DISEASES 
Chlamydia trachomatis 
C. trachomatis (serovars D – K) is transmitted from person to person through 
unprotected sexual contact and is the most common cause of bacterial STI worldwide 
(WHO, 2009). Estimates from the World Health Organisation (WHO) report that C. 
trachomatis (serovars D to L) is responsible for 92 million of the 500 million new 
STIs annually. In Australia, notifications of sexually transmitted C. trachomatis 
account for 81% of all STIs and cases have increased from 14,045 in 1999 to 74,305 
in 2010 (ABS, 2012). Prevalence of infection is 2-fold higher in adolescents (18 – 26 
years) (Fenton et al., 2001; Parish et al., 2003; Franceschi et al., 2007) and women 
are 2 – 3 times more likely than men to contract an infection (Gerbase et al., 1998). 
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The social stigma attached to STIs also plays a contributory role in the spread of 
infection. Only 25% of symptomatic patients seek medical assistance (Liu et al., 
2002), the majority of which are reluctant to notify their spouse and admit to 
continuing to have sex despite the presence of symptoms (Liu et al., 2002). C. 
trachomatis is Latin-derived from the term “to cloak”, which ironically reflects the 
silent nature of the infection. Women have the highest incidence of asymptomatic 
infection, with 70 – 90% compared to 40 – 60% in men (Stamm and Holmes, 1990). 
As a result the majority of infections continue undiagnosed and untreated. Chronic 
chlamydial infection in women can cause urethritis, cervicitis, endometritis and 
salpingitis, the long term consequences of which include PID, ectopic pregnancy and 
tubal factor infertility (Patel et al., 2008). Up to 40% of untreated infections in 
females develop PID, in which one in four cases result in infertility (WHO, 2007). 
This is thought to occur by the loss of cilia, which facilitate the movement of the 
oocyte, spermatozoa and tubular fluid, and by adhesions forming in/around the 
Fallopian tubes due to chronic inflammation (Lyons et al., 2006; Hvid et al., 2007; 
Kessler et al., 2012). Women account for 80% of the total expense of treating 
chlamydial infections (Patel et al., 2008), which cost in the order of $10 billion each 
year in the US alone (WHO, 2012). Neonates can also contract C. trachomatis as a 
result of an untreated maternal infection, with transmission occurring in 10 – 50% of 
deliveries (Smith and Taylor-Robinson, 1993). Chlamydial conjunctivitis causes up 
to 4000 infants to become blind each year and chlamydial pulmonary infections in 
early-life may contribute to the development of chronic respiratory tract diseases like 
asthma (Horvat et al., 2007; Horvat et al., 2010). The higher prevalence of infection 
and incidence of asymptomatic cases, the greater proportion of economic burden 
attributed to women and health risk to the unborn children, highlights the need for 
intervention particularly in females. 
Chlamydia pneumoniae 
Chlamydia pneumoniae is a respiratory tract pathogen transmitted from person to 
person in water droplets expelled by coughing or sneezing. Transmission is most 
common in areas of high population density, like schools, military bases and work 
places. Serological evidence suggests that 50% of people will have antibodies to C. 
pneumoniae by age 20, increasing to 80% by old age, indicating that the majority of 
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the population will contract an infection at one point in their lifetime (Grayston, 
2000). Moreover, 75% of first infections occur in early life, which highlights the 
need for early intervention to prevent infection (Aldous et al., 1992; Miyashita, 
2006). C. pneumoniae infections are primarily asymptomatic, but in 30% of cases, 
can develop into a severe respiratory tract illness like pneumonia, of which C. 
pneumoniae is the third most common cause (Kuo et al., 1995; Grayston, 2000). Re-
infections are frequent and can survive for years despite antibiotic treatment 
(Hammerschlag et al., 1992; Dean et al., 1998; Grayston, 2000). Persistent infections 
can exacerbate chronic inflammatory lung diseases like asthma and COPD 
(Clementsen et al., 2002), hypothesised to occur as a direct consequence of repeated 
unsuccessful attempts by the immune system to eradicate the infection. Factors 
contributing to a worsening disease state include the dysregulation of T helper type 2 
(Th2)-immunity, excessive scar formation and narrowing and/or obstruction of the 
airways (von Hertzen, 1998). Prolonged chlamydial infections can generate a Th2-
dominant response (Holland et al., 1993; von Hertzen, 1998). This response does not 
facilitate infection resolution, but instead, the survival and dissemination of the 
pathogen throughout the body potentially using monocytic cells as a shuttle system 
(Gaydos, 2000; Grayston, 2000; Beagley et al., 2009a). C. pneumoniae has been 
isolated from atherosclerotic plaques in coronary arteries (Kuo et al., 1993), which 
through similar inflammatory mechanisms as mentioned above, could contribute to 
CVD by hardening and narrowing of arteries (Belland et al., 2004). Self-reactive 
antibodies generated following a C. pneumoniae infection by a process of antigenic 
mimicry (Bachmaier and Penninger, 2005), have also been associated with other 
autoimmune diseases, such as Alzheimer’s disease, MS and reactive arthritis. 
Therefore, due to the asymptomatic nature of infection there is an overwhelming 
need to prevent Chlamydia infection and minimise sequelae. 
STRATEGIES FOR CONTROLLING CHLAMYDIA  
The continual burden of Chlamydia and inability to eradicate infection from the 
community lies largely in the asymptomatic nature of the infection. There are 
currently two approaches towards controlling Chlamydia, (1) mass surveillance, 
detection and antibiotic treatment or (2) the development of an effective vaccine. The 
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mass surveillance and treatment strategy works by screening an entire healthy, 
generally high risk, population to identify and treat infected persons who were 
otherwise unaware of an active infection. Antibiotic invention strategies against C. 
trachomatis have proven a cost-effective method to reduce the economic burden 
associated with PID, even in demographics with low chlamydial infection prevalence 
(Howell et al., 1998; Patel et al., 2008). In these studies, C. trachomatis infections 
are primarily diagnosed by performing the nucleic acid amplification test (NAAT) 
and treated with a single dose of 1000mg of azithromycin (Dukers-Muijrers et al., 
2012). This screening and treatment process however has numerous short-comings 
when compared to widespread vaccination. The NAAT method of infection detection 
has continual problems with specificity and reproducibility, leading to misdiagnosis 
(Hadgu and Sternberg, 2009). Furthermore, there is an increasing body of evidence 
to suggest that the standard single-dose of azithromycin is ineffective against 
eradicating an infection (Drummond et al., 2011; Dukers-Muijrers et al., 2012), as 10 
– 15% of women treated with antibiotics report a recurrent or persistent infection 
(Workowski et al., 1993). In addition to the potential emergence of antibiotic 
resistance (Sandoz and Rockey, 2010), antibiotic intervention has be suggested to 
interfere with the development of the natural herd immunity created by widespread 
infection (Su et al., 1999). Case detection and antibiotic treatment strategies 
employed in Sweden, Norway, Finland, Canada, US and Australia in the late 1980’s 
all failed to stem the rise in infection prevalence long-term (Brunham and Rekart, 
2008). Moreover, as a result of these control programs, re-infection rates actually 
increased in some countries by much as 5% per year (Brunham et al., 2005). Dubbed 
the “arrested immunity hypothesis”, it was suggested that by terminating an infection 
prematurely with antibiotics prevented the development of immunity against re-
infection, leading to an increased prevalence in the community (Brunham et al., 
1996; Bailey et al., 1999; Brunham et al., 2005). It was also recently discovered that 
the current clinical practice of testing patient samples 3 weeks following treatment 
with azithromycin, for a test-of-cure, was found to miss over 40% of unresolved 
infections (Dukers-Muijrers et al., 2012).  
It is conceivable that mass screening and treatment strategy would be equally if not 
more ineffective against the control of C. pneumoniae. C. pneumoniae infections are 
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extremely difficult to diagnose due to the low organism titres in throat and sputum 
samples (Grayston, 2000). Hence detection of C. pneumoniae is often reliant on the 
unapproved serological the microimmunofluorescence (MIF) test (Dowell et al., 
2001; Kumar and Hammerschlag, 2007), which is also unable to accurately 
differentiate between past and present infections (Villegas et al., 2010). C. 
pneumonia infection have also been reported to persist for years despite frequent and 
extended course antibiotics (Hammerschlag et al., 1992). 
Therefore, the current strategy of detection and treatment is not only ineffective at 
controlling the prevalence of infection (Brunham et al., 2005; Brunham and Rekart, 
2008), but could in fact be contributing towards the uncontrolled spread of infection 
(Hadgu and Sternberg, 2009). As a result an efficacious vaccine is recognised by 
both the WHO and Centres for Disease Control (CDC) to have the greatest potential 
to impact on infection and disease prevalence (Brunham et al., 2005; Gray et al., 
2009). 
CONTROLLING CHLAMYDIA THROUGH VACCINATION 
The ultimate goal of a chlamydial vaccine is to reduce the prevalence of disease (eg. 
infertility), to which all healthcare expenditure is linked. A chlamydial vaccine 
would ideally target both males and females for the greatest impact on infection and 
disease prevalence (Gray et al., 2009). However, there are limitations to the type of 
adaptive immune responses that can be generated in the male reproductive tract, 
which complicates the development of a vaccine that elicits protection against  
infection in both males and females. The testes are considered an “immune-
privileged” site, which means they can tolerate low levels of foreign antigen without 
eliciting an immune response (Fijak and Meinhardt, 2006). As spermatozoa mature 
during adolescences following the development of self-tolerance (Tung et al., 1971; 
Tung et al., 1981), suppression of inflammation in the testes is crucial to prevent 
autoimmunity to sperm. This is a mechanism of self-preservation to prevent 
infertility by autoimmunity. The blood-testis barrier is the primary impediment to the 
generation of auto-reactive antibodies against spermatozoa (Fijak and Meinhardt, 
2006). A pro-inflammatory cell-mediated response, required for optimal protection 
against a chlamydial infection (Morrison and Caldwell, 2002), has been shown to 
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disrupt the blood-testis barrier and lead to autoimmune orchitis and infertility 
(Matsuzaki et al., 1997; Itoh et al., 1998). Furthermore, as cell-mediated immunity 
generated following exposure to C. pneumoniae can respond to C. trachomatis 
antigens (Telyatnikova and Hill Gaston, 2006), a vaccine against a Chlamydia 
respiratory tract infection may also need to be restricted to females to prevent any 
potential cross-reaction and inflammation caused by the cell-mediated response in 
the male genital tract. Some studies suggest males should be a priority (Patterson and 
Rank, 1996) and that a chlamydial vaccine that solely induces immunoglobulin A 
(IgA) could provide partial protection against infection without causing 
autoimmunity (Hickey et al., 2004). However, the predominant focus of chlamydial 
vaccine design has been towards a female vaccine, as most of the severe sequelae 
occurs in woman (Patel et al., 2008). A positive impact on infection and disease can 
be achieved if a female vaccine meets one of the two following scenarios.  
(1) A vaccine completely prevents an infection from becoming established. Thus, 
transmission of infection cannot occur or diseases develop if the infectious 
Chlamydia are neutralised before undergoing even a single round of replication. This 
is known as “sterilising immunity”, where a vaccine elicits completely immunity to 
infection and disease following exposure, without the possibility of transmission. 
Mathematical modelling suggests a vaccine eliciting sterilising immunity against C. 
trachomatis could potentially eradicate all infection from the human population 
within a 20 year time frame (Gray et al., 2009). Only a prior infection has proven 
successful in animal models to provide complete, albeit transient, sterilising 
immunity (Barron et al., 1984; Rank et al., 1988a; Ramsey et al., 1989; Patterson 
and Rank, 1996). The protection and longevity of immunity acquired following a 
natural infection, is predominantly dependent on the recruitment and maintenance of 
T cells at the site of infection (Ramsey et al., 1989; Igietseme and Rank, 1991; Su et 
al., 1997; Igietseme et al., 2000; He et al., 2005). Therefore, a vaccine that aims to 
elicit complete and long-lived sterilising immunity against Chlamydia must retain T 
cell responses in the mucosal tissues. The recruitment of T cells into the genital tract 
is possible following vaccination (Marks et al., 2011a). The induction of lymphoid 
aggregates and long-lived tissue-resident memory T cells (TRM) in the cervico-vagina 
has also been described in mice and humans following viral and bacterial genital 
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tract infections (Kiviat et al., 1990; Mackay et al., 2012). However, a continual 
presence of activated T cells could increase the incidence of adverse pregnancy 
outcomes (Maruyama et al., 1992) and susceptibility to other more life-threatening 
STIs like human immunodeficiency virus (HIV) (Levine et al., 1998). Maintaining 
protective T cells in the genital tract is not only undesirable, but also unlikely. In the 
absence of continual cytokine and chemokine stimulation, most T cells (except TRM) 
preferentially re-circulate back into the periphery, which would alleviate sterilising 
immunity against Chlamydia (Hawkins et al., 2000). Moreover, mice have been 
shown to possess IL-10-secreting dendritic cells (DCs) in the lower genital tract that 
suppress protective T cell immunity (Marks et al., 2011b). Perhaps the greatest 
barrier against retention of T cells in the genital tract is the monthly tissue re-
modelling and anti-inflammatory hormonal fluctuations that occur in the female 
genital tract over the estrous cycle. TRM have been found lodged in the vagina and 
can persist in the skin beyond 1 year following treatment with a non-specific 
inflammatory stimulus, however it is currently unclear what effect sex hormones will 
have on their ability to populate the epithelium. Although, complete protection is 
most desirable, induction of sterilising immunity is becoming increasingly unlikely 
(Beagley et al., 2009b). No vaccine to date has been capable of inducing sterilising 
immunity and due to the nature of the pathogen and the physiology of the genital 
tract it infects; such a vaccine is unlikely to emerge in the near future. 
(2) If the induction of sterilising immunity is not possible, a vaccine that prevents the 
development of pathology by stopping the infection from ascending to the upper 
reproductive tract and reduced the chance of further sexual transmission by lowering 
the duration and/or quantity of Chlamydia shed into the genital tract may also be 
beneficial (Gray et al., 2009). Figure 2.2 illustrates the mechanism in which a non-
sterilising vaccine can enhance herd immunity and potentially eradicate infection and 
disease from the human population. The chlamydial load shed during a natural 
course of infection (red line) is far greater than the critical bacterial load required to 
infect a naive individual (black dotted line), thus the infection is transmitted to the 
next susceptible host. A vaccine can raise the infectious threshold (green dotted line) 
to a level near the maximum chlamydial load shed during a natural course of 
infection (red line), which reduces the duration a vaccinated individual is susceptible 
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to contracting an infection. Vaccination can also reduce the chlamydial load shed 
over the course of an infection (green line), again minimising the duration that a 
susceptible host can be infected (black dotted line). Transmission can be prevented 
entirely between two vaccinated individuals, as the lowered chlamydial load shed 
(green line) does not surpass the elevated threshold (green dotted line) necessary for 
infection transmission. Therefore, implementing a vaccine conveying even partial 
protection i.e. increasing infectious threshold, reducing pathology and chlamydial 
shedding could also have a positive effect on Chlamydia-associated sequelae (Gray 
et al., 2009). 
Figure 2.2: Mechanisms of herd immunity induced by non-sterilising vaccines. 
The solid lines represent the chlamydial load shed during an active infection (vaccinated 
and unvaccinated), while the dotted lines signify the chlamydial load required to 
establish an infection in a new host (vaccinated and unvaccinated) (Gray et al., 2009). If 
the infection threshold is raised following vaccination (green dotted line), the vaccinee is 
susceptible to contracting an infection, but only from an unvaccinated person at the peak 
of their bacterial shedding (red solid line). If the peak of chlamydial load can be reduced 
following vaccination (green solid line), an unvaccinated person is susceptible to 
contract an infection, but only from the infected vaccinee at the peak of their bacterial 
shedding (black dotted line). However, between two vaccinees, the peak of chlamydial 
load shed at the peak of their infection does not meet the minimum infectious threshold 
for transmission to occur. 
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HUMAN IMMUNE RESPONSE TOWARDS CHLAMYDIA 
To design an effective human vaccine against Chlamydia, it is important to 
understand human infection kinetics. This means identifying the immune mediators 
influencing infection resolution and development of pathology. Unfortunately, 
ethical considerations are the major challenge impeding the study of untreated 
chlamydial infections in humans, as once an infection is detected it must be treated 
promptly with antibiotics. However, an intimate knowledge of human infection will 
help develop more accurate animal models, more capable of predicting a vaccines 
potential to prevent infection transmission and reduce disease in a human population. 
C. trachomatis 
Factors involved in the resolution of a human infection and development of 
pathology are still largely unknown. Women with a prior history of chlamydial 
infection(s) generally resolve an infection faster than those without a previous 
infection (Geisler et al., 2008), indicating the presence of partial immunity after 
repeat infections. Despite both T and B cells being recruited to the lower genital tract 
following infection (Mittal et al., 2004; Ficarra et al., 2008), the cell-mediated 
response appears more important than antibodies in the context of a human genital 
tract infection. Polymorphisms in antigen-presenting molecules, human leukocyte 
antigen (HLA) class I and II, were associated with higher incidences of chlamydial 
infections (Geisler et al., 2004), suggesting that T cell priming is important in human 
to prevent and resolve infections. HIV-positive patients, with a reduction in cluster of 
differentiation (CD) 4
+
 T cells, were also determined to be at a greater risk of 
developing PID (Kimani et al., 1996), indicating a role for CD4
+
 T cells in 
preventing infection ascension and pathology in humans. Levels of IFNγ were also 
greater in cervical/vaginal secretions of women and non-human primates with 
recurrent infection (Van Voorhis et al., 1997a; Agrawal et al., 2007), which 
demonstrates that T helper type 1 (Th1) cytokines increase upon repeated infections 
and are associated with increased immunity and reduced disease (Debattista et al., 
2002; Kinnunen et al., 2002). Systemic and mucosal antibodies (IgA and IgG) can be 
detected following a natural infection in women (Mittal et al., 1996; Pate et al., 
2001; Ghaem-Maghami et al., 2003; Agrawal et al., 2007), although there is no 
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association between IgG levels and protective immunity in non-human primates 
(Wolner-Hanssen et al., 1991). There is however some negative association between 
serum antibody levels and severity of disease following C. trachomatis infections in 
humans (El Hakim et al., 2010), particular against chlamydial antigens which mimic 
certain human proteins like heat-shock protein (HSP) 60 (Bachmaier and Penninger, 
2005). Acute inflammation, characterised by an influx of polymorphonuclear 
leukocytes (PMN), occurs in humans and non-human primates following infection 
(Ripa et al., 1979; Kiviat et al., 1990; Molestina et al., 1999; Geisler et al., 2005; 
Ficarra et al., 2008; Patel et al., 2010) and has strong associations the development 
of disease (Wiesenfeld et al., 2002; Patel et al., 2010). Cervical cells isolated from 
Chlamydia-positive fertile and infertile women secreted IFNγ and IL-12 or IL-1β, 
IL-4, IL-6, IL-8 and IL-10 when stimulated with C. trachomatis, respectively 
(Agrawal et al., 2009). This suggests innate- (IL-1β, IL-6 and IL-8) and Th2-related 
(IL-4 and IL-10) cytokines contribute towards disease in humans following infection, 
while type-1 cytokines (IFNγ and IL-12) mediate the resolution of an active genital 
tract infection.  
C. pneumoniae 
The immunological information regarding C. pneumoniae infections in humans is 
predominantly based on serological analysis due to the invasiveness of lung sample 
collection methods. Despite the limited amount the human data available, the main 
factors implicated in mediating immunity appear similar between the two chlamydial 
species. The incidence of C. pneumoniae infections in HIV-positive patients is 
inversely proportion to CD4
+
 T cell counts (Tositti et al., 2005). Increased levels of 
IFNγ-secreting CD4+ T cells can be detected in peripheral blood mononuclear cells 
(PBMCs) following a C. pneumoniae infection in humans, which also coincided with 
the infection resolution (Halme et al., 2000; Bunk et al., 2010). Antibodies to 
antigens like HSP60 also appear to have a negative association with severity of 
disease following C. pneumoniae infections in humans (Molestina et al., 2002; 
Hoshida et al., 2005; Mukhopadhyay et al., 2006).  
Overall, protection against infection and disease following a Chlamydia infection in 
humans requires a dominant cell-mediated response. Chlamydia infection research in 
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humans has obvious technical and ethical limitations (Geisler, 2010), thus progress 
towards a human chlamydial vaccine is largely reliant on animal models. 
THE MOUSE AS A MODEL OF CHLAMYDIAL INFECTION  
An animal model with the capacity to mimic the disease process elicited by 
Chlamydia, as it occurs naturally in the human host, not only provides important 
information on host/pathogen interactions but also an ethical means to test 
intervention strategies like vaccines. It is estimated that over half of highly cited 
animal research does not translate to the level of a human randomised trial due to 
inconsistencies between the model and humans (Ioannidis, 2005; Hackam and 
Redelmeier, 2006). Therefore, utilising an animal model that accurately reflects the 
many important aspects of human infection and disease is vital for the successful 
development of a vaccine for humans. Non-human primates (Van Voorhis et al., 
1997b), pigs (Schautteet and Vanrompay, 2011) and guinea pigs (Rank et al., 2003) 
are the most desirable models for chlamydial infection research, as these best 
replicate human anatomy/physiology, infection, immunity and disease. These models 
however have numerous practical disadvantages that have restricted their widespread 
use. In contrast, mice have the benefits of size and ease of handling, relatively small 
financial cost and a plentiful supply of mouse immune reagents. Most importantly, 
mice also accurately represent most aspects of acute infections in humans (Morrison 
and Caldwell, 2002), making the mouse the experimental model of choice.  
Host-specific tropisms 
Two murine infection models using a variety of mouse backgrounds are in use today, 
one utilising either human pathogen C. trachomatis or C. pneumoniae the other the 
mouse-adapted pathogen C. muridarum. Each chlamydial species displays distinct 
host-specific tropisms, which have co-evolved to support optimal bacterial growth 
within a specific tissue of a certain host. Human Chlamydia species (C. trachomatis 
or C. pneumoniae) share more host-specific tropisms in common than non-human 
chlamydial species (C. muridarum or C. caviae) (Mital and Hackstadt, 2011). 
Divergence does however exist between human pathogens, particularly in regards to 
tissue-specificity (Moelleken and Hegemann, 2008). Tropisms are immensely 
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important to consider when choosing an animal model as these can include critical 
bacterial compensatory responses to their respective host’s immune defences (Ito et 
al., 1990; Beatty et al., 1994; Caldwell et al., 2003; Nelson et al., 2005a; Shah et al., 
2005a; Coers et al., 2008; Coers et al., 2009; Ramsey et al., 2009; Mital and 
Hackstadt, 2011). For example, IFNγ stimulates numerous antimicrobial actions (e.g. 
indoleamine 2,3-dioxygenase (IDO), inducible nitric oxide synthase (iNOS), iron 
deprivation and p47 guanosine-5'-triphosphate (GTP)ases, expression of which 
differs based on both the host species (human or mouse) and tissue (epithelial, 
fibroblast, macrophage/monocyte) (Roshick et al., 2006). In human cells, the major 
protective mechanism against C. trachomatis is IDO-catalysed tryptophan 
degradation, which starves the auxotrophic chlamydial inclusion of the essential 
amino acid tryptophan (Beatty et al., 1994). The validity of this mechanism has been 
supported in vitro by using tryptophan supplementation to restore C. trachomatis and 
C. muridarum replication in IFNγ pre-treated human cell lines (Nelson et al., 2005a). 
The human-adapted C. trachomatis has evolved an immune evasion strategy within a 
highly variable genomic plasticity zone (Fehlner-Gardiner et al., 2002). The C. 
trachomatis genital tract serovars D – K encode a functional tryptophan synthase 
(trp) that enables them to utilise extracellular indole, produced by commensal 
bacteria, to support chlamydial replication by circumventing IFNγ-mediated 
protection in humans (Caldwell et al., 2003). The mouse-derived C. muridarum does 
not have the capacity to escape this protective effect, lacking vital trp genes 
(Caldwell et al., 2003), hence the murine pathogen is more susceptible to IFNγ-
induced IDO defence mechanism in human cell lines and cannot be rescued with the 
addition of indole (Nelson et al., 2005a). A similar host tropism can be seen in 
murine cells in relation to the natural human pathogen C. trachomatis. Intravaginal 
(IVag) inoculation of mice with C. trachomatis in most cases results in a mild, self-
limiting, lower reproductive tract infection, with minimal ascension to upper 
reproductive tract (Ito et al., 1990). Some studies employ direct intrabursal 
inoculation to elicit the upper reproductive tract symptoms although this does not 
simulate the natural route of infection. Overall, the failure of C. trachomatis to cause 
a significant infection in the mouse suggests the major antimicrobial action induced 
by IFNγ in mice is independent of IDO (Nelson et al., 2005a) and is more than likely 
a mechanism that C. trachomatis cannot avoid. Conversely, challenge of mice with 
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C. muridarum causes ascending infection and severe upper reproductive tract 
associated sequelae (hydrosalpinx, tubal occlusion and infertility) (Shah et al., 
2005a), similar disease spectrum to that seen following C. trachomatis genital tract 
infection in humans. This suggests that C. muridarum may also encode an IFNγ 
immune evasion strategy, which differs to C. trachomatis, but is capable of 
overcoming IFNγ-mediated protection in the mouse. IFNγ induced defence in mice is 
considerably more complicated and it is yet to be determined whether IFNγ has a 
direct inhibitory effect, as seen for C. trachomatis in human cells, or if protection is 
mediated by stimulating a particular T cell population (Cotter et al., 1997a). The 
complexity is evident in a study by Nelson et al., using IFNγ-/-, IDO-/- and iNOS-/- 
mice, which were challenged with C. trachomatis. Only the IFNγ-deficient animals 
showed more severe infection when compared to wild type (WT) animals. This 
indicates that eradication of C. trachomatis in the mouse is independent of IDO, the 
principle mechanism of protection against C. trachomatis in human cells. 
Interestingly, when the same knockout (KO) strains were challenged with C. 
muridarum, contradictory to a number of previous reports (Rank et al., 1992; Cotter 
et al., 1997b), there was no difference in infection magnitude or duration signifying 
that protection in mice against C. muridarum is independent of IFNγ, IDO and iNOS. 
It is worth noting that conflicting studies used alternate strains of C. muridarum 
(Weiss verses Nigg), previously shown to have largely different virulence 
phenotypes (Ramsey et al., 2009), which may imply that even within strains of 
Chlamydia both pathogen susceptibility and host response to IFNγ may vary 
considerably. Alternatively, there is another as yet undiscovered mechanism in the 
mouse capable of conferring protection against infection, but masked by the 
profound effects of IFNs. Looking more closely at protein expression in IFNγ-
stimulated mouse cells Nelson et al., (2005a) implicated a family of p47 immunity-
related GTPases (IRGs) in the inhibition of C. trachomatis growth in mice. The 
authors suggested that IRGs may reduce lipid trafficking to the chlamydial inclusion 
and concluded that C. muridarum may inactivate host-cell IRGs as their immune 
evasion strategy. The list of factors in mice contributing to resistance to C. 
trachomatis infection has been refined to IRG genes irgm1, irgm3 and irgb10 (Coers 
et al., 2008), and C. muridarum escape, to cytotoxins encoded in the plasticity zone 
inactivating IRG effector proteins (Nelson et al., 2005a). Recent studies have sought 
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to confirm the role of IRGs in mice during a C. trachomatis (IRG-sensitive) infection 
in vivo, by utilising irgm1/irgm3 double-deficient mice (Coers et al., 2011). 
Irgm1/irgm3
-/-
 mice initially displayed an increase in bacterial burden, but cleared an 
infection as effectively as the WT animals. Therefore, the control of an infection in 
its early stages requires the innate effector mechanisms driven by irgm1 and irgm3. 
In the absence of irgm1 and irgm3 however, a compensatory adaptive immune 
response was responsible for the normal resolution of an active infection. While there 
are many questions that still remain unanswered regarding mechanisms of IFNγ-
mediated protection, there are distinct differences in not only the human and mouse-
adapted Chlamydia but also in the respective host’s responses induced by IFNγ, 
which compromise the efficacy of the current mouse models. Without the availability 
of transgenic humanised mice, replacing the IRG-mediated resistance system 
(mouse) with the IDO-mediated resistance system (humans) (Coers et al., 2009), it 
would appear rational to use the mouse with its co-evolved and natural pathogen C. 
muridarum to replicate human Chlamydia infections for vaccine trials. 
Genital tract infection model 
Progesterone-primed female mice can be infected with C. muridarum via the vaginal 
vault (Ramsey et al., 2009), the natural route of a C. trachomatis infection in 
humans. An IVag infection in mice leads to the colonisation of the vagina and a 
period of shedding infectious chlamydial organisms for a period of 14 – 50 days 
(Cochrane et al., 2010). Shortly after the establishment of the infection in the lower 
reproductive tract, the infection ascends to colonise the upper reproductive tract 
(cervix, uterine horns and oviducts) (Carey et al., 2009). This is followed by the 
development of hydrosalpinx, which is an accumulation of clear serous fluid in the 
oviduct (Carey et al., 2009), the mouse equivalent to the human Fallopian tubes. 
Hydrosalpinx is characteristic of the scarring associated with tubal factor infertility in 
humans and the swelling size of the oviduct is directly proportional to the severity of 
pathology and extent of the blockage (Shah et al., 2005b; Imtiaz et al., 2006) These 
blockages are thought to occur by similar mechanisms to humans (Kessler et al., 
2012), by scarring and adhesion of the oviducts and the disruption of the cilia 
function/contractile activity responsible for clearing oviduct secretions (Shibahara et 
al., 2001; Dixon et al., 2010). The major disadvantage of the mouse genital tract 
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infection model is that mice require an initial pre-treatment with progesterone to 
enhance susceptibility to an IVag infection by synchronising animals in diestrus 
(Tuffrey and Taylor-Robinson, 1981), which can alter the immunological balance of 
the mice to favour Th2 cytokine production (Kita et al., 1989; White et al., 1997). 
Respiratory tract infection model 
Mice can be infected by inhalation of C. muridarum (Ramsey et al., 2009), which is 
the natural route of a C. pneumoniae infection in humans. Animals infected 
intranasally with C. muridarum undergo a stage of dramatic weight loss known as 
cachexia. Cachexia is indicator of chronic inflammation and development of 
pneumonia, which effects energy expenditure and eating behaviour resulting in 
weight loss (van Heeckeren et al., 2000). C. muridarum infected bone marrow-
derived DC (BMDCs) can also polarise naive CD4
+
 T cells during antigen 
presentation to adopt a Th2 phenotype and produce IL-4, IL-5 and IL-13 (Kaiko et 
al., 2008). This may enhance IgE and mucus production, eosinophil infiltration and 
mediate the thickening and fibrotic scarring of the airways associated with COPD, 
allergic sensitisation and exacerbation of asthma (Horvat et al., 2007; Kaiko et al., 
2008; Horvat et al., 2010). Similar to C. pneumonia infection in humans, C. 
muridarum can also disseminate throughout the mouse following an IN infection 
(Jupelli et al., 2008). Although the specific mechanisms are still undefined in the 
mouse, BMDCs can be infected with C. muridarum in vitro and then transmit an 
infection to recipient mice following their adoptive-transfer (Rey-Ladino et al., 
2007). C. muridarum is also able to colonise and inflame cardiac tissue following IN 
infection, a contributory risk factor in the development of CVD (Fan et al., 1999). 
Autoimmune diseases in humans attributed to antigenic mimicry have also been 
reported to some extent in the mouse model. A systemic infection of mice with 
Chlamydia increased the severity of experimental allergic encephalitis (EAE) (Du et 
al., 2002), which is largely considered the animal model of MS. Intra-articular 
injection of C. muridarum into the knee joint after an initial sensitisation with 
chlamydial antigens, causes the histopathological changes associated with arthritis. 
However, the role cross-reactive antibodies play in pathogenesis in the mouse is still 
unclear (Hough and Rank, 1988; Rank et al., 1988b; Du et al., 2002). While the 
mouse model accurately replicates the many diseases associated with a C. 
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trachomatis and C. pneumoniae infection in humans, it is also important that the 
mechanisms of pathogenesis are similar to that which occurs in humans to accurately 
assess potential vaccines. 
THE MOUSE AS A MODEL OF CHLAMYDIAL PATHOGENESIS 
One significant difference between mice and humans is that infections in mice are 
self-limiting and pathology often develops after a single challenge. Contrastingly, 
humans can develop long-term chronic infections (Dean et al., 1998) and the risk of 
developing pathology increases after repeated infections (Kimani et al., 1996; Hillis 
et al., 1997; Bakken et al., 2007). Currently, two hypothesises have been proposed to 
explain the immune-mediated pathogenesis associated with chlamydial infection, the 
cellular- and immunological-paradigms (Stephens, 2003; Brunham and Rekart, 2008; 
Darville and Hiltke, 2010).  
Cellular paradigm 
The cellular-paradigm (Figure 2.3), suggests that pathogenesis is initiated and 
sustained by the pro-inflammatory cytokines/chemokines secreted by Chlamydia-
infected epithelial cells, which in an ongoing chronic infection promote cellular 
proliferation, tissue remodelling and scarring. Local production of pro-inflammatory 
cytokines have been shown to be a key initiator of direct tissue destruction, even in 
the absence of leukocytes (Hvid et al., 2007). However, these pathological effects of 
infection are also likely to be exacerbated further following the recruitment and 
infiltration of tissue-damaging innate and adaptive immune cell populations (Lee et 
al., 2010b).  
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Figure 2.3: Illustration of cellular paradigm of pathogenesis.  
(A) The epithelium and local innate populations like macrophages secrete pro-inflammatory cytokines and chemokines (including IL-1β, tumour 
necrosis factor (TNF)-α, IL-6, IL-8 and granulocyte-macrophage colony-stimulating factor (GM-CSF)) in response to an infection. This increases 
expression of adhesion molecules (intercellular adhesion molecule (ICAM)-1 and mucosal addressin cell adhesion molecule (MAdCAM)-1/vascular 
cell adhesion molecule (VCAM)-1) on the endothelium. (B) Epithelial cells together with the newly recruited neutrophils secrete matrix 
metalloproteinases (MMPs) and more pro-inflammatory cytokines, which promote extracellular matrix deposition and damage to the epithelia. (C) The 
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adaptive immune response consisting of CD4
+
, CD8
+
 and B cells are recruited and polarised towards Th1 response by IFNγ-secreting natural killer 
(NK) cells. (D) Following the resolution of infection, inflammation subsides, leaving tissue damage (Darville and Hiltke, 2010). 
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Immunological paradigm 
The immunological-paradigm (Figure 2.4) involves two aspects, a delayed-type 
hypersensitivity (DTH) reaction and/or autoimmune cross-reactivity (molecular 
mimicry) (Bachmaier and Penninger, 2005; Swanborg et al., 2006). Support for this 
paradigm comes mostly from the primate (Van Voorhis et al., 1997b) and guinea pig 
(Rank et al., 1995) models, more akin to human anatomy and physiology. It shows 
that pathology worsens upon repeat infections and associates with the exponential 
increase in the proportion of Chlamydia-specific CD4
+
 and CD8
+
 cells, compared to 
innate leukocytes, recruited to the site of infection. Whilst T cells are known to 
mediate infection resolution, they can also promote immunopathology and 
persistence of infection, leading to tissue damage (Holland et al., 1996; Van Voorhis 
et al., 1997a; Wang et al., 1999; Yang et al., 1999; Rank et al., 2000). In addition, 
auto-reactive T cells and antibodies directed toward chlamydial HSP60, which shares 
approximately 50% homology with human HSP60, could also increase upon 
recurrent infection. These also have the potential to cause severe tissue damage 
(Peeling et al., 1997), but these claims are yet to be completely substantiated (Ness et 
al., 2008).  
Despite mice and human kinetics of pathogenesis appearing to support opposing 
paradigms, both hypotheses are not mutually exclusive and studies have implicated 
the existence of either paradigms in mice and humans (Hvid et al., 2007; Lu et al., 
2011). The key point is however that chlamydial pathogenesis occurs as a result of 
the host immune response (innate or adaptive) and not the direct effect of the 
bacteria, which complicates vaccine design.  
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Figure 2.4: Illustration of immunological paradigm of pathogenesis.  
(A) Following re-infection, the epithelium and local innate populations secrete pro-inflammatory cytokines and chemokines, which increase expression 
of adhesion molecules on the endothelium. (B) The resulting influx of cells is dominated by pro-inflammatory CD4
+
 and CD8
+
 adaptive immune cells, 
which facilitate the resolution of infection by secretion of pro-inflammatory cytokines and potentially contribute towards immunopathology. (C) An 
anti-inflammatory response driven by Th2 and inducible T regulatory cells (Treg) may suppress tissue-damaging inflammation, but also promote 
persistence of any residual uncleared infection. (D) A recurrent infection or reactivation of a persistent infection may cause further tissue damage 
Legend
Epithelial cell
Epithelial cell
(infected)
Neutrophil
Macrophage
Epithelial cell
(infected-lysed)
Epithelial cell
(infection resolving)
Adhesion molecule
T regulatory cell
Th1
T helper type 1
CD8
Cytotoxic T cell
B
B cell and antibody
Endothelial cell
B cell and 
auto-active antibody
B
P
Epithelial cell
(infected-persistent)
Treg
Epithelial cell
(damaged)
TNFα
IL-8
GM-CSF
IL-1β
IL-6
ICAM-1 VCAM-1 MAdCAM-1
+
ICAM-1 VCAM-1 MAdCAM-1
CD8
Th1
Th1
Th1
Th1
CD8
Th1
IFNγ
TNFα+
B
B
Th1
Th1
Th1
CD8
Th1
P
P
Th2
Th2
Th2
Th2
IFNγ
TNFα
-
-
-
Treg
Treg
ICAM-1 VCAM-1 MAdCAM-1
CD8
Th1
Th1
Th1
Th1
CD8
Th1
IFNγ
TNFα+
B
CD8 CD8
Auto-activity against
HSP60
B
B
 28 
 
through the expansion of an even greater adaptive immune response, which may include HSP60-specific auto-reactive B and T cells that damage the 
epithelia directly. 
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THE MOUSE AS A MODEL OF PROTECTIVE IMMUNITY  
To develop an effective vaccine, it is important to understand how each aspect of the 
immune response protects against a chlamydial infection or contributes towards 
pathology. This section will discuss protective immunity in the C. muridarum model, 
in the context of both reproductive and respiratory tract infections. Reference to the 
C. trachomatis and C. pneumoniae mouse models will also be included, but only for 
key studies or when no information on C. muridarum is available. Similarities and 
differences between the mouse and human models will also be included where 
appropriate. 
The innate immune response 
The innate immune response is the first line of defence against an infection. The 
primary function of the innate response during a chlamydial infection is to control 
and contain an infection, but also recruit and activate the adaptive immune response. 
The innate response, by comparison to the adaptive response, is inefficient at 
clearing a chlamydial infection (Rank et al., 1985; Cotter et al., 1997b; Hawkins et 
al., 2002) and is commonly associated with the exacerbation of disease. 
Pattern recognition receptors (PRRs) 
The innate response is triggered following recognition of conserved microbial 
structures called pathogen-associated molecular patterns (PAMPs) or by 
nuclear/cytosolic material released during tissue injury known as damage-associated 
molecular patterns (DAMPs). Toll-like receptors (TLRs), the nucleotide-binding, 
oligomerisation domain (NOD)-like receptors (NLRs), the retinoic acid-inducible 
gene-like receptors (RLRs) and the C-type lectin receptors (CLRs) are the major 
groups of PRRs, responsible for detecting PAMPs and DAMPs. These receptors are 
expressed predominantly by innate immune effector cells, such as macrophages, 
neutrophils and DCs that are abundant in the mucosa, as well as both epithelial and 
endothelial cells (Kawai and Akira, 2005; Joyee and Yang, 2008). C. muridarum 
interacts with a number of surface (TLR2, 3 and 4) and cytosolic PRRs (TLR9 and 
Nod1) (Darville et al., 2003; Welter-Stahl et al., 2006; Joyee and Yang, 2008; 
Ouburg et al., 2009; Derbigny et al., 2010; He et al., 2011; Derbigny et al., 2012), 
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although only chlamydial lipopolysaccharide (LPS) and HSP60 have been 
definitively identified as PAMPs (Joyee and Yang, 2008). Interestingly, it is the 
subtle differences in innate cytokine responses influenced by PRR ligation between 
mouse strains that control susceptibility to infection and pathogenesis (Darville et al., 
2001; Watanabe et al., 2004; Jiang et al., 2010). The C57BL/6 strain is the most 
resistant to an infection, followed by BALB/c and C3H/HeN. Pro-inflammatory 
cytokines are secreted early on during an infection in the C57BL/6 strain, which 
coincides with the rapid eradication of a chlamydial infection. The more susceptible 
mouse strains C3H/HeN and BALB/c however, display a delayed and prolonged 
induction of pro-inflammatory cytokines, a longer course of infection and more 
severe pathology by comparison to C57BL/6 mice (Darville et al., 2001; Jiang et al., 
2010). Furthermore, the involvement of PRRs also differs considerably following 
genital and respiratory infections (Darville et al., 2003; Naiki et al., 2005; Welter-
Stahl et al., 2006; Ouburg et al., 2009; Zhang et al., 2009; Chen et al., 2010; 
Derbigny et al., 2010; He et al., 2011; Nagarajan et al., 2011; O'Connell et al., 2011; 
Derbigny et al., 2012).  
Despite their activation, Nod1, TLR4 and TLR9 have no effect on bacterial burden or 
pathology following a genital tract infection (Darville et al., 2003; Welter-Stahl et 
al., 2006; Ouburg et al., 2009). C. muridarum was found to be a strong inducer of 
tissue-damaging IFNβ by oviduct epithelial cell lines in a toll/interleukin-1 receptor 
(TIR)-domain-containing adapter-inducing interferon-β (TRIF)- and interferon 
regulatory transcription factor (IRF) 3-dependent manner (Derbigny et al., 2010; 
Derbigny et al., 2012). Therefore, TLR3 may contribute to the development of 
pathology in mice following a genital tract infection, although this is yet to be shown 
in vivo. Mice deficient in TLR2 have a comparable course of infection to WT mice, 
but have significantly reduced upper reproductive tract tissue damage (Darville et al., 
2003). Moreover, the plasmid-cured strain of C. muridarum has a decreased ability to 
activated TLR2 (O'Connell et al., 2011). Wild-type mice infected with plasmid-free 
C. muridarum display a similar course to TLR2-deficient mice infected with WT C. 
muridarum (O'Connell et al., 2011), indicating a strong pathological role for TLR2 
following a genital tract infection. The myeloid differentiation primary response gene 
(MyD) 88, downstream of all TLR’s except TLR3, is essential for nuclear factor-κ-B 
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(NFκB) signalling and transcription of pro-inflammatory cytokines. MyD88-/- mice 
exhibit delayed clearance and develop severe pathology compared to WT animals 
following a genital tract infection, which was attributed to a decreased ability to 
prime the adaptive immune response (Chen et al., 2010; Nagarajan et al., 2011). 
Contrastingly to the effects seen in the genital tract model, TLR2 inhibits severe lung 
inflammation by suppressing the same pro-inflammatory response over-expressed 
and deemed damaging during a genital tract infection (He et al., 2011). Similarly 
with the genital tract model, MyD88-deficient mice have exaggerated respiratory 
tract infection compared to WT mice (Zhang et al., 2009). These mice not only 
display a reduced level of cytokines and chemokines, but also an impaired ability to 
recruit and initiate the adaptive response. The innate response therefore mediates the 
development of pathology and generation of the adaptive immune response 
following a chlamydial infection, in a site-specific manner, by regulating host 
cytokine and chemokines secretions (Rasmussen et al., 1997; Johnson, 2004; 
Watanabe et al., 2004).  
Epithelial cells 
Infected murine cells secrete a myriad of cytokines and chemokines, including IL-1β, 
TNFα, IL-6, IL-8 and GM-CSF, in response to a C. muridarum infection (Darville et 
al., 2001; Rank et al., 2010) similar to that seen in humans (Agrawal et al., 2009). 
Although epithelial cells have the capacity to mediate a degree of self-protection 
against infection, the epithelium primary acts as a surveillance system, recruiting 
immune cells better capable of eradicating the infection. However, pro-inflammatory 
cytokines/chemokines secreted by Chlamydia-infected epithelial cells are the 
hypothesised drivers of pathology in the cellular paradigm of pathogenesis (Hogquist 
et al., 1991; Zhang and Phan, 1996; Perfettini et al., 2000; Stephens, 2003; Hvid et 
al., 2007; Darville and Hiltke, 2010). 
Neutrophils 
Neutrophils are recruited early in massive numbers in the mouse during the acute 
inflammation phase, similar to that seen in humans (Ripa et al., 1979; Kiviat et al., 
1990; Molestina et al., 1999; Geisler et al., 2005; Ficarra et al., 2008; Patel et al., 
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2010). Characterised as professional phagocytic cells, neutrophils remove microbial 
products and other cellular debris, but also mediate tissue repair and remodelling. 
Neutrophils exert killing activity predominantly by production of superoxides, 
reactive nitrogen species, proteolytic enzymes and antimicrobial peptides (Bratton 
and Henson, 2011). Neutrophils can also discharge filaments of deoxyribonucleic 
acid (DNA) and chromatin, bound with antimicrobial compounds known as 
neutrophil extracellular traps (NET), to contain the spread of infection and activate T 
cells (Tillack et al., 2012). There is no doubt that neutrophils control Chlamydia in 
the early stages of a genital tract infection, as neutrophil depletion increases 
chlamydial progenies during the preliminary rounds of replication (Barteneva et al., 
1996; Rank et al., 2011). It has been suggested however that neutrophils may also 
facilitate the spread of an infection by actively “sluffing” and rupturing the infected 
epithelium (Rank et al., 2008; Rank et al., 2011). The longevity and degree of 
neutrophil influx has long been associated with the development of upper genital 
tract pathology (Darville et al., 1997; Shah et al., 2005b). Mice deficient in the 
chemokine receptor CXCR2, which mediates acute inflammation and neutrophil 
recruitment, develop significantly lower rates of infertility compared to WT animals 
(Lee et al., 2010a). Animals infected with the plasmid-deficient strain of C. 
muridarum (CM3.1), secrete less chemotatic factors, recruit less neutrophils and 
show increased neutrophil apoptosis compared to animals infected with the WT 
strain (Frazer et al., 2011). Despite displaying a normal course of infection, CM3.1-
infected animals are relatively impervious to pathology, which further implicates the 
pathological role of neutrophils. Moreover, neutrophil degranulation products such as 
MMP9 and reactive oxygen species (ROS) have also been shown to contribute 
towards pathology (Ramsey et al., 2001a; Ramsey et al., 2005).  
Neutrophils control an infection and enhance the development of pathology 
following a genital tract challenge. However, neutrophils appear to contribute more 
to disease than infection resolution in the respiratory tract model of infection. Mouse 
strains BALB/c and C3H/HeN mice are more susceptible to infection and pathology 
following a respiratory tract infection than the resistant C57BL/6 strain. BALB/c and 
C3H/HeN mice show a greater influx of neutrophils during a respiratory tract 
infection, suggesting neutrophils are not only inefficient at controlling the infection 
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but also causally linked with severity of pathology (Bai et al., 2005; Tang et al., 
2009; Jiang et al., 2010). C. pneumoniae has been shown to infect neutrophils and 
delay apoptosis (van Zandbergen et al., 2004), which in the genital tract model has 
been associated with tissue damage (Barteneva et al., 1996). Recruitment of 
neutrophils by C. pneumoniae has also been suggested to enhance replication in 
epithelial cells (Rodriguez et al., 2005). Therefore, neutrophils play a complex yet 
predominantly pathological role during chlamydial infection in mice as they do in 
humans (Wiesenfeld et al., 2002; Patel et al., 2010). 
Macrophages 
Macrophages are also professional phagocytic cells, equipped with a similar 
antimicrobial arsenal to neutrophils, but with the additional ability to process and 
present antigens to T cells. Despite the ability to generate the adaptive immune 
response, macrophages are also significant contributors towards immunopathology in 
mice. Macrophages and neutrophils are the major sources of IL-1β, which elicits 
modest protection from a genital tract infection, but also has a strong correlation with 
tubal factor infertility in mice and humans (Hvid et al., 2007; Agrawal et al., 2009; 
Prantner et al., 2009; Nagarajan et al., 2012). Caspase-1 cleaves pro-IL-1β to the 
mature and biologically active form of IL-1β (Thornberry et al., 1992). Capase-1-/- 
mice exhibit a normal primary and secondary course of infection, but significantly 
less pathology than WT animals (Cheng et al., 2008). Activation of caspase-1 and 
secretion of active IL-1β by macrophages in vitro is stimulated through the NLRP3 
inflammasome (Abdul-Sater et al., 2010). However, depletion of NLRP3 and the 
crucial adaptor molecule apoptosis associated speck-like protein containing caspase 
recruitment domain (ASC), had no significant effect on IL-1β levels or the 
development of pathology in vivo (Nagarajan et al., 2012), indicating the redundancy 
of the inflammasome in IL-1β-induced pathology. Macrophages also express 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and iNOS, 
responsible for the generation of antimicrobial oxygen and nitrogen free radicals, 
respectively. These free radicals have contrasting roles in the development of chronic 
chlamydial disease, despite lacking any effect on infection. Reactive nitrogen species 
(RNS) prevent chronic disease by regulating ROS, which activate MMPs responsible 
for extracellular matrix remodelling and induction of tissue scarring (Ramsey et al., 
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2001b). However, RNS secretions by macrophages have also been shown to increase 
the risk of infertility by transiently disrupting the oviduct pacemaker, responsible for 
clearing oviduct secretions (Dixon et al., 2010). 
Fewer studies have looked at the role of macrophages during a lung infection. 
Alveolar macrophages have been shown to restrict the growth of C. muridarum (Qiu 
et al., 2008). IFNRA
-/-
 mice were also shown to be significantly more resistant to 
infection and develop less lung pathology, due to a greater influx and less apoptosis 
of macrophages (Qiu et al., 2008). Interestingly, caspase-1 and IL-1β are critical for 
host defence against C. pneumoniae infection and pathology, contrasting with the 
effects in the genital tract infection model (Cheng et al., 2008; Prantner et al., 2009). 
Caspase-1-deficient mice had delayed cytokine production and reduced iNOS levels 
in alveolar macrophages. Macrophages have been suggested to contribute to 
persistence and the spread of systemic C. pneumoniae in mice and humans (Beagley 
et al., 2009a). Therefore, macrophages appear to have contrasting 
protective/pathological roles in mice during chlamydial respiratory and reproductive 
tract infections, respectively. It is important to point out that this section only 
discussed “classically-activated” macrophages (M1), which secrete microbicides and 
are associated with DTH and tissue damage (Gordon, 2003). Currently there is no 
information regarding the anti-inflammatory “alternative-activated” macrophages 
(M2), which secrete arginases and facilitate tissue repair (Gordon, 2003), in the 
context of a chlamydial infection. 
Natural killer cells cells 
These cells have three main functions, cytotoxic lysis, cytokine and chemokine 
secretion, and contact-dependent co-stimulation (Peixoto deToledo et al., 2009). 
Natural killer cells are recruited following a genital tract infection, in a MyD88-
dependent manner (Nagarajan et al., 2011), recognise/lyse Chlamydia-infected cells 
and secrete large amounts of IFNγ (Williams et al., 1997; Tseng and Rank, 1998). 
This response efficiently reduces bacterial burden by polarising a pro-inflammatory 
Th1-type immune response (Tseng and Rank, 1998). The role NK cells play in 
pathogenesis however, has not yet been discussed in the context of the genital tract 
model. 
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Similarly, C. muridarum stimulates NK cells to produce IFNγ following a respiratory 
tract challenge (Williams et al., 1993; Han et al., 2008; Zhao et al., 2011). Their 
involvement in the control of infection was initially thought to be minimal (Williams 
et al., 1987), although a subsequent study has indicated that NK depletion 
exacerbates disease and infection, by significantly affecting DC maturation (Jiao et 
al., 2011). Natural killer cells also prevent the Chlamydia-induced Th2-driven 
allergic-sensitisation response commonly associated with asthma (Han et al., 2008). 
Therefore, NK cells play a predominantly protective role against chlamydial 
infection and disease. 
The adaptive immune response 
Adaptive immunity is characterised by an ability to develop and retain 
immunological memory. This is divided into the T cell-driven cell-mediated and the 
antibody-producing B cell responses. Generally, the cell-mediated responses targets 
intracellular pathogens and the humoral response drives antibody production, 
responsible for the elimination of extracellular pathogens (Guerra-Infante et al., 
1999; Mathews et al., 2001; Debattista et al., 2003). As an active chlamydial 
infection involves the presence of both the extracellular EBs and intracellular RBs, 
protection theoretically requires a balance between the antibody and cell-mediated 
responses. The importance of generating T and B cell responses against Chlamydia is 
clearly evident in severely immuno-compromised mice. Severe-combined 
immunodeficiency (SCID) and athymic nude mice, deficient in cell-mediated and 
antibody responses (except IgM), develop chronic Chlamydia infections (Rank et al., 
1985; Cotter et al., 1997b; Hawkins et al., 2002). Adoptive transfer of Chlamydia-
specific T cells clear unresolved infections in mice with compromised cell-mediated 
responses (Ramsey and Rank, 1991; Thoma-Uszynski et al., 1998) and enhance 
infection eradication in immune competent animals (Su and Caldwell, 1995; 
Morrison et al., 2000; Morrison et al., 2011). Passive immunisation with 
convalescent serum or monoclonal antibodies has also proven effective against 
preventing a re-infection and pathology (Pal et al., 1997b; Su et al., 1997; Murthy et 
al., 2004; Pal et al., 2008). Therefore, development of T cell- and B cell-driven 
adaptive immune responses following immunisation is crucial to eradicate an 
infection and prevent against re-infection, respectively (Farris and Morrison, 2011). 
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Despite some differences in the involvement of innate immune population in 
infection and pathology between infection models, there is little difference in the 
adaptive immune responses required to elicit protection against genital and 
respiratory infections. 
T lymphocytes 
T cells are defined by the expression of the T cell receptor (TCR) (αβ and γδ 
heterodimers) that recognises antigens presented on major histocompatability 
complexes (MHC). T cell receptor β-chain and not δ-chain-expressing T cells are 
required to clear an infection (Perry et al., 1997), which includes the majority of 
helper, cytotoxic and regulatory T cell types. In addition to the antigen-specific 
signal from the TCR/MHC complex, effective T cell activation requires a second 
survival signal generated through surface co-receptors. Interaction between T cell co-
stimulatory molecules (CD28, CD40L and inducible co-stimulatory molecule 
(ICOS)) and their reciprocal receptor/ligands (CD80/CD86, CD40 and inducible co-
stimulatory ligand (ICOSL)) expressed on antigen-presenting cells (APCs), 
respectively, heavily influences protection against Chlamydia (Marks et al., 2007; 
Chen et al., 2009a; Kadkhoda et al., 2010). Co-stimulatory molecules also function 
to polarise T cells into protective, non-protective or regulatory subsets (Smith et al., 
2003; Tang et al., 2003; de Jong et al., 2004).  
CD4
+
 T helper (Th) cells 
MHC class II-restricted CD4
+
 Th cells do not have a direct effector function, but 
instead “help” other immune cells to clear an infection by promoting antibody 
production, cytolytic and phagocytic activities. CD4
+
 Th cells are the most important 
mediators of immunity against Chlamydia genital and respiratory infections and the 
associated pathology (Landers et al., 1991; Ramsey and Rank, 1991; Su and 
Caldwell, 1995; Perry et al., 1997; Thoma-Uszynski et al., 1998; Morrison et al., 
2000; Smith et al., 2003; Tang et al., 2003; de Jong et al., 2004; Marks et al., 2007; 
Chen et al., 2009a; Kadkhoda et al., 2010; Morrison et al., 2011; Peng et al., 2011). 
Mice deficient in mature CD4
+ 
Th cells (MHC class II
-/-
) (Grusby et al., 1991) or 
with reduced Th activity (CD4
-/-
) (Killeen et al., 1993), either fail to resolve an 
infection or have delayed development of immunity (Morrison et al., 1995). 
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Furthermore, the recruitment and maintenance of CD4
+
 T cells at the site of infection 
coincides with infection resolution and dictates the longevity of immunity against re-
infection, respectively (Igietseme and Rank, 1991; Igietseme et al., 1999). The 
importance of CD4
+
 T cells is also apparent in human studies (Kimani et al., 1996; 
Van Voorhis et al., 1997a; Debattista et al., 2002; Kinnunen et al., 2002; Geisler et 
al., 2004; Agrawal et al., 2007; Agrawal et al., 2009).  
Naive CD4
+
 Th cells (Th0) diverge following clonal expansion into different Th 
subsets characterised by a unique signature of cytokines (O'Garra, 1998). Despite 
their plasticity, Th cell are conventionally assigned a type based on their production 
of IFNγ (Th1), IL-4 (Th2) or IL-17 (Th17) (Spellberg and Edwards, 2001; 
Harrington et al., 2006). There are many different types of Th cells, but these three 
are important for chlamydial infections.. 
T helper type 1 cells 
Identified by the production of IFNγ, CD4+ Th1 cells are the dominant protective 
subset against genital and respiratory tract infections with Chlamydia (Igietseme et 
al., 1993; Su and Caldwell, 1995; Cotter et al., 1997b; Johansson et al., 1997; Perry 
et al., 1997; Lampe et al., 1998; Igietseme et al., 1999; Lu and Zhong, 1999; Wang 
et al., 1999; Yang et al., 1999; Yang, 2001; Rothfuchs et al., 2004; Jayarapu et al., 
2009; Kadkhoda et al., 2010). The generation of Th1 cells is dependent on IL-12 
production by DCs. Adoptive transfer of Chlamydia-pulsed DCs secreting IL-12 
prior to challenge elicit a Th1-biased response and induce strong immunity against a 
chlamydial genital tract infection and pathology (Su et al., 1998). Similarly, 
intravenous transfer of IL-12p40
-/-
 DCs fail to effectively prime a Th1-dominant 
response and are unable to elicit protection against a lung infection in mice when 
compared to WT DCs (Lu and Zhong, 1999). Lymphocytes isolated from mice 
deficient in IL-10, a negative regulator of the Th1 immunity, showed a significant 
induction of IL-12 and IFNγ following re-stimulation when compared to WT 
lymphocytes. IL-10-deficient mice displayed enhanced of protective immunity 
against infection and pathology in both challenge models (Yang et al., 1999; 
Igietseme et al., 2000). Therefore, production of IL-12 by DCs is crucial for 
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eradicating the bulk of bacterial burden through the recruitment, activation and 
polarisation of IFNγ-secreting CD4+ Th1 cells (Perry et al., 1997).  
Interferon-γ is required to completely resolve and prevent systemic spread of a 
chronic chlamydial infection and the associated pathology (Rank et al., 1992; Cotter 
et al., 1997b; Perry et al., 1997; Williams et al., 1997; Wang et al., 1999; Nelson et 
al., 2005b; Jupelli et al., 2008). Similarly, IFNγR-deficient mice exhibit greater 
chlamydial burden and dissemination of infection (Johansson et al., 1997; Ito and 
Lyons, 1999; Jupelli et al., 2010). Interferon-γ can stimulate numerous host cell 
defence mechanism including IDO, iNOS and iron deprivation, although activation 
of p47 GTPases are in part responsible for mediating protection in mice (Nelson et 
al., 2005b; Coers et al., 2011). Interferon-γ is also known to have a synergistic 
relationship with a number of different cytokines, including TNFα and IL-17 (Amber 
et al., 1988; Shemer-Avni et al., 1988; Holtmann et al., 1990; Fichorova and 
Anderson, 1999; Robinson et al., 2003; Gabr et al., 2011). CD4
+
 Th1 cells secreting 
multiple cytokines (eg. IFNγ and TNFα), have proven far more effective than single 
cytokine-producing T cells in conferring protection from various mucosal pathogens 
(Darrah et al., 2007; Forbes et al., 2008), including Chlamydia (Igietseme et al., 
1993; Olsen et al., 2010; Yu et al., 2010; Yu et al., 2011; Yu et al., 2012). Although 
the mechanism by which IFNγ elicits protection in mice is still unclear (Cotter et al., 
1997b; Coers et al., 2011), the primary aim of a chlamydial vaccine is to elicit a 
robust Th1 response. 
T helper type 2 cells 
Interleukin-4-dependent CD4
+
 Th2 cells are largely considered to be non-protective 
against Chlamydia (Wang et al., 1999; Yang, 2001). T helper type 2 cytokines (IL-4, 
IL-5, IL-10, IL-13) have no influence on the clearance of an infection (Perry et al., 
1997; Williams et al., 1997; Hawkins et al., 2002) and are often associated with the 
exacerbation of pathology following a primary infection, due their suppressive effect 
on the Th1 response (Yang et al., 1996; Perry et al., 1997; Wang et al., 1999; Kaiko 
et al., 2008; Chen et al., 2010; Asquith et al., 2011). However, CD4
+
 Th2 polarised 
cells aid in the production of serum and mucosal IgA antibodies (Morrison et al., 
1995; Su and Caldwell, 1995; Morrison and Morrison, 2000; Morrison et al., 2000; 
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Hawkins et al., 2002), necessary for protection against re-infection (Pal et al., 1997b; 
Pal et al., 2008). As negative regulators of the Th1 response, Th2 may also be 
involved in regulation (Debattista et al., 2003), minimising the potential 
inflammatory damage inherent of Th1 over-expression (Buendia et al., 2002). 
Therefore, a vaccine will also need to induce a Th2 response, at least to promote the 
production of antibodies. 
T helper type 17 cells  
Activated by IL-1β, IL-6 and IL-23, IL-17-secreting CD4+ Th17 cells primarily 
recruit and activate neutrophils (Basso et al., 2009; Korn et al., 2009). The early 
MyD88-dependent induction of IL-17 is critical for protection against a respiratory 
tract challenge (Bai et al., 2009; Zhang et al., 2009), but this is most likely unrelated 
to the recruitment of neutrophils (Bai et al., 2005). Mice treated with an IL-17-
neutralising antibody display significantly greater weight loss, bacterial burden and 
pathological damage following respiratory tract infection compared to the isotype 
control treated animals (Bai et al., 2009; Zhang et al., 2009). Interleukin-17 does not 
have a direct anti-chlamydial effect in vitro, but enhances the production of other 
pro-inflammatory cytokines and chemokines responsible for recruiting other immune 
cells (Zhang et al., 2009). Interleukin-17 also modulates the induction of IL-12 by 
DCs, which is thought to enhance protection by promoting Th1 immunity (Bai et al., 
2009; Scurlock et al., 2010). However, enhanced expression of IL-17/IL-17R in the 
lung tissues has been linked with susceptibility to infection and disease in the 
respiratory tract model (Zhou et al., 2009). Attempts to elucidate the role of IL-17 
signalling in the genital tract model by KO of IL-17RA, resulted in the induction of a 
number of complex compensatory mechanisms (Scurlock et al., 2010), suggesting 
that signalling through IL-17RA is redundant for normal resolution of infection. As 
IL-17 appears to exhibit both protective and pathological properties (Yu et al., 2010; 
Lu et al., 2011) the Th17 response may need to be avoided for a chlamydial vaccine. 
T regulatory cells 
Secreting IL-10 and transforming growth factor (TGF)-β, CD4+CD25+FoxP3+ Treg 
cells are most well known for their induction of tolerance. Inducible Treg also control 
collateral tissue damage caused by a vigorous pro-inflammatory response in a 
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contact-dependent and -independent manner (Curotto de Lafaille and Lafaille, 2009; 
Jiang and Kelly, 2011). Currently, the role Treg play during a Chlamydia infection is 
unknown. However, expression of the Treg transcription factor forkhead box P3 
(FoxP3) mirrors the increase in expression of T-bet (Th1 transcription factor) in the 
genital tract following an infection (Moniz et al., 2010; Marks et al., 2011b). This 
may indicate that Treg are responsible for controlling Th1 immunity and suppression 
of tissue damage in the genital tract model. Mice deficient in ICOS, present on T 
cells, have also been implicated Treg in the control of Th1-driven immunopathology 
following a genital tract challenge (Marks et al., 2007). In the absence of ICOS, mice 
displayed enhanced Th1 immunity and infection resolution, but also exacerbated 
pathology. This coincided with an impaired development of Treg and IL-10 
expression. Although Treg also appear to play a similar role in the respiratory tract 
model, controlling Th1 responses and preventing the onset of the allergic 
sensitisation common in asthma (Crother et al., 2011; Wantia et al., 2011), it is 
unclear what role Treg could play in a chlamydial vaccine-induced response. 
CD8
+ 
cytotoxic lymphocytes (CTLs) 
The primary function of CD8
+ 
T cells is to mediate the destruction of infected cells. 
Chlamydia-specific CD8
+
 T cells can recognise and lyse infected epithelial cells in 
vitro (Lampe et al., 1998), although CTL-mediated perforin-induced cytolysis has no 
significant impact on the resolution of a genital tract infection and may in fact 
exacerbate oviduct pathology (Morrison et al., 1995; Perry et al., 1999a; Morrison et 
al., 2000; Morrison and Morrison, 2001; Murthy et al., 2011a). Similarly, CTLs also 
play a subordinate role against C. muridarum in the respiratory tract model (Magee 
et al., 1995; Williams et al., 1997). The poor protection induced by CTLs may be in 
part due to an inhibition of chlamydial antigen presentation by the infected 
epithelium, due to the elusive intracellular chlamydial vesicles and the 
immunosuppressive affect of the chlamydial protease-like activity factor (CPAF) on 
MHC molecule expression (Su and Caldwell, 1995; Zhong et al., 2000). Some 
studies have reported protection against a chlamydial infection following the transfer 
of CD8
+
 T cells, although the heightened immunity was suggested to be driven by 
the production of pro-inflammatory cytokines (IFNγ and TNFα) and not the cytolytic 
activity (Igietseme et al., 1994; Starnbach et al., 1994; Thoma-Uszynski et al., 1998; 
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Rothfuchs et al., 2004). Therefore, MHC class I-restricted CD8
+ 
CTLs exhibit both 
protective and pathological roles against Chlamydia, determined largely by specific 
cytokine secretions (Igietseme et al., 1994; Murthy et al., 2011a).  
B lymphocytes 
B cells can act as APCs, but protect primarily through the production of antibodies. 
B cell-deficient mice (µMT
-/-
 and Igh
-/-
) resolve a primary genital tract infection 
similar to WT animals, but are significantly more susceptible to rechallenge (Su et 
al., 1997; Williams et al., 1997). B cells are also crucial to prevent both a primary 
and secondary respiratory tract infection, particularly through the induction of T cell 
responses (Yang and Brunham, 1998). Immunoglobulin A and IgG neutralise 
Chlamydia in vitro (Pal et al., 1997b; Peterson et al., 1998) and increased 
Chlamydia-specific antibody titres associate directly with improved clearance and 
reduced pathology in vivo (Morrison et al., 1995; Su et al., 1997; Yang and 
Brunham, 1998; Murthy et al., 2004; Morrison and Morrison, 2005; Rodriguez et al., 
2006). Immunoglobulin A is thought to reduce infection by directly preventing 
chlamydial attachment to the host cells, as  KO of the polymeric immunoglobulin 
receptor (pIgR), responsible for receptor-mediated transport of IgA into the lumen, 
significantly increases chlamydial infectivity in vivo (Cunningham et al., 2008). The 
Chlamydia-neutralising potential of IgG was found to be independent of aggregation, 
the induction of complement or inhibition of attachment in vitro (Caldwell and Perry, 
1982). Mice deficient in antibody-binding Fc receptors show an increase in bacterial 
burden after genital tract re-infection, indicating the potential involvement of IgG-
dependent cellular cytotoxicity (ADCC), opsonisation and engulfment by 
macrophages (Moore et al., 2002). Anti-chlamydial antibodies also enhance antigen 
presentation for the induction of a Th1 response and early clearance of infection in 
an Fc-dependent manner (Moore et al., 2002). Interestingly, it has also been 
suggested that IgG may neutralise an infection intracellularly following the 
internalisation of Chlamydia and the assembly of the inclusion membrane (Caldwell 
and Perry, 1982).  
In summary, key aspects of the cell-mediated response, namely the MHC class II-
restricted CD4
+
 Th1 (Morrison et al., 1995; Penttila et al., 1998; Yang et al., 1998) 
 42 
 
and the pro-inflammatory cytokines IFNγ (Cotter et al., 1997b; Lampe et al., 1998; 
Rothfuchs et al., 2004) and IL-12 (Perry et al., 1997; Lu and Zhong, 1999) are the 
major defensive mechanisms against primary and secondary Chlamydia infections 
and the development of pathology in both mice and humans (Kimani et al., 1996; 
Van Voorhis et al., 1997a; Debattista et al., 2002; Kinnunen et al., 2002; Geisler et 
al., 2004; Agrawal et al., 2007; Agrawal et al., 2009). Antibodies, particularly 
secretory IgA, have also been directly linked with the reduction of chlamydial 
shedding, resistance against re-infection and prevention of pathology (Su et al., 
1997; Yang and Brunham, 1998; Morrison and Morrison, 2005). The contribution of 
each immune cell type to protective immunity is still widely disputed (Rank and 
Batteiger, 1989; Penttila et al., 1998; Johansson and Lycke, 2001; Morrison and 
Morrison, 2001; Morrison and Morrison, 2005; Nelson et al., 2005b). The 
overwhelming consensus is however that an efficacious vaccine, protective against 
both genital and respiratory tract challenges must generate a strong Th1 cell-
mediated response with an accessory mucosal antibody response, capable of 
preventing the establishment and transmission of infection as well as pathology 
(Beagley and Timms, 2000; Longbottom and Livingstone, 2006). 
HISTORY OF CHLAMYDIAL VACCINE DEVELOPMENT 
Whole organism vaccines 
First generation vaccines, consisting of live attenuated or inactivated whole 
organisms, form the basis of some of the most effective human vaccines (eg. 
smallpox and yellow fever). The protection against infection conferred following 
immunisation with growth attenuated Chlamydia strains in animal models has shown 
the potential benefit of a live attenuated vaccine for the human population (Rodolakis 
and Bernard, 1984; Su et al., 2000). Unfortunately, no growth attenuated strains of C. 
pneumoniae or C. trachomatis exist due to an inability to genetically manipulate 
Chlamydia, which until recently did not exist (Wang et al., 2011b). Most studies 
have instead utilised virulence attenuated (avirulent) strains of Chlamydia to assess 
the protective capabilities of an attenuated vaccine. Avirulent chlamydial strains that 
are cured of the “cryptic” plasmid have similar growth characteristics as the WT 
strain, but cause minimal disease following an infection (O'Connell et al., 2007). 
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Mice immunised with the C. muridarum plasmid-cured strain CM3.1, were partially 
protected against repeated challenges with the homologous virulent strain, but did 
not develop adverse upper reproductive tract pathology (O'Connell et al., 2007). 
Similar results were obtained with the plasmid-free human biovar C. trachomatis L2 
(25667R) against a genital infection in the mouse (Olivares-Zavaleta et al., 2010) 
and the plasmid-deficient C. trachomatis serovar A (A2497P
-
) against an ocular 
infection in non-human primates (Kari et al., 2011). However, this approach for a 
human vaccine has a number of short-comings. Attenuated vaccines using avirluent 
strains elicit a serovar-specific response and provide no immunity against subsequent 
challenges with non-homologous strains (Olivares-Zavaleta et al., 2010). Curing 
Chlamydia of the cryptic plasmid also does not always induce an avirluent phenotype 
in all chlamydial species or animal models (Frazer et al., 2012). Furthermore, 
immunisation with an attenuated vaccine could prime recipients for pathology, 
similar to how patients with a history of repeated infections are more likely to 
develop pathology (immunological paradigm) (Kimani et al., 1996; Hillis et al., 
1997; Brunham and Rey-Ladino, 2005; Bakken et al., 2007), potentially by 
generating a self-reactive adaptive response (eg. HSP60-specific).  
Whole inactivated organism vaccines against C. felis and C. abortus, which reduce 
acute disease (abortion), are commercially available for veterinary use (Longbottom 
and Livingstone, 2006). The protection elicited by these whole organism vaccines 
however, is short-lived, serovar-specific and unable to prevent colonisation, 
chlamydial shedding or the secondary sequelae associated with chronic infection 
(Longbottom and Livingstone, 2006). Moreover, immunisation with whole 
inactivated organism vaccines has been shown in some instances to exacerbate 
pathology. Early whole inactivated vaccines against trachoma, the ocular chlamydial 
infection causing blindness, enhanced DTH reaction and the severity of disease in 
some patients (Grayston et al., 1963; Dhir et al., 1967; Woolridge et al., 1967). 
These findings were later replicated in non-human primate models (Collier et al., 
1967; Wang et al., 1967; MacDonald et al., 1984), which suggested that Chlamydia 
contain both immunoprotective and immunopathological antigens. Consequently, a 
whole organism approach towards a human vaccine has largely been abandoned and 
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the predominant focus of vaccine development today has shifted towards second 
generation subunit vaccines. 
Subunit vaccines 
Subunit vaccines generally consist of microbial components, such as proteins, 
peptides, polysaccharides or DNA, as opposed to the whole intact organism. Protein-
based vaccines have consistently induced greater protection against chlamydial 
infections than any other microbial subunits (Brunham and Rey-Ladino, 2005; Farris 
and Morrison, 2011). Subunit vaccines have been trialled using chlamydial outer 
membrane proteins, type III secretion system (T3SS) effector proteins, secretory and 
inclusion membrane proteins, given individually or in combination with varying 
success (Pal et al., 2005; Li et al., 2007; Sun et al., 2009; Wang et al., 2009). The 
chlamydial MOMP is currently one of the strongest subunit vaccine candidates. The 
MOMP constitutes approximately 60% of the chlamydial outer membrane protein 
mass (Brunham and Peeling, 1994) and contributes largely to the structural integrity 
of Chlamydia. Unlike T3SS (Tarp), secretory (CPAF) and inclusion membrane 
proteins (Inc’s), the MOMP is expressed throughout all stages of the developmental 
cycle (Belland et al., 2003). Therefore, MOMP-specific immunity can recognise 
EBs, RBs and even the persistent abberant form (Hogan et al., 2004), and target 
Chlamydia for immune destruction at all stages of replication (Igietseme et al., 
2005). The MOMP also elicits protective cell-mediated and antibody responses 
(Farris et al., 2010), identical to that required to prevent and eradicate a Chlamydia 
infection. Immunisation with the MOMP has proven protective against infection and 
pathology in a number of animal models, including the mouse, guinea pig, pig, koala 
and non-human primate (Berry et al., 2004; Skelding et al., 2006; Sun et al., 2009; 
Andrew et al., 2011; Cheng et al., 2011b; Schautteet et al., 2011; Kollipara et al., 
2012; Schautteet et al., 2012). A disadvantage of MOMP-based vaccination is that it 
often generates serovar-specific immunity that is primarily directed towards four 
surface exposed highly variable domains (Ramsey et al., 2009). Some cross 
protection may exist within chlamydial serogroups (Zhang et al., 1987; Zhang et al., 
1989), although a MOMP-based chlamydial vaccine may require a polyvalent 
approach encompassing antigens isolated from the most prevalent serovars in the 
target human population (Mossman et al., 2008). Alternatively, a multi-subunit 
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vaccine may be adopted, which contains the MOMP together with antigens highly 
conserved amongst Chlamydiales. The greatest limitation of any subunit vaccine 
however is often their inability to generate long-lasting immunity following 
immunisation. Unlike whole organism vaccines that can be self-replicating and -
adjuvanting, subunit vaccines will require better adjuvants and delivery systems to 
boost immunity, if they’re to elicit greater protection than a natural infection 
(Igietseme et al., 2005). Protection against infection is also reliant on the induction of 
a mucosal response. Therefore, a vaccine must also be delivered by an appropriate 
route of immunisation, capable of eliciting a localised immune response at the 
anatomical portal of entry of the invading pathogen. 
ROUTES OF IMMUNISATION 
Vaccines are traditionally administered via systemic routes (intramuscular (IM) or 
subcutaneous (SC)) using needles. The majority of parenteral vaccines currently 
approved for use in humans prevent infections caused by invasive mucosal pathogens 
(e.g. human papillomavirus (HPV) or influenza) through the induction of neutralising 
serum antibodies (Smith et al., 2012). However, vaccines that elicit systemic 
humoral immunity alone are unable to protect against Chlamydia (Su et al., 1995; 
Cheng et al., 2011a). Systemic vaccines that induce a greater cell-mediated response 
improve protection against Chlamydia infection, although immunity still remained 
partial (Pal et al., 1997a; Pal et al., 2001). Alternatively, studies that initially primed 
animals via a mucosal route then boosted them systemically have shown far greater 
protection against Chlamydia than the parenteral vaccine alone (Ralli-Jain et al., 
2010). This is thought to be because parenteral vaccines are relatively poor inducers 
of localised mucosal responses (Muszkat et al., 2000; Holmgren and Czerkinsky, 
2005; Cong et al., 2007; Pedersen et al., 2011) that are vital for protection against 
pathogens like Chlamydia, which enter through and are predominantly confined to 
the epithelium.  
The underlying mechanisms of how mucosal immunity develops is still unclear, 
although it appears to be determined by the micro-environment of the immunisation 
site (Chang and Kweon, 2010), the phenotype of the resident APCs (Dudda et al., 
2005) and the tissue-selective polarisation of the draining lymph nodes (Campbell 
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and Butcher, 2002; Calzascia et al., 2005). For example, induction of T cell homing 
to the gastrointestinal tract is dependent on the secretion of retinoic acid by DCs 
during antigen presentation (Strober, 2008). Dendritic cells that secrete retinoic acid 
develop this phenotype in the gut by metabolising Vitamin A, which is absorbed in 
the gastrointestinal tract from food (Strober, 2008). A similar mechanism influences 
T cell homing to the skin, although this is mediated instead by DCs that have 
metabolised sunlight-derived Vitamin D (Sigmundsdottir et al., 2007). Lymph nodes 
draining the epithelium also imprint their own unique pattern of selectins (P- and L-
selectins) and integrins (α4, β1, β7, α4β7, and αEβ7) on activated lymphocytes during 
clonal expansion (Calzascia et al., 2005), which often favours homing to mucosal 
surfaces. Systemic immunisation on the other hand down-regulates mucosa-
associated homing receptors (Campbell and Butcher, 2002), essential for recruitment 
to mucosal surfaces at times of infection. Therefore, vaccines targeted to the 
epithelium elicit mucosal immunity by stimulating innate cell populations 
preconditioned to generate immune responses at mucosal surfaces (Brokstad et al., 
2002; Holmgren and Czerkinsky, 2005). 
Every epithelium displays a unique pattern of selectins and addressins that acts as an 
area code for passing lymphocytes. The homing profiles imprinted on lymphocytes 
by tissue-resident APCs following mucosal immunisation, direct activated cells back 
to the epithelium where the initial antigen interaction occurred by recognition of this 
code. Many mucosal tissues however express similar patterns of adhesion molecules 
and chemokines. Therefore, lymphocytes activated following mucosal immunisation 
are often distributed amongst a variety of mucosal effector site throughout the body, 
in addition to the location where the antigen was encountered initially (Smith et al., 
2012). This is often referred to as the common-mucosal immune system (CMIS) 
(Figure 2.5). For example, a previous respiratory tract infection with Chlamydia 
protects mice against a subsequent lung infection, but also a genital tract challenge 
(Pal et al., 1996). This distribution of protection relies on a distinct homing pattern 
imprinted on T and B cells (lymphocyte function-associated antigen (LFA)-1 and 
α4β7) and expression of their reciprocal mucosal addressins (ICAM-1, MAdCAM-1 
and VCAM-1) by epithelial and endothelial cells at both sites of infection (Kelly and 
Rank, 1997; Perry et al., 1998; Kelly et al., 2000; Kelly et al., 2001; Kelly et al., 
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2009). As the homing potential of circulating lymphocytes is dependent on the site of 
activation (Quiding-Jarbrink et al., 1995; Kantele et al., 1997; Quiding-Jarbrink et 
al., 1997), choosing a route of immunisation that targets the epithelium and favours 
immunity at the major sites of chlamydial infection would improve the utility of a 
vaccine against Chlamydia immensely. We have selected three routes of non-
invasive vaccine delivery that not only direct immunity to the desired mucosal 
compartments in a variety of ways (Quiding-Jarbrink et al., 1997; Sigmundsdottir 
and Butcher, 2008), but are also approved for human treatment in some form or 
another (Mathias and Hussain, 2009). 
 
Figure 2.5: Illustration of the CMIS. 
Mucosal [IN (red) and SL (green)] and cutaneous [TC (blue)] immunisation promote 
homing of activated lymphocytes to the inductive site and distant mucosal effector sites, 
like the respiratory, gastrointestinal and reproductive tracts. The thicker the arrow, the 
greater the potential of lymphocytes activated following immunisation to home to the 
indicated tissue. Parenteral immunisation via the IM and SC routes promotes systemic 
immunity, largely confined within the circulatory systems. Systemic immunisation can 
elicit mucosal IgG, although the source of this is from serum rather than the result of 
local production (Czerkinsky and Holmgren, 2010a; Czerkinsky and Holmgren, 2010b).  
Intranasal
Sublingual
Transcutaneous
Intramuscular &
Subcutaneous
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Transcutaneous immunisation 
Transcutaneous immunisation involves the application of a vaccine directly onto 
intact skin. This route targets professional APCs called Langerhans’ cells (LC) and 
dermal DCs that densely pack the epidermis and dermis at levels greater than 
100,000 cells/cm
2 
(Chen et al., 2009b), making the skin a highly attractive route for 
vaccine delivery. The programming and homing of protective immunity following 
TC immunisation was shown to be intrinsically linked to sunlight-induced Vitamin 
D3 by resident DCs in the skin (Sigmundsdottir et al., 2007). Skin-derived DCs that 
have metabolised Vitamin D3 promote expression of the chemokine receptor CCR10 
on naive T cells upon antigen presentation, which can recruit cells via a 
CCL27/CCL28 chemokine gradient established by the genital and lung epithelia at 
times of inflammation (Lazarus et al., 2003; Cha et al., 2011). There have been a 
number of human clinical trials of TC vaccines that have reported protection against 
enteric and respiratory pathogens (Li et al., 2011a). Some studies even found 
superior cell-mediated and mucosal antibody responses following TC vaccination 
than those elicited by more traditional administration routes like IM or SC (Etchart et 
al., 2007; Combadiere et al., 2010). Most importantly, no severe adverse reactions 
were noted in the recipients following any of the vaccine trials (Guerena-Burgueno et 
al., 2002; Glenn et al., 2003; Etchart et al., 2007; Frech et al., 2008; Hirobe et al., 
2012), which indicates that TC immunisation is protective as well as safe in humans. 
Transcutaneous immunisation has also been found to elicit mucosal responses and 
induce protection against genital and respiratory tract infections in animal models. In 
the context of a chlamydial vaccine, TC immunisation with the MOMP improved 
infection resolution in both the respiratory and reproductive challenge models 
(Gockel et al., 2000; Berry et al., 2004; Skelding et al., 2006). Animals displayed 
enhanced IFNγ-expressing cell-mediated responses in the lymph nodes draining both 
sites of infection and the presence of antibody-secreting cells in the lung and vaginal 
tissues (Berry et al., 2004; Skelding et al., 2006; Hickey et al., 2009). This indicates 
that the TC route is highly effective at promoting mucosal immunity in animal and 
human models. The greatest impediment to vaccines delivered via the TC route 
however is the poor permeability of the stratum corneum, which restricts the uptake 
of macromolecules greater than 500Da in size (Bos and Meinardi, 2000). Both 
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physical and chemical methods have however been used successfully to remove 
and/or penetrate the upper stratified layers (Warger et al., 2007). Immune responses 
induced following TC delivery can be improved further through the recruitment of 
even greater numbers of APCs with chemoattractants (Hickey et al., 2005) and by 
increasing the exposure time to vaccine constituents (Naito et al., 2007). 
Sublingual immunisation 
More commonly used for delivery of low-molecular weight drugs and allergen-
specific immunotherapy (Zhang et al., 2002; Leatherman et al., 2007), SL delivery, 
applied underneath the tongue, is a relatively new route yet to be trialled extensively 
in humans for a vaccine delivery. Immune cells of lingual tissue, recently mapped in 
detail in mice (Mascarell et al., 2009), closely resemble the type and distribution of 
APCs found in the skin (Kweon, 2011). However, the buccal mucosa is up to four 
thousand times more permeable than the skin (Sohi et al., 2009), which makes for 
easier passage of vaccines directly into the surrounding tissues and hence a more 
attractive avenue for vaccine delivery. The dissemination of protective immunity 
initiated in the SL mucosa is dependent on CCR7
+
 DCs, which prime T and B cells 
to migrate towards the chemokine CCL28, expressed by epithelial cells at numerous 
sites in the body including the reproductive and respiratory tracts (Song et al., 2009; 
Czerkinsky and Holmgren, 2010a). A clinical trial of SL immunisation using the 
polyvalent vaccine Bactek®, significantly reduced recurrent respiratory tract 
infections in patients with altered immune responses by increasing levels of antigen-
specific T cells (Alecsandru et al., 2011). This study and others have also reported 
that SL immunisation in human is well tolerated and free of any adverse reactions 
(Grosclaude et al., 2002; Agostinis et al., 2005; Olaguibel and Alvarez Puebla, 2005; 
Agostinis et al., 2008; Alecsandru et al., 2011). Sublingual immunisation has also 
had great success in a variety of animal models (Amuguni et al., 2011). Sublingual 
immunisation has been shown to elicit equivalent or superior immunity against HPV 
and influenza than systemic methods of vaccination in mice, due to a greater 
induction of local responses at the site of infection (Cuburu et al., 2009; Shim et al., 
2011). Similar to TC immunisation, SL immunisation elicits broad cell-mediated 
(CD4
+
 and CD8
+
) and mucosal antibody (IgG and IgA) responses in the reproductive 
and respiratory tract tissues of mice (Saeki et al., 2000; Cuburu et al., 2007; Song et 
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al., 2008; Cuburu et al., 2009; Song et al., 2009; Domm et al., 2011). The SL route 
has not yet been studied comprehensively in regards to a Chlamydia infection, 
despite its potential to improve mucosal immunity (Carmichael et al., 2011). 
Intranasal immunisation 
Intranasal immunisation circumvents many of the limitations encountered by TC and 
SL delivery in targeting the nasopharynx-associated lymphoid tissue (NALT) 
(Waldeyer’s ring in humans), which consists of highly vascularised and permeable 
epithelial localised micro-fold (M) cells (Bockman and Cooper, 1973; Kiyono and 
Fukuyama, 2004). Specialised in processing and presenting antigenic 
macromolecules to T and B cells for the induction of antigen-specific mucosal 
responses, M cells are excellent targets for improving uptake and efficiency of 
mucosal vaccines. IN immunisation induces expression of high levels of CCR10, 
α4β1 and α4β7 on activated lymphocytes, which can be recruited to the genital and 
respiratory tract by corresponding ligand/receptor (Kiyono and Fukuyama, 2004). 
Intranasal immunisation has been successful in protecting mice against Chlamydia 
genital and respiratory tract challenges. Protection was conferred following 
vaccination by the generation of IFNγ-secreting T lymphocytes, IgA/IgG2a class 
switched B lymphocytes and recruitment of antibody-secreting cells to the site of 
infection (Skelding et al., 2006; Tammiruusu et al., 2007; Sun et al., 2009; Andrew 
et al., 2011). Intransal vaccines represent a large proportion of the needle-free 
vaccines currently approved or in clinical trials in humans (Harper et al., 2003; 
Bukreyev et al., 2004), second only to orally administered vaccines (Slutter et al., 
2008). FluMist® is a trivalent live-attenuated influenza vaccine delivered 
intranasally, which provides a superior local IgA response in the nasal cavity (Boyce 
et al., 1999) than the more commonly used inactivated influenza vaccine delivered 
parenterally (Brokstad et al., 2002). Despite inducing significantly less influenza-
specific serum antibodies than the traditional inactivated IM vaccine, both were 
comparable at preventing culture-positive influenza (Edwards et al., 1994; Beyer et 
al., 2002). Intranasal immunisation with a recombinant HPV16 L1 virus-like particle 
(VLP) vaccine administered IN was also found to induce secretory IgA antibodies in 
vaginal secretion of human female volunteers, whereas the IM route did not 
(Nardelli-Haefliger et al., 2005). Similarly, vaginal IgG and IgA were also detected 
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following IN immunisation with HIV-1 gp160 (Pialoux et al., 2008). Intranasal 
vaccination has been proven effective at inducing protective immune responses at 
various mucosal surfaces and is largely well tolerated in human trials, with the 
occasional mild case of rhinorrhea (Nichol et al., 1999; Pialoux et al., 2008). 
However, there have been some reports of facial paresis following IN immunisation, 
due to toxin-based mucosal adjuvants (discussed below) that have restricted the 
development of IN vaccines (Fujihashi et al., 2002; Couch, 2004; Kiyono and 
Fukuyama, 2004; Mutsch et al., 2004).  
Mucosal and cutaneous immunisation offers numerous advantages over parenteral 
immunisation. Vaccines utilising needle-free routes are much safer than parenteral 
vaccines and often result in fewer side effects (Bennett et al., 2002; Glenn et al., 
2003). Moreover, it has been reported that up to 50% of immunisation injections in 
developing countries are unsafe and between 20 – 80% of new cases of hepatitis B 
virus (HBV) can be attributed to incorrect injection practices (Simonsen et al., 1999). 
Needle-free vaccines are also significantly more cost-effective than parenteral 
vaccines, if the added financial burden of training and employment of trained 
personnel and transmission of blood-borne disease is taken into account. The oral 
polio vaccine (OPV) alone has a lower cost ($6.33(USD)) than the injectable 
inactivated polio vaccine (IPV) ($8.42(USD)) (Miller et al., 1996). Even if cases of 
vaccine-associated paralytic poliomyelitis (VAPP) caused by OPV (occurring in 1 in 
750,000 immunisations (Racaniello, 2006)) are considered, the needle-free OPV is 
still the most cost-effective option (Miller et al., 1996). Furthermore, the direct and 
indirect costs of parenteral vaccination in the developing world can increase the cost 
per injection by over 40-fold (Ekwueme et al., 2002). Maximising community 
compliance and speed of immunisation is also vital to facilitate rapid immunisation 
of large populations (potentially during outbreaks) and enhance vaccine uptake 
critical for herd immunity (Giudice and Campbell, 2006). Most importantly, vaccines 
targeting the epithelium elicit mucosal immunity critical for protection against 
mucosal pathogens like Chlamydia. Despite their potential benefits only a handful of 
needle-free vaccines are licensed for human use, the majority of which are self-
replicating or -adjuvanting whole organism vaccines (Slutter et al., 2008; Smith et 
al., 2012). A subunit approach, like that required for a chlamydial vaccine, needs a 
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powerful adjuvant to initiate and sustain immunological memory (Czerkinsky et al., 
1999; Fujihashi and McGhee, 2004). Similarly, vaccines targeted to the epithelium 
also require a potent adjuvant to overcome the induction of tolerance that occurs 
following mucosal exposure to an antigen.  
MUCOSAL TOLERANCE 
Mucosal tolerance is a state of reduced antigen-specific immunological 
responsiveness elicited by mucosal exposure to a given antigen. Evolved to suppress 
unwanted immune responses to foreign but innocuous antigens like food, dust and 
commensal micro-organisms, mucosal tolerance is characterised by deletion or 
clonal anergy of antigen-specific T cells and the generation of Treg (Smith et al., 
2012). One key determinant identified for the induction of oral tolerance was the 
dosage of antigen fed. High antigen dosages were found to promote anergy/deletion 
of antigen-specific cells, whereas low doses preferentially induced TGFβ-secreting 
and immunosuppressive Treg (Weiner et al., 2011). Mucosal tolerance is also thought 
to be in part the consequence of antigen presentation in the absence of effective co-
stimulation (Weiner et al., 2011). Therefore, vaccines targeting the mucosal 
epithelium must promote the expression of co-stimulatory molecules to overcome 
immune suppression and effectively prime T cell for the induction of mucosal 
immunity. 
ADJUVANTS 
The term adjuvant is derived from the Latin word adjuvare meaning “to help” 
(Lycke, 2010). Adjuvants provide help by creating local non-specific inflammation 
or acting as depot, slowly releasing antigen. Both mechanisms recruit and mature 
APCs, critical to enhance their capacity to co-stimulate naive T cells and generate 
long-lived T cell immunity (Lycke, 2007). The importance of APCs maturation for 
optimal protection against Chlamydia is clearly evident in the study by He et al., 
(2005). The adoptive transfer of IL-10-deficient DCs pulsed with UV-inactivated 
EBs, predisposed to developing a Th1-dominant response, reduced the peak of 
infectious burden by 4 log10 and resolved the infection by day 6 p.i, compared to day 
42 p.i for control animals. These DCs were found to express an elevated level of 
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activation and maturation markers, CD11c, CD40, CD80, CD83 and CD86, and 
possessed heightened T cell-priming abilities (He et al., 2005). Therefore, DC 
maturation determines the intensity and longevity of immunity that develops against 
Chlamydia, a factor readily manipulated with modern adjuvants. 
Cytosine-phosphate-Guanine-oligodeoxynucleotide  
DNA methylation typically occurs on CpG motifs and is vital for cellular 
development and differentiation in eukaryotes. The host innate immune system has 
learned to recognise and respond to prokaryotic DNA, which traditionally has low or 
no methylation of CpG motifs (Sun et al., 1997). Endonuclease-resistant 
(phosphorothioate-modified) synthetic oligodeoxynucleotide containing 
unmethylated CpG islands (CpG-ODN) are now used as adjuvants, which imitate 
and initiate the host response associated with the presence of microbial DNA. The 
immunomodulatory effects of CpG are well characterised, signalling through the 
endosomal TLR9 PRR (Wagner, 2004). Toll-like receptor 9 is expressed by 
keratinocytes, LCs, plasmacytoid DCs (pDCs), myeloid DCs (mDCs), 
macrophages/monocytes, mast cells and B cells in mice (Wagner, 2004), the majority 
of which are abundant in the epithelium. As an excellent stimulator of innate 
immunity in the epithelium, CpG has become one of the most commonly used 
mucosal adjuvants in vaccine research. There are three structurally distinct classes of 
synthetic CpGs, D (A), K (B) and C types, of which D and K are most commonly 
used (Klinman et al., 2007). Only K type CpGs will be discussed in this section as 
these are more suited to vaccines targeted to the epithelium because their adjuvant 
activity is not restricted like D type CpGs to cells that express CXCL16 (Gursel et 
al., 2006). K type CpGs elicit a pro-inflammatory response, producing TNFα and IL-
12 in a MyD88-dependent manner (Roman et al., 1997; Jakob et al., 1998), which in 
turn augments the crucial Th1 response (Chu et al., 1997). Moreover, this adjuvant 
type also up-regulates antigen-presenting and co-stimulatory molecules MHCII, 
CD40 and CD86 on APCs (Sparwasser et al., 1998), invaluable in generating long-
lived immunity and overcoming mucosal tolerance. In clinical trials, CpG co-
administered with hepatitis B, influenza and anthrax vaccines by injection, increased 
both cell-mediated and antibody responses in human volunteers with no apparent 
side effects (Klinman et al., 2000; Halperin et al., 2003; Rynkiewicz et al., 2011). 
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Mucosal application of CpG in animal models induced protection against 
reproductive and respiratory tract pathogens, by improving antigen-specific Th1 and 
mucosal antibody responses (Moldoveanu et al., 1998; Berry et al., 2004; Tengvall et 
al., 2006). This shows the potential benefit of CpGs for vaccine development against 
mucosal pathogens, but because a chlamydial vaccine also requires a strong 
induction of mucosal IgA antibodies, CpG is sometimes used in conjunction with a 
more Th2-polarising mucosal adjuvant, like CT, to further enhance antibody 
production (Berry et al., 2004; Skelding et al., 2006; Cheng et al., 2009; Finco et al., 
2011).  
Cholera toxin 
Cholera toxin is an enterotoxin secreted by Vibrio cholera that can act as a potent 
mucosal adjuvant. Cholera toxin consists of two subunits, CTA1 (active) and CTB 
(binding), linked by the CTA2 subunit (Figure 2.6). The adjuvanticity of CT relies on 
the ability of the holotoxin to bind and exert its activity within the target host cells 
(Guidry et al., 1997; Agren et al., 1999b). The CTB subunit consists of a pentamer of 
high-affinity binding molecules that target the monosialoganglioside GM1 receptor, 
essential for normal cellular metabolism (Connell, 2007). As GM1 receptors are 
expressed on all nucleated cells, CT is a potent stimulator of innate responses. 
Following binding and internalisation, CT travels through the endoplasmic reticulum 
where the enzymatically active CTA1 subunit is separated from the CTB subunit by 
the degradasome and released into the cytosol. The CTA1 subunit catalyses 
adenosine diphosphate (ADP)-ribosylation of adenylate cyclase leading to an 
accumulation of cyclic adenosine monophosphate (cAMP). This causes an 
electrolyte imbalance and rapid efflux of water from the effected cells, which causes 
the severe diarrhoea commonly associated with a gastrointestinal infection with V. 
cholera. Although the precise immunomodulatory mechanisms behind adjuvanticity 
are still unknown, CT has been found to increase epithelial permeability, pro-
inflammatory cytokine production, IgA class switching and expression of co-
stimulatory molecules CD80, CD86 and CD83 by APCs (Bromander et al., 1991; 
Agren et al., 1997; Cong et al., 1997; Lavelle et al., 2004; Holmgren and 
Czerkinsky, 2005; Lycke, 2005). Cholera toxin elicits predominantly a Th2 dominant 
phenotype, although a mixed Th1/Th2 response is also frequently reported (Gagliardi 
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et al., 2000; Eriksson et al., 2003). Intranasal immunisation with p55gag adjuvanted 
with CT, induced antigen-specific IgG/IgA and Th1/Th2-type CD4
+
 cells in vaginal 
mucosa in non-human primates (Imaoka et al., 1998). A recent human clinical trial 
reported that TC immunisation with the functionally similar LT, elicited gastric anti-
toxoid responses, which resulted in reduced severity of enterotoxigenic Escherichia 
coli (ETEC) associated illnesses (travellers’ diarrhoea) without any toxic side effects 
(McKenzie et al., 2007; Frech et al., 2008). DUKORAL® a licensed orally 
administered vaccine against V. cholera O1, adjuvanted with recombinant CTB, 
provided 100% protection for 4 – 6 months and was efficacious for the majority of 
recipients for up to 5 years (Sanchez and Holmgren, 2010). Therefore, enterotoxins 
and their constituents have proven effective as an adjuvant for needle-free vaccines, 
by inducing mucosal immunity in animal and human trials. 
Cholera toxin/Cytosine-phosphate-Guanine-oligodeoxynucleotide  
As protection against Chlamydia requires both a Th1 cell-mediated and Th2-driven 
antibody response, many vaccines have adopted the use of Th1 and Th2 polarising 
adjuvant combinations The combination of CT and CpG co-administered with the 
MOMP and delivered via needle-free routes significantly reduced the duration and 
magnitude of Chlamydia infections in the murine respiratory and reproductive tract 
model (Berry et al., 2004; Skelding et al., 2006; Cheng et al., 2009). Meeting the 
criteria outlined for an ideal chlamydial vaccine, i.e. providing a balanced Th1 
response with a local mucosal Chlamydia-specific Th2-driven antibody response 
capable of reducing likelihood of transmission, CT/CpG plus the MOMP has become 
our experimental “gold standard” Chlamydia vaccine. However, the toxicity of these 
adjuvants has prevented their approval for human use. Repeated doses of CpG were 
shown to have a strong correlation with the enhancement of autoimmunity, tissue 
abnormalities and susceptibility to toxic shock syndrome (Heikenwalder et al., 2004; 
Klinman et al., 2007; DeFrancesco, 2008). Safety concerns have also arisen over 
ADP-ribosyltransferase adjuvants delivered via the IN immunisation route, following 
the withdrawal of Nasalflu® from the market. Nasalflu®, a trivalent influenza 
vaccine containing the inactivated flu virosome together with the LT adjuvant, 
induced a high influenza-specific mucosal IgG and IgA titres that was associated 
with 85-90% protection against infection in humans (Glueck, 2001). Even though the 
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vaccine was efficacious, the promiscuity of the adjuvant to bind all nucleated cells, 
including nerve tissues, led to central nervous system (CNS) complications (Bell’s 
palsy) in some patients (Fujihashi et al., 2002; Couch, 2004; Kiyono and Fukuyama, 
2004; Mutsch et al., 2004). Cases of Bell’s palsy were also reported in phase I 
clinical trials of IN delivered M. tuberculosis and HIV vaccines which also contained 
the LT adjuvant (Lewis et al., 2009). This is a perfect example of the problems 
facing needle-free vaccine development and highlights the need to develop either 
safer ways to deliver these adjuvants or create detoxified derivatives of the 
problematic yet successful (in animal models) enterotoxins. The potency of mucosal 
adjuvants, necessary to overcome tolerance toward co-administered antigens, is often 
too toxic for use in a human prophylactic vaccine. Although, utilisation of different 
routes of immunisation can limit the toxicity associated with certain adjuvants like 
CT and CpG (Heikenwalder et al., 2004; Klinman et al., 2007; DeFrancesco, 2008; 
Lewis et al., 2009), while still harnessing their adjuvanticity. The great success of 
adjuvants like CT in animal models and human trials has been a major driver for the 
development of non-toxic, yet immunogenic adjuvant derivatives that can be used in 
humans for the induction of mucosal immunity. 
Cholera toxin A1 subunit-dimer of immunoglobulin binding subunit (CTA1-DD) 
Separating the toxicity of CT from the adjuvanticity has proven particularly difficult, 
as both characteristics are coupled with the binding and enzymatic activity of the 
holotoxin (Guidry et al., 1997; Agren et al., 1999b). The CTB subunit alone has 
proven to be a poor adjuvant, consistently inducing antigen-specific tolerance (Sun et 
al., 1994; Holmgren et al., 2003). Cholera toxin B subunit vaccines have even been 
used as suppressers of autoimmune diseases (Sun et al., 1994; Sun et al., 1996; 
Bergerot et al., 1997; Sobel et al., 1998; Sun et al., 2006). Although physical 
coupling of an antigen to the B subunit can enhance antigen uptake across the 
mucosal barrier and improve antigen-presentation, CTB and other detoxified mutants 
of CT that contain the binding subunit, still retain the risk of CNS accumulation 
following IN immunisation (van Ginkel et al., 2000; Lycke, 2005; van Ginkel et al., 
2005). Mutants containing the CTA1 ADP-ribosyltransferase subunit on the other 
hand, now linked conclusively to immunogenicity (Rappuoli et al., 1999; Hasselberg 
et al., 2010), have shown more promise. The CTA1-DD adjuvant consists of the 
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enzymatically active CTA1 subunit of CT, genetically linked to a dimer of an Ig-
binding domain (D) from the staphylococcal protein A (Agren et al., 1997). This 
specifically targets the activity of the CTA1 subunit primarily, but not exclusively 
(Akhiani et al., 2006), towards B cells opposed to all nucleated cells as with CT 
(Agren et al., 1997; Agren et al., 1998; Agren et al., 1999a; Agren et al., 1999b; 
Agren et al., 2000). Encompassing both binding and enzyme activity, CTA1-DD 
retains the adjuvanticity of the native holotoxin, but most importantly, not its toxicity 
(Agren et al., 1997; Agren et al., 1999b). Primates and mice can be given >200µg of 
CTA1-DD without any profound side effects, whereas an equivalent amount of CT is 
normally lethal in mice (Agren et al., 1997; Agren et al., 1999b; Lycke, 2004; 
Sundling et al., 2008). CTA1-DD also does not accumulate in nerve tissue following 
IN immunisation (Eriksson et al., 2004), which makes CTA1-DD an excellent 
candidate for mucosal vaccine delivered by the IN route.  
Although the ADP-ribosylating activity of the CTA1 subunit is crucial, the precise 
underlying mechanisms behind the adjuvanticity of CTA1-DD, like CT, are still 
largely unknown. The CTA1-DD adjuvant has been shown to target the membrane-
bound B cell receptor (BCR) expressed by naive B cells, complement receptors on 
follicular dendritic cells (FDC) and potentially bind free Ig to form immune 
complexes (Figure 2.6) (Agren et al., 1998; Fang et al., 2010; Mattsson et al., 2011). 
Binding to membrane bound Ig, CTA1-DD up-regulates expression of CD86 and 
CD80 on B cells (Agren et al., 1997), which is needed for adequate priming of T 
cells and to overcome mucosal tolerance. The CTA1-DD adjuvant also has an anti-
apoptotic affect on B cells that stimulates germinal centre (GC) formation, 
responsible for IgA class switching recombination (CSR), generating long-lived 
memory B cells and antibody-secreting plasma cells (Agren et al., 1997; Agren et al., 
1999b; Bemark et al., 2011). Both binding and enzymatic activity are critical for 
stimulation of B cells (Agren et al., 1999b). Interestingly, it was found that increased 
cAMP levels, suggested to be critically linked with the immunogenicity of CT, were 
not elevated in B cells treated with CTA1-DD (Agren et al., 1998). Moreover, 
stimulation of the anti-apoptotic B cell factor Bcl-2 by CTA1-DD occurred in 
athymic mice, contrary to the holotoxin that failed to prevent apoptosis in the 
absence of T cells (Agren et al., 2000). Despite differing from CT only by binding 
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ability, CTA1-DD appears to have an entirely different mechanism of action on B 
cells. 
Even though CTA1-DD was designed to target B cells, its immunogenicity is 
partially retained in µMT mice (B cell-deficient) (Akhiani et al., 2006). This 
suggests the adjuvanticity of CTA1-DD is primarily B cell-dependent, but B cell-
independent mechanisms may also be involved (Figure 2.6). Capable of binding to 
both Fc and Fab antibody fragments, CTA1-DD may cross-link free Ig to form 
immune complexes. Pre-incubation of CTA1-DD with polyclonal IgG induced 
greater degranulation and TNFα production by mast cells than CTA1-DD alone, 
which was attributed to the formation of immune complexes and cross-linking of Fc 
receptors (Fang et al., 2010). Production of TNFα could be detected in all controls 
containing the Ig-binding domain, implicating the DD motif and not the CTA1 
subunit in this stimulatory response. However, the immune complex does not appear 
to develop in vivo following intravenous (IV) or intraperitoneal (IP) administration 
CTA1-DD (Agren et al., 2000). Furthermore, FcγR-deficient mice exhibited an 
unaltered antigen-specific response to CTA1-DD-adjuvanted vaccines (Agren et al., 
2000; Akhiani et al., 2006), suggesting that the antibody complex may be an in vitro 
artefact and not contribute to the immunogenicity of CTA1-DD in vivo.  
More recently, CTA1-DD was also found to bind to follicular dendritic cells (FDC) 
in B cell follicles, not by the immune complex FcR mechanism, but in a CR2-
dependent manner (Mattsson et al., 2011). Intravenous (IV) immunisation with 
CTA1-DD enhanced the formation of GCs, antibody production and T cell-
dependent responses by activation of the complement pathway, a function abrogated 
in CR2
-/-
 mice. This action was dependent on the both binding and enzyme motifs. 
Interestingly, enhancement of antibody production was severely impaired in CR2-
deficient mice given CTA1-DD intranasally, which may indicate that this function 
could also be activated after mucosal immunisation.  
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Figure 2.6: Illustration of the current published and theorized mechanisms behind the adjuvanticity of CTA1-DD. 
The adjuvant function of CTA1-DD, consisting of the CTA1 subunit of CT bound to a dimer of staphylococcal Ig-binding proteins, involves B cell-
dependent and -independent mechanisms. The B cell-dependent mechanism entails binding of membrane bound Ig on B cells, which promotes the 
expression of co-stimulatory molecules CD80 and CD86. B cell-independent mechanisms involves the activation of FDCs by complement receptor 
CR2 and the formation of the immune complex by cross-linking free antibodies, which may subsequently activate mast cells. CTA1-DD is known to 
promote mucosal immunity by enhancing antigen presentation, T cell activation, cytokine production, GC formation and antibody production. 
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Mucosal delivery of CTA1-DD has been shown to promote antibody and cell-
mediated responses. The CTA1-DD adjuvant invokes a balanced Th1/Th2 response 
(Eriksson and Lycke, 2003), essential in developing protective immunity against 
Chlamydia. Trialled experimentally in research against HIV (Sundling et al., 2008), 
Influenza A (De Filette et al., 2006), Helicobacter pylori (Akhiani et al., 2006), 
Mycobacterium tuberculosis (Andersen et al., 2007) and Rotavirus (Choi et al., 
2002; McNeal et al., 2007), CTA1-DD improved mucosal immune response in all 
studies and protection in models of infectious challenge. A pilot study by 
Cunningham et al., (2009), assessed the ability of IN immunisation with the MOMP 
co-administered with or without CTA1-DD to promote mucosal immunity. The 
animals receiving the MOMP plus CTA1-DD produced significantly higher systemic 
and mucosal Chlamydia-neutralising antibodies than the antigen control 
(Cunningham et al., 2009), a responses conclusively linked with improved clearance 
and reduced pathology in vivo (Morrison et al., 1995; Su et al., 1997; Yang and 
Brunham, 1998; Murthy et al., 2004; Morrison and Morrison, 2005; Rodriguez et al., 
2006). Interestingly, the levels of MOMP-specific antibodies, as determined by 
enzyme-linked immunosorbent assay (ELISA), were remarkably similar with and 
without the addition of the CTA1-DD. It was suggested that direct interaction 
between the adjuvant and B cells may have influenced antigen recognition or epitope 
selection leading to higher neutralising antibodies and a reduced level of chlamydial 
shedding following an IVag challenge. This particular study has provided valuable 
insight into the immune-mediating capability of CTA1-DD, its potential to substitute 
toxic mucosal adjuvants in a novel Chlamydia vaccine.  
SUMMARY 
A vaccine is needed to control the chlamydial pandemic. Thus far, there has been 
limited progress towards the development of an effective human vaccine against 
Chlamydia, partly due to an inability of current adjuvants to stimulate mucosal 
immunity without compromising safety. This study assessed the ability of the novel 
non-toxic mucosal adjuvant CTA1-DD to stimulate mucosal immunity, by direct 
comparison to the proven yet toxic CT/CpG. Different needle-free immunisation 
routes were also utilised not only to stimulate the CMIS, but to potentially lessen the 
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toxicity CT/CpG without affecting immunogenicity. Protection against Chlamydia 
genital and respiratory tract infections were used to evaluate each vaccines efficacy 
and possibility to benefit the human population. 
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CHAPTER THREE: GENERAL MATERIALS 
AND METHODS 
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GENERAL REAGENTS AND CONSUMABLES 
Concentrated powder and liquid chemicals, where not specified, were obtained from 
Merck Pty Ltd, Kilsyth, Australia. Consumables, such as disposable tubes and pipette 
tips were obtained from Lab Advantage, Murarrie, Australia unless otherwise stated. 
CHLAMYDIA STRAINS AND CELL LINES 
Cell lines 
The McCoy mouse fibroblast cell line was used for propagation and quantification of 
C. muridarum. Original stocks were purchased from the American Type Culture 
Collection (ATCC, Virginia, USA). McCoy cell stocks were cryopreserved in media 
containing 10%v/v dimethyl sulfoxide (DMSO) (Sigma-Aldrich Pty Ltd, Castle Hill, 
Australia) and continually checked by polymerase chain reaction (PCR) for 
Mycoplasma contamination. 
Chlamydia strain 
C. muridarum Weiss strain VR-123, formerly mouse pneumonitis biovar of C. 
trachomatis (MoPn), was obtained from the ATCC. 
CELL CULTURE SOLUTIONS 
Phosphate buffered saline (PBS) 
Phosphate buffered saline was prepared by dissolving 8g of NaCl, 0.2g of KCl, 1.44g 
of NaHPO4 and 0.24g of KH2PO4 in 1L of double distilled water (ddH2O) (Millipore 
MilliQ water purification system – Millipore Australia Pty Ltd, Australia) and pH 
adjusted to 7.4 using NaOH. 
Fetal calf serum (FCS) 
Fetal calf serum (Lonza Australia Pty Ltd, Mt Waverley, Australia) was heat-
inactivated by placing the bottle in a 56°C water bath for 45 min, to ensure 
destruction of protease and complement. 
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Cell culture growth medium 
McCoy cells and C. muridarum we supplemented complete Dulbecco’s minimal 
essential medium (DMEM) containing 5% FCS, 4mM L-glutamine, 50µg/ml 
gentamycin (Invitrogen, Mt Waverley, Australia) and 100µg/ml streptomycin 
sulphate (Sigma-Aldrich).  
Trypsin 
A 10X solution of trypsin ethylenediaminetetraacetic acid (EDTA).4Na (Invitrogen) 
was diluted to 2X with sterile PBS before use. 
Sucrose phosphate glutamine buffer (SPG) 
Sterile SPG was used as a cryopreservative for storage of all chlamydial stocks and 
samples. SPG was prepared to contain a final concentration of 219mM sucrose, 
3.8mM KH2PO4, 8.6mM Na2HPO4 and 4.9mM glutamic acid, dissolved in ddH2O. 
The pH was adjusted to 7.0 before the sterilising by autoclaving. 
CHLAMYDIA CELL CULTURE 
Growth and maintenance of McCoy cells 
McCoy cell were continually passaged in 175cm
2
 tissue culture flasks (BD 
Bioscience, North Ryde, Australia) in complete DMEM in a 37°C humidified 
incubated with 5% CO2 until 100% confluent. All reagents were pre-warmed to 37°C 
in a water bath prior to use. Spent media was discarded into a waste bottle containing 
12.5%w/v sodium hypochlorite. The monolayer was subsequently washed with 
sterile PBS and discarded into the waste container before adding 3mL of trypsin to 
the flask. The flask was sealed and placed into the incubator for 2 min. To facilitate 
cell detachment, the sides of the flask were gentle tapped. Once cells were dislodged, 
5mL of complete DMEM was added to the flask to inhibit tryptic activity. This cell 
suspension was then split over the required amount of flasks, supplemented with a 
further volume of media and returned to the incubator.  
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Propagation of Chlamydia 
Samples of C. muridarum EBs obtained from the ATCC were subsequently 
propagated in our laboratory. A frozen culture flask, infected with C. muridarum and 
stored in SPG, was removed from the -80°C and partially thawed in the incubator. 
Sterile glass bead were added to the flask and the infected cells were sonicated in 
bath sonicator (Cole-Parmer 8891 Ultrasonic cleaner – John Morris Scientific, Eagle 
Farm, Australia) for 10 min. The media was then transferred to a 50mL tube and 
centrifuged at 4°C for 5 min at 500xg to remove insoluble cellular debris. The 
supernatant was transferred to a fresh tube and either stored at -80°C or used to infect 
an 80% confluent flask of McCoy cells. As a general rule, no more than one eighth 
of the supernatant was used to infect a subsequent flask. Two – 4 hr after infection, 
host cell protein synthesis was inhibited by replacing the media in the flask to media 
containing 1µg/mL of cycloheximide (Invitrogen). The infected cells were then 
incubated in a humidified incubator at 37°C with 5% CO2 for between 24 – 30 hr, or 
until active inclusions containing EBs could be visualised under an Olympus CK2 
inverted light microscope (Olympus Australia Pty Ltd, Mt Waverley, Australia). 
Infection was stopped by adding an equal volume of SPG to the media then freezing 
at -80°C. Frozen flasks were used for further propagation of Chlamydia. 
Ultra-purification of Chlamydia 
Frozen flasks were defrosted and sonicated as describe above. Chlamydia was semi-
purified from the infected supernatants by centrifuging at 20,000xg for 20 min at 
4°C. The subsequent pellet was resuspended in media containing 500U/mL heparin 
sulphate (Sigma-Aldrich), 10mM MgCl2 and 40U/mL DNase I (Roche, Castle Hill, 
Australia) and incubated at 37°C for 30 min. Chlamydia was pelleted at 20,000xg 
and the bacterial pellet was washed repeatedly and resuspended in ice-cold SPG. 
This solution was then layered over 29%v/v urografin Ultravist® (Sigma-Aldrich) 
and spun at 70,000xg for 30 min in a Optima® L-90K ultracentrifuge (Beckman 
Coulter, Gladsville, Australia). The chlamydial pellet was washed repeatedly and 
resuspended in SPG, then layered over a gradient column containing 40%, 34% and 
29% urografin and again spun at 70,000xg for 30 min. Chlamydial EBs were 
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removed from the interface between the 34% and 40% urografin layers, washed, then 
stored in small aliquots of SPG and frozen down at -80°C.  
Quantification of Chlamydia 
Using a confluent flask of McCoy cells, cells were detached and counted with a 
haemocytometer using 0.4%w/v trypan blue (Sigma-Aldrich) as a live/dead cell 
discriminator. The cell suspension was diluted to a final concentration of 1 x 10
5
 
cells/mL and 500µL containing 5 x 10
4 
cells was placed into each well of a 48-well 
plate (BD Bioscience) and incubated overnight at 37°C in a humidified incubator. 
The concentration of Chlamydia in the frozen stocks was determined by serial 
dilution of a known volume of the original stock onto the 80% confluent monolayer. 
Chlamydia was propagated as described above before stopping the infection by 
fixation and staining with a Chlamydia-specific antibody (see below).  
Sheep anti-C. muridarum polyclonal serum 
Sheep anti-Chlamydia serum was ordered from the Institute of Medical and 
Veterinary Science (IMVS), Dulwich, Australia. A Merino/Border Leicester x-bred 
wether sheep, was immunised SC with 1mg of recombinant C. muridarum MOMP in 
complete Freunds adjuvant, repeated every 3 – 5 weeks a total of three times in 
incomplete Freunds. The sheep was bled 3 weeks after the final boost. The blood was 
allowed to clot at 4°C for overnight, after which the serum was separated from whole 
blood by centrifugation. Murine cross-reactive antibodies were removed from the 
sheep anti-serum following incubation at 4˚C for 1 hr with 107 BALB/c 
splenocytes/mL of serum. Aliquots of adsorbed serum were stored at -80°C. 
Fixing an staining for Chlamydia 
Following propagation and the visualisation of active inclusions, the media was 
removed from the wells and washed with PBS. The infected monolayer was then 
fixed with 100% methanol for 10 min then subsequently washed with PBS. In 
preparation for Chlamydia-specific staining, non-specific binding was blocked 
overnight at 4°C with a blocking solution containing 5%v/v FCS, 0.05%w/v sodium 
azide in PBST (0.05%v/v Tween20). Cells were then incubated with a 1/500 dilution 
of the Chlamydia-specific sheep anti-serum in blocking solution for 1 hr at 37°C. 
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Rinsed thoroughly with PBST following incubation, cells were then treated with 
blocking solution containing 1µg/mL of donkey anti-sheep AlexaFluor-488 
secondary (Invitrogen) and 10ng/mL 4',6-diamidino-2-phenylindole, dihydrochloride 
(DAPI) (Invitrogen) for 1 hr at 37°C. Cells were then rinsed thoroughly with PBST 
and stored in PBS at 4˚C in the dark. Images from 4 random fields of view (FOV) 
were taken from each well using a Nikon Eclipse TE2000-U fluorescent inverted 
microscope with Nikon Digital Eclipse DXM 1200C camera (Nikon Pty Ltd, 
Lidcombe, Australia). Chlamydial inclusion-forming units (IFU) were counted using 
MetaMorph Imaging Series 7.6 software (Molecular Devices, Sunnyvale, USA) 
based on fluorescent pixel area and intensity above background. Quantification of 
chlamydial IFU/well was calculated by multiplying the number of IFU/FOV by the 
FOV/well. Quantification of chlamydial IFU/mL was calculated by multiplying the 
number of IFU/well by 1000 and dividing by the volume aliquoted into each well in 
µL. 
RECOMBINANT MOMP PREPARATION 
Native MOMP (nMOMP), isolated directly from chlamydial EBs, has been shown to 
elicit a protective response equivalent to that induced following a live infection (Pal 
et al., 2005; Sun et al., 2009). Recombinant MOMP (MOMP), closely mimicking 
conformational epitopes of nMOMP, can also induce a similar level of protection 
without the larger cost associated with production (Sun et al., 2009).  
Luria-Bertani (LB) broth and agar 
Luria-Bertani broth was prepared by dissolving 10g of tryptone, 5g of yeast extract 
(Oxiod, Australia Pty Ltd, Thebarton, Australia) and 10g of NaCl in 1L of ddH2O. 
Luria Bertani agar contained of LB broth with the addition of 15g of agar (Oxoid). 
Each solution was sterilised by autoclaving at 121°C for 15 min.   
Bacterial clone 
Recombinant C. muridarum MOMP was purified from the E. coli clone 
(DH5α[pMMM3]), transformed with the pMAL-c2 ampicillin-resistant vector 
encoding the recombinant maltose-binding protein (MBP) fusion protein (a generous 
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gift from Harlan Caldwell, Rocky Mountain Laboratories) (Su et al., 1996). Clones 
were stored in LB broth containing 80%w/v glycerol at -80°C. 
Large scale recombinant protein expression and purification 
A single colony of DH5α[pMMM3] was isolated from a glycerol stock using the 
sixteen streak method on LB agar plates containing 100µg/µL of ampicillin (Roche) 
and then incubated at 37°C overnight. A 15mL overnight starter culture grown from 
a single colony was used to infect a 1L within a 2L conical flask. This large scale 
culture was incubated at 37°C under 220rpm rotation until the turbidity of the media 
reached optical density (OD) of 0.4, measured at a wavelength of 400nm using a 
DU800 spectrophotometer (Beckman Coulter). Expression of the recombinant 
protein was induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) 
(Sigma-Aldrich Pty Ltd, Castle Hill, Australia) to the culture at a final concentration 
of 0.15mM and incubating for a further 2 hr. The bacterial pellet was sonicated 
(Ultrasonic liquid processor, Misonix, Farmingdale, USA) using spun at 4,000xg to 
pellet the insoluble inclusion bodies containing the MOMP protein. The inclusion 
bodies were solubilised using 8M urea containing a bacterial protease inhibitor 
cocktail (Cat No. P8465, Sigma-Aldrich) and incubated for a further 2 hr at 37°C 
under 100rpm rotation. The soluble MOMP protein fraction was then dialysed in a 
stepwise manner, using a decreasing gradient of urea until eventually equilibrated 
against PBS. The refolded MOMP-MBP (81kDa, 39kDa and 41kDa, respectively) 
(Su et al., 1996) preparation was then further purified and concentrated by size 
exclusion using the Centriprep® centrifugal filter unit, Ultracel-50 membrane 50kDa 
molecular weight cut-off (MWCO) column (Millipore Australia Pty Ltd, North 
Ryde, Australia). The purified MOMP was quantified with the BCA Protein Assay®
 
kit (Thermo Fischer Scientific, Rockford, Illinois, USA)) and visualised by sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). To maintain 
solubility and a more natural conformation of the MOMP, MBP was not cleaved 
from the purified protein (Su et al., 1996). Immunoreactivity of the MOMP was 
assessed against samples from a natural infection and hence the native MOMP 
conformation, using western blotting and lymphocyte proliferation assays. The final 
product was concentrated to 20mg/mL and stored at -80°C in aliquots to prevent 
repeated freeze thawing. 
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Lipopolysaccharide removal and quantification 
Lipopolysaccharide was quantified using ToxinSensor® chromogenic Limulus 
amebocyte lystate (LAL) endotoxin assay kit (Cat No. L00350, Genscript Inc, 
Pistcataway, New Jersey, USA) as per the manufacturer’s instructions. LPS 
contamination was removed by diluting the concentrated MOMP preparation to 
0.5mg/mL with sodium deoxycholate (Sigma-Aldrich) to the critical micelle 
concentration of 0.1%w/v (Jang et al., 2009), then concentrating again by size 
exclusion using the centrifugal filtration. This process was repeated until LPS was 
reduced to quantities below 0.1µg/dose (Eriksson et al., 2004). Residual sodium 
deoxycholate was removed by dialysis against PBS. 
ANIMALS HOUSING 
Ethics statement 
All studies and procedures were approved by the QUT Animal Ethics Committee 
(approval number 0800000432).  
Mice 
Female BALB/c mice were sourced from the Animal Resource Centre (ARC) 
(Canningvale, Western Australia) at 6 weeks of age. Five animals were used in each 
group unless otherwise stated. Animals were given food and water ad libitum and 
maintained in a temperature controlled environmental with a cycle of 12 hr of light 
and 12 hr of darkness. Animals were euthanised humanly by IP injection with 
Lethabarb® (200 mg/kg) (Virbac Animal Health, Reagents Park, Australia).  
ADJUVANTS 
Cholera toxin A1 subunit-dimer of immunoglobulin binding subunit  
The CTA1-DD adjuvant was a generous gift from Nils Lycke at MIVAC, 
Gothenburg, Sweden. The CTA1-DD adjuvant was purified as previously described 
(Agren et al., 1997) and stored in PBS at -80°C. 
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Cholera toxin 
Lyophilised CT (List Biological Laboratories, Sapphire Bioscience Pty Ltd, Redfern, 
Australia) was resuspended in PBS and stored at 4°C.  
Cytosine-phosphate-Guanine-oligodeoxynucleotide 1826 
The CpG-ODN 1826
c 
adjuvant (5′-TCC ATG ACG TTC CTG ACG TT-3′) (Sigma-
Aldrich) was made on a nuclease-resistant phosphothioate backbone (Jakob et al., 
1998). Lyophilised CpG-ODN was resuspended in PBS and stored at -20°C. 
IMMUNISATION 
Mice were immunised on days 0, 7, 14 and 28 as described below. This 
immunisation schedule was chosen because it will allow a retrospective comparison 
between past and present work (Berry et al., 2004; Hickey et al., 2005; Skelding et 
al., 2006; Cunningham et al., 2009; Hickey et al., 2009). Each route included antigen 
(MOMP), adjuvant (CTA1-DD and CT/CpG-ODN) and unimmunised (PBS) control 
groups. All vaccines were made fresh before each immunisation. 
Intranasal immunisation 
Animals in the IN group were lightly anesthetised with 4%v/v isofluorane by 
inhalation (Abbott Australasia Pty Ltd, Botany, Australia). The anesthetised mice 
were placed on their backs, held at a downward angle (Figure 3.1) then immunised 
with the MOMP (100µg) and either CTA1-DD (20µg) (MIVAC) or CT (List 
Biological Laboratories) (5µg)/CpG-ODN 1826
c
 (Sigma-Aldrich) (10µg) mixed in a 
10µl volume, 5µl applied to each nare.  
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Figure 3.1: Photo of IN immunisation.  
The mouse was firstly anesthetised with isofluorane and then held on its back at a 
downward angle. The vaccine was administered slowly to each nare in a volume 
totalling no more than 10µL. The mouse was then placed back in the cage to recover 
completely. 
Transcutaneous immunisation 
Animals in the TC group were heavily sedated with an IP injection with ketamine 
(Parnell Laboratory Pty Ltd, Alexandria, Australia) (100mg/Kg) and xylazine (Bayer 
Australia Ltd, Pymble, Australia) (10mg/Kg). A 1.5cm
2
 space on the backs of mice 
at the base of the tail was then shaved using clippers, with care taken not to break the 
skin. The skin was pre-treated first with acetone, then with a solution containing 
dodecylpyridinium chloride (DPC) (0.33%w/v), isopropyl myristate (IPM) 
(0.33%w/v) and methyl pyrolidone (MPR) (0.33%w/v) (Sigma-Aldrich) (Karande et 
al., 2009) and finally rehydrated with copious amounts of PBS. Each permeation and 
rehydration step was applied directly to the skin with a transfer pipette individually. 
Each step was also accompanied by a vigorous yet gentle abrasion of the skin with a 
piece of paper towel doused in the same reagent. Mice then received GM-CSF 
(12.5ng) (Hickey et al., 2005) with the MOMP (200µg) and either CTA1-DD (20µg) 
or CT (10µg)/CpG-ODN 1826
c 
(10µg) mixed in a volume of 50µL. The 
immunisation was contained for a 24 hr time period using a patch system consisting 
of gauze, Opisite Flexifix® (Smith & Nephew Australia, Mt Waverley, Australia) 
and Micropore® surgical tape (3M Australia, North Ryde, Australia) (Figure 3.2). 
This immunisation protocol was modified and improved from previous studies 
(Berry et al., 2004; Hickey et al., 2005) (Appendix 1) 
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Figure 3.2: Photo of TC immunisation and diagram of the patch system.  
Assemble of the patch system (right picture) began by (1) shaving the lower back of the 
anesthetised mouse above the tail. The shaved area was then permeabilised using 
acetone and DPC, IPM, MPR. The permeabilised skin was then washed repeatedly with 
PBS in preparation for the vaccine. (2) The vaccine was spread over a small area of the 
permeabilised skin and covered with gauze. (3) The vaccine was retained on the skin 
with a waterproof seal of Opisite Flexifix®. The patch was then secured to the mouse 
using surgical tape (left picture). The mouse was then placed back in the cage to recover 
completely. 
Sublingual immunisation 
The SL group was also heavily sedated with ketamine and xylazine. The MOMP 
(100µg) was mixed with either CTA1-DD (20µg) or CT (5µg)/CpG-ODN 1826
c 
(10µg) in a 7µL volume was applied directly to the ventral side of the tongue (Figure 
3.3) and left for 1 hr with the head of the mice maintained in ante-flexion (Cuburu et 
al., 2007). Antigen dose curve was optimised for SL immunisation for the MOMP 
antigen using antigen-specific proliferation and serum IgG (Appendix 2). 
 
 
1.
2.
3.
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Figure 3.3: Photo of SL immunisation.  
The mouse was firstly anesthetised and placed in a position (ante-flexion) to prevent the 
vaccine entering the gastrointestinal tract. The vaccine was administered underneath the 
tongue (picture), in a volume no greater than 7µL. The mouse was then placed back in 
the cage to recover completely. 
Statistical analysis 
All data was presented as the mean ± standard deviation (SD). All statistics were 
performed using GraphPad Prism® version 5.00 (GraphPad Software Inc, California, 
USA). Significant differences were determined using a one-way analysis of variance 
(ANOVA) with Tukey’s post-test. Significance was set at P < 0.05 for all tests. P 
>0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
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INTRODUCTION 
Animal and human studies have indicated that CD4
+ 
Th cells, predominantly those 
secreting IFNγ, are essential for protection against chlamydial infection and disease. 
CD4
+ 
Th1 cells target chlamydial RBs undergoing active replication by activating the 
infected host cell’s defences against intracellular pathogens (Cotter et al., 1997b). 
This response restricts the growth and hence the amount of Chlamydia shed into the 
lumen and available for transmission (Perry et al., 1997). However, CD4
+ 
Th1 cells 
are unable to directly prevent extracellular Chlamydia from infecting new host cells 
during the establishment of infection. Protection against attachment of chlamydial 
EBs and the spread of infection to a new host or cell requires an antibody response. 
Antibodies can neutralise extracellular Chlamydia by directly preventing attachment 
or by opsonising EBs for engulfment by phagocytes (Moore et al., 2002). This form 
of protection is predominantly responsible for raising the infectious threshold 
necessary to establish an infection (Su et al., 1997; Williams et al., 1997). Therefore, 
due to the unique biphasic chlamydial lifecycle, containing both extracellular and 
intracellular forms, an effective vaccine against Chlamydia needs to elicit a Th1-
driven cell-mediated as well as Th2-driven humoral antibody response. Furthermore, 
the effectiveness of a vaccine can be enhanced further if the Chlamydia-specific T 
and B cell responses are localised to or capable of being rapidly recruited to the 
anatomical portal of entry for the invading pathogen, in what is known as a mucosal 
response.  
Parenteral vaccines can successfully prevent infections caused by invasive mucosal 
pathogens by inducing neutralising antibodies. These vaccines are relatively poor 
inducers of localised mucosal responses (Muszkat et al., 2000; Holmgren and 
Czerkinsky, 2005; Cong et al., 2007; Pedersen et al., 2011), which are necessary for 
protection against pathogens such as Chlamydia, which enter through and are 
predominantly confined to the epithelium. Targeting vaccination to the epithelium 
more effectively generates mucosal immunity, yet such vaccines often require a 
powerful adjuvant to overcome the induction of tolerance that often occurs following 
mucosal exposure to an antigen (Smith et al., 2012). Whilst immunologically 
effective in animal models, the use of potent adjuvants like the GM1-ADP 
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ribosylating toxins (CT or LT) or TLR agonists can be problematic in humans due to 
inherent toxicity (Heikenwalder et al., 2004; Mutsch et al., 2004). However, the 
great success of these adjuvants in animal models has been a major driver for the 
development of non-toxic, yet immunogenic adjuvant derivatives that can be used 
safely in humans for the induction of both systemic and mucosal immunity. 
The CTA1-DD adjuvant is an example of such an agent, derived from the native CT 
holotoxin. The CTA1-DD adjuvant consists of the enzymatically active CTA1 
subunit of CT, genetically linked to a dimer of an Ig-binding domain (Agren et al., 
1997). Inclusion of the DD moiety targets immunogenic activity primarily to Ig-
expressing B cells (Eriksson et al., 2004; De Filette et al., 2006). The CTA1-DD 
adjuvant retains the adjuvanticity of CT, inducing robust cell-mediated and mucosal 
antibody responses (Sundling et al., 2008), but most importantly is up to 1000-fold 
less toxic in primates than the native holotoxin (Lycke, 2004; Sundling et al., 2008). 
In addition to the potential for clinical safety (Sundling et al., 2008), the success of 
CTA1-DD in enhancing mucosal immune responses to mucosal vaccines suggests 
that CTA1-DD may be an ideal adjuvant candidate for a human chlamydial vaccine 
(Akhiani et al., 2006; De Filette et al., 2006; Andersen et al., 2007; McNeal et al., 
2007; Sundling et al., 2008; Cunningham et al., 2009). 
The route a vaccine is administered influences the localisation of the immune 
response (respiratory and/or genital tract) via the CMIS. The immunisation route 
chosen can also effectively limit the toxicity of certain adjuvants, while still retaining 
their immunogenicity. Cholera toxin and CpG are excellent mucosal adjuvants, 
capable of manipulating innate responses for the induction of robust and long-lived 
IFNγ-secreting CD4+ T cells and mucosal IgA (Berry et al., 2004; Skelding et al., 
2006). Their inherent toxicity however, restricts their use in humans via particular 
routes. For example, the potent enterotoxin adjuvants delivered via the IN route can 
bind and accumulate in the CNS with harmful neurological affects and when 
delivered by the oral route cause diarrhoeal disease. Enterotoxins applied topically 
however, have been shown to induce a similar immune response to that observed 
following nasal delivery (Skelding et al., 2006) without the toxic side effects. Recent 
human clinical trials employing skin delivery of LT, elicited gastric anti-toxoid 
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responses, which resulted in reduced severity of travellers’ diarrhoea (McKenzie et 
al., 2007; Frech et al., 2008). Importantly, neither study reported any adverse events.  
Here we compared two adjuvants, CTA1-DD and the CT/CpG combination, together 
with the MOMP. Animals were vaccinated via needle-free IN, SL or TC 
immunisation routes, to induce mucosal responses and limit adjuvant toxicity. In this 
chapter, we measured the induction of antigen-specific systemic and mucosal 
immune T and B cell responses in the genital and respiratory tracts following 
vaccination.  
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MATERIALS AND METHODS 
Timeline 
 
Figure 4.1: Experimental timeline for assessment of systemic and mucosal immune 
responses.  
Mice were immunised on days 0, 7, 14 and 28 and culled 7 days after the final boost. 
Samples collected included the spleen, mediastinal lymph node (MdLN), medial iliac 
lymph node (MiLN), serum, bronchoalveolar lavage (BAL), uterine horn lavage (UHL) 
and vaginal lavage (VL). 
Vaccination toxicity 
The health of each animal was monitored daily following vaccination according to a 
strict set of criteria approved by the QUT Animal Ethics Committee. Animals were 
scored on criteria based on their overall appearance, i.e. weight, coat condition, 
movement and social interaction. Animals exhibiting multiple signs of distress were 
examined by a veterinarian and euthanised immediately. 
Sample collection 
The spleen, MdLN and MiLN (also known as the caudal and lumbar lymph nodes) 
(Hummel et al., 1986; Van den Broeck et al., 2006) were excised and pooled with 
their respective groups in complete DMEM. Blood was taken via cardiac puncture, 
allowed to clot at 4°C, after which the serum was collected by centrifugation. The 
BAL was collected by flushing the lungs once with 800µl of PBS. The VL was taken 
by flushing the vagina with 40µl of PBS collected once a day over the 4 day estrous 
cycle and then pooled for each animal. The UHL was collected by first excising the 
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tissue, then flushing each uterine horn with 100µl of PBS. Serum and lavage samples 
were stored at -80°C until required.  
In vitro stimulation and proliferation analysis 
The spleens and lymph nodes were mechanically disrupted by passing each tissue 
through a 75µm nylon filter (BD Bioscience). The single cell suspensions were then 
centrifuged at 500xg for 5 min. Each cell pellet was then resuspended in filter-
sterilised red blood cell lysis buffer containing 155mM NH4Cl, 12mM NaHCO3, 
100µM EDTA dissolved in ddH2O and adjusted to pH 7.35 for 5 min on ice. 
Following incubation the reaction was then stopped using two times the volume of 
complete DMEM. Cells were centrifuged again at 500xg for 5 min and washed a 
total of two times with Hank’s buffered salt solution (HBSS) (Invitrogen) and finally 
resuspended in complete DMEM containing 50µM β-mercaptoethanol (Sigma-
Aldrich). Lymphocytes from each tissue were diluted to 5 x 10
6
 cells/mL and 100µL 
of the cell suspension was seeded into a U-bottom 96-well plate (5 x 10
5
 cells/well) 
in triplicate. Lymphocytes were then supplemented with 100µL normal media 
(unstimulated) or stimulated with media containing either the MOMP (10µg/well) or 
concanavalin A (0.5µg/well) (data not shown) (Sigma-Aldrich) for 72 hr at 37°C 
with 5% CO2 in a humidified incubator. Following incubation 100µL of the media 
supplementing the stimulated cells was removed and stored at -80°C for analysis of 
antigen-specific cytokine production. Cells were then incubated with 0.5µCi 
3
H-
thymidine/well at 37°C with 5% CO2 in a humidified incubator over a 14 hr time 
period. Following incubation, cells were transferred to glass fibre filter paper 
(PerkinElmer, Massachusetts, USA) using Brandel 96 Harvester (Brandel, 
Gaithersburg, USA). The glass filter paper was dried and placed in a plastic sleeve 
before adding approximately 5mL of MicoBeta scintillation liquid (PerkinElmer). 
The filter paper was sealed in the plastic sleave and ionising radiation was detected 
using the Wallac 1450-030 MicroBeta TriLux Liquid Scintillation and Luminescence 
Counter (PerkinElmer). Cell proliferation was determined by the incorporation of 
3
H-
thymidine into newly synthesised DNA. Results were expressed as a stimulation 
index, dividing counts per minute (cpm) of the MOMP stimulated by the cpm of the 
media background. 
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Measurement of cytokine secretions 
Pooled supernatant from stimulated immune cell preparations were analysed for 
levels of IFNγ, IL-4, IL-10 and IL-17 using a customised BioPlex Mouse Express 
Pro Cytokine Assay 4-plex (Cat No. M60-009RDPD, Biorad Laboratories, Hercules, 
California) according to the manufacturer’s instructions and read on a Bioplex-200 
system with Luminex xMap® technology (Biorad). The levels of TNFα were also 
detected from the pooled supernatant using the DuoSet ELISA development system 
(Cat No. DY410, R&D systems – Sapphire Bioscience Pty Ltd, Waterloo, Australia) 
according the manufacturer’s instructions. Both methods used a standard curve to 
quantify cytokine concentrations. 
Antigen-specific antibodies 
Individual 96-well ELISA plates (Greiner Bio One, Kremsunster, Austria) were 
coated with recombinant MOMP. Plates were incubated overnight with 2µg/well of 
the MOMP in 50µL of borate buffered saline (BBS) containing 0.5M Boric acid, 
1.5M NaCl dissolved in ddH2O adjusted to pH 8.4. The following day plates were 
washed with PBST to remove any excess/unbound antigen and then incubated in a 
200µL blocking solution containing 5%v/v FCS, PBST for 2 hr at 37°C. Sera and 
lavage samples were serially diluted in PBST, leaving a final volume of 50µL and 
incubated at 37°C for 1 hr. Following incubation, plates were washed thoroughly 
with PBST and then incubated with a secondary antibody to detect Ig subclasses. 
Rabbit anti-mouse IgA and IgG antibodies (Southern Biotech), directly horseradish 
peroxidise (HRP)-linked, were diluted 1:1000 with blocking buffer and added to 
each well and incubated for 1 hr at 37°C. Rabbit anti-mouse IgG1 and IgG2a 
detection antibodies (Southern Biotech – In vitro Technologies Pty Ltd, Noble Park, 
Australia) were biotin-linked and required an additional streptavidin-HRP step for 
detection (Southern Biotech). Streptavidin-HRP, diluted 1:1000 in blocking buffer, 
was added to each well and incubated at 37°C for 1 hr. 50µL of 3,3,5,5-
tetramethylbenzidine (TMB) (HRP substrate) in a phosphate citrate buffer (PCB) 
(Sigma-Aldrich) was added to each well for 10 min. The colorimetric reaction 
between HRP and TMB was stopped by the addition of 50µL of 1M HCl. The OD 
was measured at 450nm on a xMark® microplate spectrophotometer (Biorad) and 
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endpoint titres were calculated for all samples using background absorbance of PBST 
plus two SD. Only groups receiving a MOMP-based vaccine induced antigen-
specific antibodies, whereas those in unimmunised and adjuvant only control groups 
did not (data not shown). 
In vitro neutralisation of C. muridarum infectivity 
Lavage and serum samples, diluted 1/10, were each incubated with 10
3
 IFU of 
purified C. muridarum in a 100µl volume for 1 hr at 37°C with 5% CO2. This 
suspension was then applied to a confluent McCoy monolayer and incubated for 3 hr. 
Following incubation the antibody/Chlamydia suspension was removed, the 
monolayer washed with PBS and replaced with media containing 1µg/ml of 
cycloheximide. Infection was stopped and stained as described in Chapter 3. 
Percentage neutralisation was determined using the equation % neutralisation = [% 
cells infected (immune sample) - % cells infected (pre-sample)] / % cells infected (no 
sample). 
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RESULTS 
Toxicity 
Adjuvant safety is an essential consideration for human vaccines. We therefore 
determined the percentage of animals surviving each immunisation strategy by 
considering the number of animals requiring euthanasia due to vaccine-related 
sickness. Animals immunised with CTA1-DD, given with or without the MOMP, 
had a 100% survival rate regardless of route of administration (Figure 4.2). 
Conversely, IN delivery of CT/CpG result in only a 78% and 95% survival rate when 
given with or without the antigen, respectively. However, no animals immunised 
with the CT/CpG-based vaccine by both SL and TC required euthanasia due to 
sickness. 
 
Figure 4.2: Percentage survival of mice following immunisation.  
The percentage survival refers to the percentage of mice remaining from a specific 
group, as some mice required euthanasia due to a deterioration of their health following 
immunisation. The overall condition of each animal was assessed daily following 
vaccination. Animals displaying multiple signs of distress were euthanised immediately. 
No animals needed to be euthanised beyond day 10 after the initial immunisation. 
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Antigen-specific proliferation and cytokine production following in vitro 
stimulation with the MOMP 
Antigen-experienced cells proliferate rapidly in response to an antigenic stimulus, 
due to decreased co-stimulatory requirements (Seder and Ahmed, 2003). We 
therefore examined antigen-specific proliferation, following in vitro re-stimulation 
with recombinant MOMP, to assess whether vaccination induced a MOMP-specific 
recall response. Cytokines produced during expansion following MOMP stimulation 
indicates how antigen-experienced cells will react when the MOMP is detected in 
vivo, following an infection. Specific cytokines can also determine the polarisation of 
the immune response (pro- or anti-inflammatory) and identify the cell types 
proliferating following stimulation, eg. T cells. As mentioned, protection against 
chlamydial infection is predominantly reliant on a pro-inflammatory cell-mediated 
response (Farris and Morrison, 2011), therefore generating T cells secreting 
cytokines like IFNγ is vital for an efficacious vaccine. We measured a number of 
cytokines predominantly produced by T cells (IFNγ, IL-4 and IL-17), in addition to 
other inducers and regulators of inflammation (TNFα and IL-10, respectively). 
Furthermore, proliferation and cytokine production by lymphocytes isolated from the 
spleen or the lymph nodes draining the genital and respiratory tracts were used to 
indicate the induction of a systemic or mucosal response, respectively.  
Spleen 
Intranasal immunisation with either vaccine (CTA1-DD or CT/CpG-containing) 
elicited a significant level of MOMP-specific proliferation by splenocytes when 
compared to the unimmunised control group (P<0.001) (Figure 4.3). Immunisation 
with the CT/CpG-based vaccine by the IN route induced a significantly greater 
amount of proliferation than the CTA1-DD-based vaccine, delivered via the same 
route (P<0.001). Antigen-specific proliferation was also significantly elevated in 
animals immunised with the CT/CpG-based vaccine by the SL (P<0.01) and TC 
routes (P<0.001) when compared to the unimmunised, but not when immunised with 
the CTA1-DD adjuvanted vaccine by the same routes. Levels of antigen-specific 
proliferation were highest following IN vaccination, indicating a greater potential of 
this route to induce a systemic response. Immunisation with the CT/CpG adjuvanted 
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vaccine consistently elicited a greater antigen-specific systemic recall response than 
CTA1-DD in the spleen, regardless of the route of immunisation.  
Figure 4.3: Antigen-specific proliferation by cells isolated from the spleen and 
stimulated in vitro with the MOMP. 
The spleens were excised from vaccinated animals, pooled and homogenised to create a 
single-cell suspension. Splenocytes were stimulated with the MOMP or media for 72 hr 
and then incubated with thymidine for an additional 14 hr. Cell proliferation was 
determined by incorporation of thymidine into newly synthesised DNA. The cpm value 
(ionising radiation) of the MOMP stimulated cells was divided by the cpm value 
obtained from the media stimulated cells to give a stimulation index. The stimulation 
indexes for each vaccine are grouped with their respective routes of immunisation, IN  
(    ), SL (    ) and TC (    ). Results are presented as the mean ± SD. Significant 
differences were determined using a one-way ANOVA with Tukey’s post-test. 
Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-
0.01 (**) and <0.001 (***). 
 
Splenic lymphocytes isolated from animals immunised via the IN route secreted the 
greatest quantity of cytokines following stimulation (Figure 4.4), which reflects the 
trends seen in proliferation (Figure 4.3). Immunisation with CT/CpG adjuvanted 
vaccines, by any route, resulted in significant cytokine secretions following in vitro 
stimulation with recombinant MOMP. The CTA1-DD adjuvanted vaccine effectively 
induced a cytokine response by splenocytes, when delivered via the IN and TC 
routes. Production of IFNγ was equal in animals receiving either IN delivered 
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vaccines, but this was significantly less in mice immunised topically with the 
CT/CpG-based vaccine (P<0.05). The cytokine IFNγ was not produced by stimulated 
splenocytes isolated from animals immunised with the CTA1-DD adjuvanted 
vaccine, delivered by routes other than IN. Significant levels of TNFα were also 
detected in all groups immunised with the CT/CpG-based vaccines regardless of 
route (P<0.001). Immunisation with the CTA1-DD-containing vaccine primed 
splenocytes to secrete a significant level of TNFα following re-stimulation, but only 
when the vaccine was delivered intranasally (P<0.001). Antigen-specific IL-17 
production was strongest in IN vaccinated animals and was equivalent between 
vaccines. With the exception of the SL delivered CTA1-DD containing vaccine, IL-
17 was also secreted by splenocytes isolated from all other vaccine groups, but at 
lower levels than IN immunised groups. Immunisation with the CTA1-DD 
adjuvanted vaccine via the TC route only induced a significant amount of IL-17 
(P<0.001). With the exception of the IN administered CT/CpG adjuvanted vaccines, 
no vaccine induced a significant amount of IL-10. The IL-4 cytokine was not 
detected in any vaccine group at levels above unimmunised controls. This indicates 
that antigen-specific splenocytes isolated from mice immunised with either vaccine 
showed a dominant pro-inflammatory phenotype (IFNγ, TNFα and IL-17), as 
opposed to an anti-inflammatory response (IL-4 and IL-10), following in vitro 
stimulation with the MOMP.  
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Figure 4.4: Antigen-specific cytokine production by cells isolated from the spleen and stimulated in vitro with the MOMP. 
The amount of TNFα, IFNγ, IL-4, IL-10 and IL-17 (pg/ml) produced by splenocytes following stimulation with the MOMP was quantified 
from the media supplementing the proliferating cells using Bioplex® and ELISA. Both vaccines are grouped with their respective routes of 
immunisation, IN, SL and TC. Results are presented as the mean ± SD. Significant differences were determined using a one-way ANOVA 
with Tukey’s post-test. Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
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MdLN – draining the respiratory tract 
Immunisation with the CT/CpG-based vaccine by the SL (P<0.01) and TC (P<0.001) 
routes, but not via the IN route, significantly increased antigen-specific proliferation 
by cells isolated from the MdLN following in vitro stimulation (Figure 4.5). The 
CTA1-DD-based vaccine administered topically generated a proliferative response in 
the MdLN significantly higher than control animals (P<0.05), but not when the 
vaccine was delivered via the IN or SL routes. CT/CpG delivered by SL (P<0.05) 
and TC (P<0.01) routes was however, significantly more effective than CTA1-DD at 
generating MOMP-specific recall in the MdLN. Levels of antigen-specific 
proliferation in the MdLN were greatest in animals receiving vaccines via SL and TC 
routes, highlighting the ability of these routes to prime and localise immunity in the 
lymph nodes draining the lungs.  
Figure 4.5: Antigen-specific proliferation by cells isolated from the MdLN and 
stimulated in vitro with the MOMP. 
The MdLN were excised from vaccinated animals, pooled and homogenised to create a 
single-cell suspension. Cells were stimulated with the MOMP or media for 72 hr and 
then incubated with thymidine for an additional 14 hr. Cell proliferation was determined 
by incorporation of thymidine into newly synthesised DNA. The cpm value (ionising 
radiation) of the MOMP stimulated cells was divided by the cpm value obtained from 
the media stimulated cells to give a stimulation index. The stimulation index for each 
vaccine are grouped with their respective routes of immunisation, IN (    ), SL (    ) and 
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TC (   ). Results are presented as the mean ± SD. Significant differences were 
determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P 
< 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 
(***). 
The vaccines that generated antigen-specific splenocytes, capable of proliferating 
and secreting cytokines upon stimulation, were quite different from those seen in the 
MdLN (Figure 4.6). Neither vaccine immunised intranasally elicited a significant 
cytokine response in the MdLN. Elevated cytokine levels were only detected in those 
groups previously shown to have significantly increased proliferation in the MdLN in 
response to the MOMP stimulation (Figure 4.5). This included both groups of 
animals immunised by the TC route and the group immunised with the CT/CpG-
based vaccine via the SL route. Lymphocytes isolated from these groups 
predominantly secreted IL-17 following stimulation. The cytokine IFNγ was only 
detected in groups immunised via the TC route, although significance was limited to 
the CT/CpG-based vaccine. Cytokines TNFα, IL-4 and IL-10 were not found to be 
significantly elevated in any group. This indicates that of the vaccines that generated 
a MOMP-specific response in the MdLN, all lymphocytes produced a dominant pro-
inflammatory response upon re-stimulation. 
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Figure 4.6: Antigen-specific cytokine production by cells isolated from the MdLN and stimulated in vitro with the MOMP. 
The amount of TNFα, IFNγ, IL-4, IL-10 and IL-17 (pg/ml) produced by lymphocytes isolated from the MdLN following stimulation with the 
MOMP was quantified from the media supplementing the proliferating cells using Bioplex® and ELISA. Both vaccines are grouped with 
their respective routes of immunisation, IN, SL and TC. Results are presented as the mean ± SD. Significant differences were determined 
using a one-way ANOVA with Tukey’s post-test. Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 
(**) and <0.001 (***). 
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MiLN – draining the reproductive tract 
Immunisation with the CT/CpG-based vaccine by the TC (P<0.001) and IN (P<0.01) 
routes, but not via the SL route, significantly increased antigen-specific proliferation 
by cells isolated from the MiLN following in vitro stimulation (Figure 4.7). The 
CTA1-DD-based vaccine administered by the SL (P<0.001) and TC (P<0.001) 
routes also generated a proliferative response in the MiLN significantly higher than 
controls, but not when the vaccine was delivered via the IN route. The greater 
potential of CT/CpG to generate antigen-specific proliferation compared to CTA1-
DD, seen previously in the spleen and MiLN, was not as obvious in the MiLN. The 
MOMP plus CTA1-DD was significantly more effective than the MOMP with 
CT/CpG when delivered by the SL route at generating MOMP-specific recall in the 
MiLN (P<0.05), although this difference was reversed following IN immunisation 
(P<0.01). Levels of antigen-specific lymphocyte proliferation in the MdLN were 
greatest in animals receiving vaccines via SL and TC routes, highlighting the ability 
of these routes to prime and localise immunity near the genital tract.  
Figure 4.7: Antigen-specific proliferation by cells isolated from the MiLN and 
stimulated in vitro with the MOMP. 
The MiLN were excised from vaccinated animals, pooled and homogenised to create a 
single-cell suspension. Cells were stimulated with the MOMP or media for 72 hr and 
then incubated with thymidine for an additional 14 hr. Cell proliferation was determined 
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by incorporation of thymidine into newly synthesised DNA. The cpm value (ionising 
radiation) of the MOMP stimulated cells was divided by the cpm value obtained from 
the media stimulated cells to give a stimulation index. The stimulation indexes for each 
vaccine are grouped with their respective routes of immunisation, IN (    ), SL (    ) and 
TC (   ). Results are presented as the mean ± SD. Significant differences were 
determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P 
< 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 
(***). 
The vaccines that induced antigen-specific proliferation and cytokine production by 
lymphocytes isolated from the MiLN, differed from the vaccines that induced these 
same responses in both the spleen and MdLN. Cytokines were significantly elevated 
in groups immunised exclusively with the CT/CpG-based vaccine (Figure 4.8). 
Animals immunised with the CTA1-DD-based vaccine failed to elicit a cytokine 
response in the MiLN, regardless of route. All CT/CpG adjuvanted vaccines induced 
significant levels of TNFα in response to the MOMP stimulation (P<0.001), but only 
SL and TC delivered vaccines elicited significant levels of IFNγ (P<0.001). 
Production of IL-17 was again the dominant cytokine detected in all groups, yet only 
the CT/CpG-based vaccine delivered via the SL route elicited IL-17 at significant 
levels (P<0.01). High background levels of IL-17 were also detected in all animals in 
the TC group in the MiLN, which also drains the site of immunisation. No vaccine 
elicited a significant induction of IL-10 or IL-4. Consistent with the spleen and 
MdLN, lymphocytes isolated from the MiLN of vaccinated animals preferentially 
elicited a pro-inflammatory response, dominated by IFNγ, TNFα and IL-17. 
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Figure 4.8: Antigen-specific cytokine production by cells isolated from the MiLN and stimulated in vitro with the MOMP. 
The amount of TNFα, IFNγ, IL-4, IL-10 and IL-17 (pg/ml) produced by lymphocytes isolated from the MdLN following stimulation with the 
MOMP was quantified from the media supplementing the proliferating cells using Bioplex® and ELISA. Both vaccines are grouped with 
their respective routes of immunisation, IN, SL and TC. Results are presented as the mean ± SD. Significant differences were determined 
using a one-way ANOVA with Tukey’s post-test. Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 
(**) and <0.001 (***). 
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Antigen-specific antibodies and Chlamydia-neutralising potential 
The presence of Chlamydia-specific antibodies can also offer protection against the 
establishment of infection and pathology (Murthy et al., 2004; Farris and Morrison, 
2011). Therefore, vaccination should also aim to elicit a Th2-driven antibody 
response in addition to Th1-driven cell-mediated immunity. We quantified the levels 
of MOMP-specific systemic and mucosal antibodies following vaccination. 
Preventing a Chlamydia infection by inhibiting attachment to the host cell is the 
primary reason for generating MOMP-specific antibodies. Therefore, we also 
assessed the ability of serum and mucosal secretions to neutralise a chlamydial 
infection in vitro. 
 Serum – systemic antibodies 
Serum IgG levels varied based on both adjuvant and immunisation route, but serum 
IgA production was unique to the IN route and independent of adjuvant (Figure 4.9). 
The CT/CpG containing vaccine elicited significantly greater MOMP-specific IgG 
levels in serum than CTA1-DD via all routes (P<0.05–0.001). Consistent with results 
seen previously (Cunningham et al., 2009), the addition of the CTA1-DD adjuvant to 
a MOMP-based vaccine did not boost antigen-specific antibodies when compared to 
the antigen alone control. Overall, the IN route appeared superior to SL and TC 
routes at inducing a systemic antibody response. Interestingly, there was no 
significant difference in IgG titres between CT/CpG-based vaccines delivered via the 
IN or TC route.  
The combination of adjuvants CT and CpG induced the desired balanced Th1/Th2 
response via all routes as shown by the IgG2a:IgG1 ratios of 1:1 (Figure 4.9). 
Similarly, CTA1-DD also elicited a balanced Th1/Th2 response via the IN and SL 
route (1:1), but a more Th2-dominant response by the TC (1:5) route. Immunisation 
with the antigen alone in the absence of a polarising adjuvant by the IN (1:2) and TC 
routes (1:50) elicit a Th2-dominant response, whereas the SL route a more balanced 
response (1:1).  
Although there were no significant differences between each vaccine delivered by 
the same route, both CTA1-DD and CT/CpG increased (between 10 – 50%) the 
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Chlamydia-neutralising capabilities of the serum when compared to the antigen only 
control (Figure 4.9). Despite the similarities in MOMP-specific antibody titres 
between the CTA1-DD-based vaccine and the antigen alone control, there was a 
significant increase in the neutralising capabilities in the serum of animals 
immunised with the CTA1-DD-containing vaccine (P<0.01–0.001). Moreover, there 
was a significant improvement in the neutralising potential of serum from animals 
immunised with the CT/CpG adjuvanted vaccine via the SL compared to TC route 
(P<0.01), despite the later group inducing significantly higher MOMP-specific IgG 
titres (P<0.01). The IN route was again the most effective when compared to SL and 
TC routes, for the induction of neutralising antibodies.  
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C. 
 
MOMP + CTA1-DD 
(%) 
MOMP + CT/CpG 
(%) 
MOMP  
(%) 
IN 80.48 ± 3.04 ** 85.26 ± 2.46 *** 60.44 ± 1.75 
SL 69.08 ± 4.16 *** 67.43 ± 7.51 *** 19.68 ± 8.14 
TC 42.54 ± 2.37 ** 40.26 ± 3.49 * 27.27 ± 3.86 
 
Figure 4.9: Antigen-specific systemic antibodies – serum.  
The induction of MOMP-specific serum (A) IgG, IgA, (B) IgG1 and IgG2a following 
vaccination was quantified by ELISA. Endpoint titres were calculated for all samples 
using background absorbance of PBST plus two SD. (B) The ratio of IgG2a:IgG1, used 
to determine Th1:Th2 polarisation, is indicated above the titre bars in each group. (C) 
Percentage of infection neutralised in vitro was determined by incubation of Chlamydia 
with a 1/10 dilution of whole serum before quantification. Results are presented as the 
mean ± SD. Significant differences were determined using a one-way ANOVA with 
Tukey’s post-test. Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 
0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
Bronchoalveolar lavage – mucosal antibodies in the respiratory tract 
In the respiratory tract secretions there were no significant differences in antibody 
titres (IgG or IgA) between CT/CpG- and CTA1-DD-based vaccinated animals, with 
the exception of animals immunised via the TC route (Figure 4.10). No IgA was 
detected following TC immunisation; however, the CT/CpG-based vaccine did elicit 
a mucosal IgG response by the same route. IgA and IgG production was detected in 
the mucosal secretions of animals immunised via the IN and SL route. The 
neutralising capacity of BAL was enhanced by both adjuvants compared to 
immunisation with the MOMP alone, however only in the BAL from animals 
immunised by the SL route was this significant (P<0.05–0.01). 
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A. 
 
B.  
 
MOMP + CTA1-DD 
(%) 
MOMP + CT/CpG 
(%) 
MOMP  
(%) 
IN 15.22 ± 10.10 7.05 ± 7.09 2.21 ± 9.34 
SL 29.31 ± 6.09 ** 25.49 ± 6.66 * 1.66 ± 6.63 
TC 5.44 ± 5.16 19.08 ± 10.73 4.70 ± 6.33 
 
Figure 4.10: Antigen-specific mucosal antibodies – BAL.  
(A) The induction of MOMP-specific IgG and IgA in the BAL following vaccination 
was quantified by ELISA. Endpoint titres were calculated for all samples using 
background absorbance of PBST plus two SD. (B) Percentage of infection neutralised in 
vitro was determined by incubation of Chlamydia with a 1/10 dilution of BAL before 
quantification. Results are presented as the mean ± SD. Significant differences were 
determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P 
< 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 
(***). 
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Vaginal and uterine horn lavages – mucosal antibodies in the reproductive 
tract 
With the exception of IgG in the TC immunised groups (P<0.05), there were no 
significant differences in antibody titres between vaccines detected in the lower 
reproductive tract (VL) (Figure 4.11). There were also no significant differences in 
IgA or IgG secretions between both vaccines by any route in the upper reproductive 
tract (UHL) (Figure 4.12). All animals immunised via the IN route consistently 
demonstrated MOMP-specific mucosal antibodies, whereas some animals in the SL 
and TC groups failed to respond, as indicated by the larger error bars. The TC 
immunised antigen only control group, also failed to elicit either antibody class in the 
uterine horn lavage. The MOMP-specific antibodies induced in the vaginal and 
uterine horn secretion following vaccination were not found to be significantly 
neutralising when compared to the antigen controls.  
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A. 
 
B. 
 
MOMP + CTA1-DD 
(%) 
MOMP + CT/CpG 
(%) 
MOMP  
(%) 
IN 26.93 ± 46.04 11.84 ± 26.97 -1.903 ± 63.67 
SL 23.45 ± 55.34 33.04 ± 54.55 -19.70 ± 34.80 
TC 28.69 ± 52.97 28.24 ± 51.07 24.67 ± 15.30 
 
Figure 4.11: Antigen-specific mucosal antibodies – VL. 
(A) The induction of MOMP-specific IgG and IgA in the VL following vaccination was 
quantified by ELISA. Endpoint titres were calculated for all samples using background 
absorbance of PBST plus two SD. (B) Percentage of infection neutralised in vitro (± SD) 
was determined by incubation of Chlamydia with a 1/10 dilution of VL before 
quantification. Results are presented as the mean ± SD. Significant differences were 
determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P 
< 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 
(***). 
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A. 
 
B.  
 
MOMP + CTA1-DD 
(%) 
MOMP + CT/CpG 
(%) 
MOMP  
(%) 
IN 16.01 ± 23.30 29.57 ± 17.17 39.04 ± 10.53 
SL 10.89 ± 34.42 22.24 ± 15.28 19.73 ± 41.94 
TC 13.82 ± 26.55 -46.10 ± 80.25 -24.17 ± 57.28 
 
Figure 4.12: Antigen-specific mucosal antibodies – UHL.  
(A) The induction of MOMP-specific IgG and IgA in the UHL following vaccination 
was quantified by ELISA. Endpoint titres were calculated for all samples using 
background absorbance of PBST plus two SD. (B) Percentage of infection neutralised in 
vitro (± SD) was determined by incubation of Chlamydia with a 1/10 dilution of UHL 
before quantification. Results are presented as the mean ± SD. Significant differences 
were determined using a one-way ANOVA with Tukey’s post-test. Significance was set 
at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 
(***). 
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DISCUSSION  
We immunised mice with the MOMP via three separate needle-free routes (IN, SL 
and TC) using two different adjuvants (CTA1-DD and CT/CpG) and compared 
antigen-specific cellular and humoral responses in both systemic and mucosal 
compartments. The CTA1-DD adjuvant delivered with or without the MOMP was 
found to be non-toxic in mice by all routes of immunisation. Conversely, CT/CpG 
administered alone or in conjunction with the MOMP was somewhat toxic by the IN 
route, but not via alternate routes (SL and TC). Following immunisation with both 
CTA1-DD- and CT/CpG-based vaccines, we could detect Chlamydia-neutralising 
antibodies in serum and mucosal secretions and MOMP-specific pro-inflammatory 
cells in the spleen and lymph nodes draining potential sites of infection. This is the 
desired balance between cell-mediated and humoral immunity identified in animal 
models to confer the greatest level of protection against the establishment of 
infection, transmission and pathology (Farris and Morrison, 2011). The route of 
immunisation affected the immunogenicity of each adjuvant, distribution of antigen-
specific cells throughout the different lymphoid tissues, antibody class switching and 
the induction of mucosal antibodies. The adjuvant predominantly affected the 
polarisation (Th1, Th2 or Th17) of the immune response and the neutralising 
potential of antigen-specific antibodies. 
The CT/CpG adjuvant was found to be toxic when delivered intranasally, an effect 
greatly exaggerated when administered together with the recombinant MOMP 
(Figure 4.2). The LPS contamination in the antigen preparation was reduced to a 
level below that is believed to be acceptable for mucosal immunisation (Eriksson et 
al., 2004). However, CpG has been reported to enhance the development of toxic 
shock syndrome even with subpathogenic doses of LPS (Sparwasser et al., 1997), 
which may have contributed to toxicity. The pathology reports (not shown) identified 
a significant influx of neutrophils and loss of epithelium integrity in the lungs and 
upper airways. This may suggest that trace amounts of the vaccine may have entered 
and caused inflammation in the lungs. Therefore, a probable cause of sickness in the 
mice that required euthanasia may have been a combination of toxic shock syndrome 
and pulmonary oedema, although this requires further investigation. 
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The route of immunisation influenced the effectiveness of each adjuvant; particularly 
CTA1-DD. Intranasal immunisation with each vaccine elicited a similar MOMP-
specific immune response. However, immunisation with the CT/CpG-based vaccine 
consistently elicited stronger antigen-specific T and B cell responses than the CTA1-
DD-containing vaccine, when both vaccines were administered by the SL or TC 
routes. This difference is likely linked closely with each adjuvant’s mechanism of 
action, the APCs targeted and their density/distribution at the site of immunisation. 
The TLR9 molecule is expressed by keratinocytes, LCs, pDCs, mDCs, 
macrophages/monocytes, mast cells and B cells in mice (Wagner, 2004), which elicit 
a Th1-polarised response upon activation with CpG (Roman et al., 1997; Jakob et al., 
1998). Cholera toxin binds all nucleated mammalian cells via the GM1-ganglioside 
receptor to enhance Th2 as well as Th1 responses (Sanchez and Holmgren, 2010). 
Together, both CpG and CT elicit the desired balance between Th1 cell-mediated and 
Th2-driven humoral immunity. The success of this adjuvant combination by all 
routes of administration can be attributed to its capacity to target and stimulate a 
number of innate cell populations localised at the site of immunisation, thus allowing 
for superior uptake/presentation of co-administered antigens and development of 
adaptive immunity.  
The CTA1-DD adjuvant is a non-toxic derivative of CT that retains many of the 
immunomodulatory properties of the holotoxin, i.e. Th1/Th2 polarising response, but 
differs greatly in target cell binding. The CTA1-DD adjuvant is thought to 
predominantly, but not exclusively, target B cells as APCs (Lycke, 2005). More 
recently, CTA1-DD has been shown to bind FDC in B cell follicles in a CR2-
dependent manner and enhance GC reactions and T cell-dependent responses by 
activation of the complement pathway (Mattsson et al., 2011). The immunogenicity 
of CTA1-DD, similar to CT, is highly dependent on binding and internalisation of 
the enzymatically active ADP-ribosyltranferase subunit for optimal adjuvanticity 
(Agren et al., 1999b). This may explain why CTA1-DD is immunogenic via the IN 
route, which targets the B cell and FDC rich NALT, but is less effective when 
administered via the TC and SL sites, routes that target tissues where these targets 
cells are not normally found in great numbers in a resting state (Bos, 2005; Mascarell 
et al., 2009). The immunogenicity of CTA1-DD has been enhanced by others 
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following immunisation via routes other than IN by (1) pre-incubating CTA1-DD 
with IgG to form immune complexes capable of degranulating mast cells (Fang et 
al., 2010) and through (2) the incorporation of CTA1-DD into the immune-
stimulating complexes (ISCOMs), thereby enhancing uptake by resident DCs 
(Helgeby et al., 2006). Our attempts to improve the immunogenicity of CTA1-DD by 
alternate routes (TC immunisation) using a B cell chemoattractant (CXCL13), failed 
to significantly improve antigen-specific responses from that of our standard GM-
CSF pre-treatment (Appendix 2). Therefore, CTA1-DD delivered via the IN route 
induced a similar Th1/Th2 balanced response to the CT/CpG adjuvant combination, 
without the toxicity associated with nasal delivery (Mutsch et al., 2004), but the 
immunogenicity of CTA1-DD appears reliant on delivery by the IN route, abundant 
in known target populations, B cells and FDCs.  
There was however some evidence to suggest that CTA1-DD was immunogenic via 
the TC route. Transcutaneous immunisation with the CTA1-DD-based vaccine 
generated a significantly higher amount of the T cell-related cytokine IL-17 (Figure 
4.4, 4.6) and MOMP-specific IgG2a antibodies (Figure 4.9) when compared to the 
antigen alone control. The same improvements in antigen-specific responses were 
not detected following SL immunisation with the same vaccine, which suggests that 
the method of TC immunisation in some way improved the immunogenicity of 
CTA1-DD. Physical differences exist between the buccal epithelium and the stratum 
corneum of the skin in regards to permeability (Sohi et al., 2009), although this 
should have favoured the induction of antigen-specific response following SL 
immunisation as opposed to topical delivery, contrasting to the effects found in our 
study. The skin and buccal mucosa also share considerable similarities in the variety 
and distribution of immune cells (Bos, 2005; Mascarell et al., 2009), therefore the 
site of immunisation is unlikely to account for the significant differences observed in 
effectiveness of CTA1-DD following immunisation by the SL and TC routes. The 
methods of TC immunisation differed from SL immunisation in three main ways. 
Trancutaneous immunisation included (1) an extended duration of contact to the 
vaccine, (2) the chemoattractant GM-CSF and (3) chemical permeation enhancers, 
all of which are known to influence the generation of antigen-specific responses 
(Hickey et al., 2005; Naito et al., 2007; Karande et al., 2009). Animals immunised 
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via the TC route were exposed to the vaccine for a period of 24 hours, compared to 
only one hour for SL immunised mice. Antigen-specific responses can be 
significantly enhanced simply by prolonging the presence of the antigen on the skin, 
even in the absence of an adjuvant (Naito et al., 2007). By extending the length of 
time the vaccine was in contact with the skin, this may have allowed more time for B 
cells to be recruited to the site of immunisation and interact with the adjuvant. The 
chemoattractant GM-CSF used prior to TC immunisation has also been shown to 
increase T and B cell responses, by as much as 16-fold (Hickey et al., 2005). This 
chemokines also recruits APCs (DCs and macrophages) that could have improved 
immunogenicity directly by rapidly internalising CTA1-DD (Agren et al., 1997) or 
indirectly through cytokine/chemokines secretions responsible for recruiting B cell 
targets (Hamilton and Anderson, 2004). The method of skin permeation used prior to 
TC but not SL immunisation, included a combination cationic surfactant, azone-like 
and fatty-acid esters, chosen primarily for their ability to disrupt the stratified 
epithelium, improve the critical passage of the vaccine into the epidermis (Karande et 
al., 2009) and facilitate the development of antigen-specific responses following TC 
immunisation  (Appendix 1). As the buccal mucosa is considerably more permeable 
than the skin (Sohi et al., 2009), SL immunisation does not require a prior pre-
treatment with permeation enhancers to elicit a robust antigen-specific response 
(Cuburu et al., 2007; Cuburu et al., 2009). The permeation enhancers used prior to 
TC immunisation however also increases the production of IL-1α (Karande et al., 
2009), a known stimulator of T cell differentiation particularly to Th2 cells as well as 
IL-17-secreting Th17 cells (Helmby and Grencis, 2004; Ben-Sasson et al., 2011). 
Large amounts of IL-17 could be detected in the MiLN draining the TC site of 
immunisation even in unimmunised animals receiving the pre-treatment only (Figure 
4.8), which provides evidence for the non-specific Th17 polarising effect of the 
permeation enhancer or the TC route. The IL-17 cytokine is known to play an 
important role in the recruitment of B cells (Wang et al., 2011a; Zhang et al., 2011), 
essential for the optimal effect of CTA1-DD (Helgeby et al., 2006). In addition, IL-
17 can also modulate DCs to polarise a Th1 response, responsible for promoting 
IgG2a production (Bai et al., 2009). Therefore, a synergistic relationship between the 
chemoattractant, the permeation enhancers and the even duration of vaccine 
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exposure, may have improved the immunogenicity of CTA1-DD by the TC route 
through the recruitment and stimulation of B cells.  
The route of immunisation also influenced the dissemination of antigen-specific 
responses to distant mucosal compartments, i.e. genital and respiratory tract, 
potentially via the CMIS. Despite other studies reporting that lymphocyte trafficking 
can be manipulated by specific vaccine constituents (Enioutina et al., 2009), our data 
suggests that antigen-specific cell homing was adjuvant-independent. Immunisation 
via the IN route induced a strong splenic antigen-specific response (Figure 4.3, 4.4). 
The SL and TC routes of immunisation on the other hand generated a systemic 
antigen-specific response, in addition to a more regional response in the lymph nodes 
draining the respiratory and reproductive mucosa (Figure 4.5 – 4.8). As a pathogen 
that infects through mucosal epithelium will usually be processed and presented by 
APCs to lymphocytes in the regional lymph nodes before reaching systemic sites like 
the spleen (Zhao et al., 2003), antigen-specific cells residing in the draining lymph 
nodes may be better positioned to react and elicit an immune response earlier during 
the course of the infection. Recruitment of lymphocytes into lymph nodes is 
mediated by the pattern of addressins and chemokines expressed by the high 
endothelial venules (HEV), which are the main site of lymphocyte entry from the 
blood. Lymphocytes require specific selectins, integrins and chemokines receptors 
complementary to the unique signature of ligands expressed by the HEV to initiate 
rolling, activation, attachment and eventual transmigration into a particular lymph 
node (von Andrian and Mempel, 2003). Generally, entry of lymphocytes into the 
lymph nodes is considered to be CCR7- and L-selectin (CD62L)-dependent. T cells 
isolated from CCR7-deficient mice and adoptively transferred of into WT animals 
accumulate in the spleen, but not the lymph nodes (Forster et al., 1999). Similarly, 
CD62L
-/-
 mice also have a significant reduction in the numbers of lymphocytes in 
present in the peripheral lymph nodes (Arbones et al., 1994). Neutralisation of 
CD62L dramatically reduces the quantity of T cells in the MiLN draining the 
reproductive tract, but not their accumulation in the spleen or MdLN (Ciabattini et 
al., 2011). The α- and β-chains of the integrins can also influence lymphocyte 
migration (Berlin et al., 1995; Steeber et al., 1998), mediating selectin-independent 
capture from blood. The proportion of T cells expressing integrin α4β7 and αEβ7 is 
 106 
 
also elevated in the MiLN compared to other secondary lymphoid tissues (Gupta et 
al., 2005; Martinelli et al., 2011), suggesting that these integrins are required to enter 
the lymph nodes draining the genital tract. The homing phenotypes of T cells isolated 
from the spleen and the MdLN draining the lungs are remarkably similar, both of 
which appear dependent on expression of α4β1 (Ferguson and Engelhard, 2010). 
However, neutralisation of α4β7 affects the entry of lymphocytes into the spleen but 
not the MdLN (Ciabattini et al., 2011). Therefore the passage of lymphocytes into 
the MiLN (CCR7
+
, CD62L
+, α4β7
+, αEβ7
+
), the MdLN (CCR7
+
, CD62L
-, α4β7
-, α4β1
+
) 
and the spleen (CCR7
-
, CD62L
-, α4β7
+, α4β1
+
) each require a unique pattern of 
homing receptors. The route of immunisation has a significant impact on the 
expression of the various adhesion molecules and chemokines receptors by antigen-
specific lymphocytes (Quiding-Jarbrink et al., 1995; Kantele et al., 1997; Quiding-
Jarbrink et al., 1997; Song et al., 2009) (discussed further below). These 
modifications not only influence the localisation of the activated cells in secondary 
lymphoid tissues, but also their ability to be recruited to mucosal surfaces at times of 
inflammation and infection to elicit protection (Kelly and Rank, 1997; Perry et al., 
1998; Feng et al., 2000; Kelly et al., 2000; Kelly et al., 2001; Kelly et al., 2009). 
Therefore, both the SL and TC routes of immunisation appear to prime and position 
antigen-specific cells in key lymph nodes where chlamydial antigens will likely be 
presented first during an active infection.  
In addition to influencing the distribution of antigen-specific cells, the route of 
immunisation also effected antibody class switching and the induction of mucosal 
antibodies. All vaccines elicited MOMP-specific IgG in serum and the levels of IgG 
in the mucosal lavages (Figure 4.10 – 4.12) mirrored trends seen in the serum (Figure 
4.9), signifying that transudation from the blood was the likely source of mucosal 
IgG (Lencer and Blumberg, 2005; Mestecky et al., 2005). However, the quantity of 
IgG in both the genital and respiratory tract lavages was similar across all groups, 
despite significant differences in their serum IgG levels. Perfusion of IgG at the 
mucosal surface appears to be limited in mice and has been reported to be a fraction 
of what is transported in humans (Wu et al., 2000; Mestecky et al., 2004; Li et al., 
2011b).  
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All immunisation routes elicited a mucosal IgA response, however only the IN route 
was capable of inducing systemic IgA (Figure 4.9). The NALT, targeted during IN 
immunisation, is abundant in GCs located beneath specialised antigen-processing M 
cells (Zuercher et al., 2002). In general, T cell-dependent IgA B cell differentiation 
occurs most effectively in GCs (Cerutti, 2008), which stimulate the expression of the 
DNA-editing enzyme activation-induced cytidine deaminase (AID) in B cells 
responsible for antibody gene diversification, i.e. affinity maturation (somatic 
hypermutaton (SHM)) and CSR. Both the skin and buccal mucosa lack the organised 
lymphoid tissues similar to the NALT, thus fail to generate systemic IgA effectively 
(Kaspsenberg and Bos, 1998; Mascarell et al., 2009). The induction of serum IgA by 
SL and TC delivered vaccines has however been reported by others using similar 
adjuvants (Maeba et al., 2005; Cuburu et al., 2007; Cuburu et al., 2009; Hervouet et 
al., 2010). The antigen, specifically the size of the antigen, appears to be an 
important factor in these studies allowing the induction of systemic IgA. Ovalbumin, 
gp41 and the Porphyromonas gingivalis outer membrane protein together with CT all 
successfully generated serum IgA, albeit low levels, following SL or TC 
immunisation. These antigens range in size from 40 – 45kDa, while recombinant 
MOMP is almost double the size at 81kDa. Transcutaneous immunisation with 
bovine serum albumin (BSA) (67kDa) and recombinant MOMP have shown a 
similar lack of antigen-specific serum IgA, despite utilising epithelial cell 
permeabilising adjuvants (John et al., 2002; Berry et al., 2004; Skelding et al., 2006; 
Rollenhagen et al., 2009), Therefore, the inability of SL and TC applied vaccines to 
induce an antigen-specific serum IgA response, may reflect the capacity of the 
antigen to enter the epithelium, migrate to the draining lymph nodes and interact with 
GCs (Sabirov and Metzger, 2008).  
The size of the antigen appeared to be a disadvantage for the induction of systemic 
IgA, although genetically linking the MOMP with MBP improves the solubility and 
correct conformational folding of the recombinant protein (Su et al., 1996; Fox et al., 
2001), vital for production of neutralising antibodies (Sun et al., 2009). Moreover, 
MBP also acts as an adjuvant (Kushwaha et al., 2001; Simmons et al., 2001a; 
Simmons et al., 2001b; Fernandez et al., 2007; Yuzawa et al., 2012). Proteins fused 
with MBP generate significantly more serum antibodies than untagged proteins 
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(Simmons et al., 2001a; Simmons et al., 2001b; Yuzawa et al., 2012), as MBP is a 
TLR4 agonist that stimulates cytokine production and expression of co-stimulatory 
molecules on DCs (Fernandez et al., 2007). This provides an explanation for why 
needle-free immunisation with recombinant MOMP, in the absence of an adjuvant, 
stimulates a strong antigen-specific response as opposed to mucosal tolerance 
(Figure 4.9) (Czerkinsky et al., 1999; Fujihashi and McGhee, 2004). 
Mucosal antigen-specific IgA was detected in the lung secretions of SL immunised 
animals, in the absence of serum IgA (Figure 4.9, 4.10). Similarly, IgA was also 
detected in both upper and lower genital tract secretions following immunisation via 
SL and TC routes (Figure 4.11, 4.12), again despite the lack of any serum IgA. The 
majority of IgA detected in mucosal secretions is produced locally by plasma cells 
rather than by active transport from the serum (at least in the gastrointestinal tract) 
(Jonard et al., 1984), which implicates a mucosal homing phenotype imprinted on B 
cells by each route of immunisation. The dissemination of antigen-specific responses 
initiated in the SL mucosa to distant mucosal compartments is hypothesised to be 
dependent on CCR7
+
CD11c
+
 DCs. This subset primes T and B cells to migrate 
towards the chemokine CCL28, expressed by epithelial cells at numerous sites in the 
body including the genital and respiratory tract mucosa (Song et al., 2009; 
Czerkinsky and Holmgren, 2010a). Similarly, DCs process Vitamin D3 in the skin to 
its active form 1,25(OH)2D3, which activates CCR10 expression and hence attraction 
of primed lymphocytes to the epidermal produced chemokine CCL27 
(Sigmundsdottir et al., 2007). The chemokines receptor CCR10 is promiscuous in 
nature and can also respond to CCL28 (Wang et al., 2000; Homey et al., 2002), the 
same chemokines driving migration of lymphocytes activated following SL 
immunisation. This may explain why antigen-specific responses are similar between 
animals immunised by SL and TC routes, due to the equal dependence on the CCR10 
and CCL27/CCL28 pathway for migration. Intranasal vaccination induced IgA in all 
mucosal secretions tested. We cannot however definitively determine the source of 
the mucosal antibodies, i.e. whether IgA transfused from the serum into the lumen or 
if it was locally produced. Antigen-specific antibody-secreting cells can localise in 
genital tract and lung tissues following IN immunisation (Berry et al., 2004; 
Skelding et al., 2006). Increased expression of the mucosal homing integrin α4β7 on 
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antibody-secreting cells has been documented following IN immunisation (Quiding-
Jarbrink et al., 1997), although homing to the genital at least appears to be β7-
independent (Goodsell et al., 2008). Immunoglobulian A-secreting plasma cells 
generated following IN immunisation have also been found to express CCR10 and 
migrate towards CCL28 (Cha et al., 2011). Therefore, all vaccines were able to 
induce the production of mucosal IgA, potentially by stimulating similar pathways of 
B cell recruitment to mucosal tissues. 
The consistent mucosal IgA production by all animals generally favoured vaccines 
containing the CT/CpG adjuvant and those delivered by the IN route (Figure 4.10 – 
4.12). B cell differentiation into IgA-secreting cells at the systemic level is largely 
believed to be dependent on the formation of GCs, whereas mucosal IgA production 
is governed by a different mechanism (Schubart et al., 1996; Kosco-Vilbois et al., 
1997; Tarlinton, 1998; Gardby et al., 2003). Mucosal IgA can be generated in the 
absence of NALT, GC formation and various other cytokines and co-stimulatory 
molecules required for producing systemic antibodies (Vajdy et al., 1995; Neumann 
et al., 1996; Gardby et al., 2003; Sabirov and Metzger, 2008). Expression of AID, 
responsible for SMH and CSR, is absolutely essential for production of both serum 
and mucosal IgA (Wei et al., 2011). Signals that induce AID-mediated CSR include 
BCR ligation, NF-κB induction signals (CD40 or TLRs), transcription factors and 
cytokines that promote B cell differentiation and/or B cell survival (Bemark et al., 
2012). Attenuation of mucosal and systemic antibodies has also been reported in 
CD80, CD86 and CD80/CD86 double-deficient mice (Garcia et al., 2004), 
highlighting the importance of providing adequate co-stimulation to B cells for 
production of mucosal IgA. As mentioned above, CTA1-DD appeared less 
immunogenic following topical or SL delivery. Therefore, an ability activate of AID 
and mature B cells may offer an additional reason why the CTA1-DD containing 
vaccine delivered by routes other than IN were unable to consistently generate IgA in 
all animals and mucosal secretions.  
In addition to the actual presence or absence of antibodies, as determined by ELISA, 
adjuvant choice and route of delivery also affected antibody function. We addressed 
this by comparing the capacity of serum and mucosal antibodies to neutralise a 
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chlamydial infection in vitro (Figure 4.9 – 4.12). The ability of an antibody to 
neutralise is thought to be dependent on the quantity, affinity and avidity of the 
antibodies (Steward et al., 1991; Chargelegue et al., 1995; Olszewska et al., 2000). 
Antibody affinity is defined by the strength of a single antibody bond determined by 
a dissociation coefficient, which is enhanced during affinity maturation by the rate of 
SHM (Wabl et al., 1999). Antibody avidity is the combined strength of multiple 
bonds and this is predominantly influenced by the isotype of the antibody and the 
number of binding sites the antibody possess (IgG = 2 and IgA = 4). Serum from IN 
vaccinated animals possessed a far superior Chlamydia neutralising capability than 
SL and TC immunised groups. The presence of IgA in the serum of IN immunised 
groups may account for this increase in neutralising capacity, through induction of 
more avid antibodies (Peterson et al., 1993; Pal et al., 1997b). Moreover, MOMP-
specific IgA is thought to reduce infectivity by preventing chlamydial attachment to 
the host cell (Cunningham et al., 2008). This function is unaffected by the 
restrictions of in vitro culture, as neutralisation only requires the presence of 
antibodies to prevent attachment. Alternatively, serum from SL and TC vaccinated 
animals, which contained only IgG, failed to neutralise Chlamydia in vitro as 
effectively as the serum from IN immunised mice. This is because MOMP-specific 
IgG-dependent protection against Chlamydia occurs through opsonisation and 
phagocytosis (absent from the in vitro neutralisation assay) and not via direct 
inhibition of attachment or complement activation (Caldwell and Perry, 1982; Moore 
et al., 2002). Therefore, IgA is more capable of neutralising Chlamydia, at least in 
vitro. 
Interestingly, in some instances there was no direct correlation between MOMP-
specific antibody titres and neutralisation. The CT/CpG-based vaccine delivered by 
the TC routes generated a significantly greater systemic IgG response than the same 
vaccine delivered by the SL route (Figure 4.9). Serum from the SL vaccinated groups 
however, exhibited higher neutralisation of infection in vitro. The reason for this is 
unknown, but could reflect the more permeable nature of the buccal mucosa (Sohi et 
al., 2009), facilitating better antigen uptake, APC maturation, SHM and resulted 
higher affinity antibodies.  
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Intranasal immunisation with the CTA1-DD-based vaccine elicited an equivalent 
serum MOMP-specific antibody response to the antigen alone group immunised by 
the same route as determined by ELISA, yet neutralisation favoured the CTA1-DD 
adjuvanted vaccine (Figure 4.9). This has been reported previously and was 
suggested to be the result of direct interaction between the adjuvant and B cells 
(Cunningham et al., 2009). The CTA1-DD adjuvant is known to up-regulate 
expression of CD86 and CD80 on B cells responsible for generating GCs and long-
term affinity matured memory B cells (Agren et al., 1997; Agren et al., 1999b; 
Bemark et al., 2011). Therefore, the route of immunisation used influenced 
neutralisation, so too did the adjuvant. 
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CONCLUSIONS 
The aim of this chapter was to characterise and compare the systemic and mucosal 
immune responses in the genital and respiratory tracts following immunisation with 
the MOMP plus CTA1-DD or CT/CpG via TC, IN and SL routes. The CT/CpG 
adjuvant can be used safely via routes other than IN to effectively elicit a robust cell-
mediated and humoral immune response. The CTA1-DD adjuvant is safe by all 
routes, but most immunogenic following IN delivery. The immune responses induce 
following immunisation with either vaccine were comparable after IN 
administration, but the greater induction of antigen-specific responses favoured the 
CT/CpG adjuvanted vaccine via the alternate SL and TC routes. The route of 
immunisation predominantly determined the distribution of T and B cells to different 
effector sites, potentially via the common mucosal immune system, whereas the 
adjuvant influenced the quality and quantity of antigen-specific cellular and humoral 
responses. However, the efficacy of each vaccine can only be truly measured 
following a live challenge with Chlamydia. 
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INTRODUCTION 
C. pneumoniae is a respiratory tract pathogen transmitted from person to person in 
water droplets propelled by coughing or sneezing. Serological evidence suggests that 
virtually everyone will be infected with C. pneumoniae at one point in their lifetime 
(Grayston, 2000). C. pneumoniae infections are primarily asymptomatic, but in 30% 
of cases, can develop into a severe respiratory tract illness like pneumonia, of which 
C. pneumoniae is the third most common cause (Kuo et al., 1995; Grayston, 2000). 
Persistent infections can exacerbate chronic inflammatory diseases like asthma, 
COPD, CVD, Alzheimer’s disease, MS and reactive arthritis (Kuo et al., 1993; 
Clementsen et al., 2002; Belland et al., 2004; Bachmaier and Penninger, 2005; Blasi 
et al., 2009). As 75% of first infections occur in early life, this highlights the need for 
early intervention through vaccination to prevent infection and exacerbation of 
chronic inflammatory diseases (Aldous et al., 1992; Miyashita, 2006).  
Development of an effective human vaccine relies on successful vaccine trials in 
animal models that replicate human infection. The C. muridarum mouse model of 
infection replicates many aspects of human infection and disease (Fan et al., 1999; 
Horvat et al., 2007; Rey-Ladino et al., 2007; Jupelli et al., 2008; Kaiko et al., 2008; 
Horvat et al., 2010). Mice can be infected with C. muridarum by inhalation, the 
natural route of infection in humans (Ramsey et al., 2009). Infected animals undergo 
a stage of dramatic weight loss known as cachexia, which is an indicator of chronic 
inflammation and development of pneumonia (van Heeckeren et al., 2000). C. 
muridarum can also induce intense thickening and fibrotic scarring of the airways 
associated with COPD, allergic sensitisation and exacerbation of asthma, by 
manipulating Th2-related cytokine production (Horvat et al., 2007; Kaiko et al., 
2008; Horvat et al., 2010). Similar to a C. pneumoniae infection in humans, C. 
muridarum can also disseminate throughout the mouse following an IN infection 
(Jupelli et al., 2008), potentially by using monocytes as a shuttle system (Rey-Ladino 
et al., 2007). C. muridarum is also able to colonise and inflame cardiac tissue 
following IN infection, a contributory risk factor in the development of CVD (Fan et 
al., 1999). Murine models of autoimmune diseases like Alzheimer’s, MS and 
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reactive arthritis have also been established (Hough and Rank, 1988; Rank et al., 
1988b; Du et al., 2002; Little et al., 2004).  
The ideal animal model for predicting a vaccines efficacy will also reflect the human 
necessity for different immune populations for protection. Humans and mice 
generate Chlamydia-specific T and B cells following a pulmonary infection. 
Antibodies in human sera from the first infection wane over 3 – 5 years (Patnode et 
al., 1990), which may explain the high re-infection rates. Similarly, the presence of 
antibodies confer resistance against a C. muridarum respiratory tract infection in 
mice (Yang and Brunham, 1998). Memory CD4
+
 Th cells secreting IFNγ can be 
detected in PBMC following a natural infection in humans (Benagiano et al., 2003; 
Benagiano et al., 2005; Carralot et al., 2005; Bunk et al., 2010) and these are the 
dominant lymphocytes driving immunity against a respiratory tract infection in the 
mouse model (Penttila et al., 1998; Penttila et al., 1999; Rothfuchs et al., 2004; 
Kadkhoda et al., 2010; Zhang et al., 2010). Therefore, the mouse model accurately 
replicates the many diseases associated with a C. pneumoniae infection in humans 
and shares a similar dependence on the different arms of the adaptive immune 
response as required in humans to eradicate an infection and prevent pathology. 
Protection against a chlamydial pulmonary infection requires both a Th1 cell-
mediated and Th2-driven antibody response, therefore many experimental vaccines 
have adopted the use of Th1 and Th2 polarising adjuvant combinations (Skelding et 
al., 2006; Cheng et al., 2009; Sun et al., 2009; Ralli-Jain et al., 2011). Intramuscular 
and SC immunisation with the MOMP and CpG-1826/Montanide ISA 720, CpG-
1826/Alum or CpG-CTB, Th1 and Th2 polarising adjuvants respectively, produced a 
high level of systemic Chlamydia-specific antibodies and IFNγ-secreting T cells (Pal 
et al., 2005; Cheng et al., 2009; Sun et al., 2009; Ralli-Jain et al., 2010). This 
response confers a considerable amount of protection against cachexia and the 
amount of recoverable Chlamydia from the lung homogenates following an IN 
infection (Skelding et al., 2006; Cheng et al., 2009; Sun et al., 2009; Ralli-Jain et al., 
2010). Despite being delivered parenterally (IM and SC), these vaccines were able to 
convey a substantial amount of protection against a mucosal pathogen because 
protective immunity in the lungs requires a systemic as well as a mucosal immune 
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response (Cheng et al., 2009; Sun et al., 2009; Ralli-Jain et al., 2010). However, the 
inclusion of a mucosal route of immunisation has been shown to improve 
effectiveness of systemically delivered vaccines (Ralli-Jain et al., 2010). Animals 
immunised with the MOMP and CpG-1826/Montanide ISA 720 via the IM, SC and 
SL routes produced greater Chlamydia-specific antibodies and IFNγ-secreting T cells 
than immunisation via systemic routes alone, which lead to less weight loss and 
lower amounts of recoverable Chlamydia following an IN infection (Ralli-Jain et al., 
2010). This highlights the importance of generating a mucosal response in addition to 
a systemic response for optimal protection against a chlamydial respiratory tract 
infection. Intranasal immunisation with the MOMP together with the Th1/Th2 
polarising adjuvant CT/CpG, elicits the required systemic response with the added 
feature of mucosal antibodies and IFNγ-expressing T cells in the lymph nodes 
draining the lungs (Skelding et al., 2006), a trait not previously reported following 
systemic immunisation alone (Pal et al., 2002; Cheng et al., 2009; Ralli-Jain et al., 
2010). These animals were not only significantly protected against cachexia, but had 
almost no recoverable Chlamydia at the usual peak of infection (Skelding et al., 
2006). A similar response was also achieved using the same vaccine administered via 
the TC route (Skelding et al., 2006), which largely eliminates the potential for 
adjuvant toxicity (Mutsch et al., 2004). However, the use of the IN route for 
protection against air-borne pathogens is highly desirable due to a strong ability to 
induce immunity in the lungs (Brandtzaeg, 2009), therefore the demand for safe yet 
effective adjuvants that can be delivered the IN route is greater than ever. 
The CTA1-DD adjuvant has proven safe in primate models via the IN route 
(Sundling et al., 2008), as it does not accumulate in the CNS (Eriksson et al., 2004). 
Combined with the highly conserved influenza antigen M2e-HBc and administered 
intranasally, CTA1-DD provided complete protection against lethal influenza 
challenge and significantly reduced morbidity in mice (De Filette et al., 2006). 
Animals immunised IN with the chlamydial MOMP, adjuvanted with CTA1-DD, 
induce strong systemic and mucosal Chlamydia-neutralising antibodies (Cunningham 
et al., 2009). However, the ability of CTA1-DD to confer protection against a 
respiratory tract infection and the associated disease is yet to be investigated. 
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In the previous chapter we quantified and compared the systemic and mucosal 
immune responses of two vaccines delivered by multiple routes. Here we assessed 
the ability of each vaccination strategy to induce protection against a live C. 
muridarum pulmonary infection. Protection was determined by the ability of each 
vaccination strategy to prevent infection and pathological damage.  
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MATERIALS AND METHODS 
Timeline 
Figure 5.1: Experimental timeline for assessment of protection against a 
respiratory tract infection and pathology.  
Mice were immunised on days 0, 7, 14 and 28 and infected intranasally 7 days after the 
final boost. Mice were weighed daily until sacrifice on day 45, 10 days post-infection 
(p.i). Lungs were collected for assessment of bacterial burden and disease. 
Intranasal C. muridarum challenge and monitoring 
Intranasal challenge was conducted as previously described (Skelding et al., 2006). 
Briefly, 7 days after the final boost, animals were challenged intranasally with 10
3
 
IFU of purified C. muridarum in a 10µL volume, 5µL applied to each nare (Skelding 
et al., 2006; Jupelli et al., 2008; Ramsey et al., 2009), as described for IN 
immunisation in the Chapter 3. Uninfected animals (no infection control) in addition 
to those recovering from a primary C. muridarum respiratory infection (live infection 
control), strongly resistant to re-infection, were also included as controls. All animals 
were weighed daily to monitor chronic inflammation and development of pneumonia 
indirectly through cachexia (Yang et al., 1996). Percentage weight change was 
calculated by using the equation % weight change = [(body weight post-infection – 
body weight pre-infection) ÷ body weight pre-infection] × 100. All animals were 
euthanised on day 10 p.i at the peak of infectious burden and pathology for 
assessment of vaccine efficacy (Horvat et al., 2010). 
Quantification of chlamydial burden in the respiratory tract tissues  
Quantification of recoverable amount of Chlamydia from lung homogenates was 
performed as previously described (Skelding et al., 2006). The lungs from each 
mouse were excised and homogenised in 320µl of SPG using the OMNI TH tissue 
0 7 14 28 35 45
Sacrifice • Lungs
Weigh
Days
Immunisation
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homogeniser with the 7mm saw-toothed stainless steel attachment (OMNI 
International, Kennesaw USA). Total genomic DNA was extracted using the Wizard 
Genomic DNA Purification Kit (Cat No A1120, Promega, Alexandria, Australia) 
according to the manufacturer’s instructions. Briefly, 50µL of tissue homogenate was 
digested overnight using proteinase K (Promega). DNA was then bound to a silica 
gel membrane, washed and finally eluted in nuclease-free water. DNA purify was 
assessed by the 260/280nm ratio using the ND-1000 nanodrop spectrophotometer 
(ThermoScientific, Wilmington, USA). Samples were stored at -80°C until required. 
Quantitative real-time PCR (qRT-PCR) was used to determine C. muridarum DNA 
levels from total mouse lung genomic DNA using a standard curve of the PCR 
product. The primer sequence used in the qRT-PCR amplified the outer membrane 
protein A (ompA) gene encoding the MOMP of C. muridarum is as follows: 5′-GCC 
GTT TTG GGT TCT GCT T-3′ and 5′-CGA GAC GTA GGC TGA TGG C-3′ 
(Sigma-Aldrich). Each reaction contained a final concentration of 1µM of 
forward/reverse primers, 200µM dNTP’s, 1.5mM MgCl2, 1X buffer, 0.15X SYBR 
green, and 5U of Platinum Taq polymerase (Invitrogen) made up to a final 20µL 
volume using sterile endonuclease-free water. Cycling conditions began with a 
standard 95°C for 20 sec, followed by a 64°C annealing for 20 sec and a 72°C 
extension for 15 sec repeated for a total of 30 cycles. qRT-PCR was performed using 
the Corbet Rotorgene Q (QIAGEN Pty Ltd, Chadstone centre, Australia). 
Histopathology scoring 
The lungs from each mouse were excised and preserved by fixing in 70%v/v ethanol. 
Tissues were then imbedded in paraffin, sectioned (5µm) and stained with Masson’s 
trichrome (QML Diagnostics, Murarrie, Australia). Five random FOV of each 
section for each mouse were scored, by three individuals in a blinded fashion, based 
on fibrotic scaring of the lung tissue (Table 1.1). The final results were the average of 
all scores.  
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Table 5.1: Histopathological scoring system for mouse lungs 
Category Score Description Inflammation 
Fibrosis 
0 Lack of fibrosis around tissue Absent 
1 Some fibrosis around tissue Mild 
2 
Some tissue has significant fibrosis 
Moderate 
Majority of tissue has some fibrosis 
3 
The majority of tissue has significant 
fibrosis 
Severe 
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RESULTS 
The effectiveness of each vaccine to protect against infection following live C. 
muridarum IN challenge 
Cachexia 
Cachexia is defined as a state of malnutrition, anorexia and muscle wasting (Emery, 
1999). This type of weight loss is a commonly used marker of chronic inflammation 
and lung disease as it associates with increased concentrations of TNFα, IL-1β and 
neutrophil-attracting chemokines KC (CXCL1) and MIP-2 (CXCL2) in the BAL 
(van Heeckeren et al., 2000). As live Chlamydia induce increased production of 
these cytokines and chemokines during an infection in a dose-dependent manner 
(Zaharik et al., 2007; Zhang et al., 2009; Zhou et al., 2009; Rank et al., 2010), 
cachexia can be used to monitor the development and clearance of pneumonia. 
Following an infection, unimmunised animals developed severe cachexia. The 
percentage weight loss of these naive animals peaked on day 9 p.i at approximately 7% 
(Figure 5.2). The live infection control animals, after recovering from a primary 
infection, were strongly protected against weight loss and hence re-infection. This group 
began regaining weight by day 4 p.i, significantly faster than the naive unimmunised 
animals at day 10 p.i  (P <0.001). This signifies that the pneumonia that developed in the 
live infection control was relatively mild compared to that in the naive unimmunised 
animals. The weights of the no infection control animals fluctuated initially after the 
mock infection and then steadily increased from day 5. The no infection control group 
had a net positive weight gain over the 10 day time period, which was significant 
compared to infected control animals (P <0.001), indicating that cachexia was absent in 
uninfected animals. Immunisation with the CT/CpG-based vaccine significantly 
protected animals from weight loss regardless of the immunisation route (P <0.05 – 
0.01) (Figure 5.2). The immunity elicited by the CT/CpG adjuvanted vaccine was 
comparable to that of the live infection control group. The route of immunisation 
influenced the protection elicited by the CTA1-DD-containing vaccine. Only IN 
delivery of the CTA1-DD-containing vaccine significantly prevented weight loss (P 
<0.05) when compared to the unimmunised control. The protection against pneumonia 
conferred by this vaccine was however equivalent to the strongly resistant live infection 
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control group. Neither SL nor TC immunisation with the CTA1-DD containing 
vaccine prevented the development of cachexia following infection. 
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A. B. 
  
Figure 5.2: Percentage weight change of animals following IN challenge with C. muridarum.  
Each mouse was weighed prior to infection to establish a starting weight and daily following infection to determine weight change. Percentage weight 
change was each animal was calculated by comparing the pre-infection body weight to daily p.i body weights. This figure depicts the effect each 
vaccination strategy has on weight change following an IN infection. (A) CT/CpG- or (B) CTA1-DD-based vaccines are grouped to show the effect the 
route of immunisation has on protection. Unimmunised (primary infection), live infection (secondary infection) and no infection controls are also 
included. Antigen (see below) and adjuvant controls were excluded from graphed data for simplicity (Appendix 3). Results are presented as the mean ± 
SD. Significant differences were determined using a one-way ANOVA with Tukey’s post-test by comparing the weight changes between groups at the 
same point in time. One P value, the most significant, is given for groups showing a significant change. Significance was set at P < 0.05 for all tests. P 
>0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
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The protection against cachexia induced following IN immunisation was not 
significantly different between each vaccine or the live infection control, but weight loss 
was significantly lower in the vaccinated groups than the unimmunised controls (P 
<0.05) (Figure 5.3). However, the protection against weight loss elicited following IN 
immunisation with the MOMP antigen was similar, with or without an adjuvant.  
Figure 5.3: Percentage weight change of animals following IN challenge with C. 
muridarum following IN immunisation.  
Each mouse was weighed prior to infection to establish a starting weight and daily 
following infection to determine weight change. Percentage weight change was for each 
animal was calculated by comparing the pre-infection body weight to daily p.i body 
weights. This figure depicts the effect each vaccination strategy has on weight change 
following an IN infection. Both CT/CpG- and CTA1-DD-based vaccines delivered via 
the IN route are grouped together to show the effect each adjuvant has on protection. 
Antigen, unimmunised (primary infection), live infection (secondary infection) and no 
infection controls are also included. Adjuvant controls were excluded from graphed data 
for simplicity (Appendix 3). Results are presented as the mean ± SD. Significant 
differences were determined using a one-way ANOVA with Tukey’s post-test by 
comparing the weight changes between groups at the same point in time. One P value, 
the most significant, is given for groups showing a significant change. Significance was 
set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and 
<0.001 (***). 
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Animals immunised with the SL delivered CT/CpG-based vaccine were the most 
protected against weight loss, losing a maximum of 2% of their initial weight before 
beginning to regain weight again by day 2 p.i (Figure 5.4). These mice were 
significantly protected from pneumonia when compared to the unimmunised (P <0.01) 
and antigen alone controls (P <0.05). Sublingual immunisation with the CTA1-DD 
adjuvanted vaccine provided no protection. Weight loss in this group actually exceeded 
that of the unimmunised controls.  
Figure 5.4: Percentage weight change of animals following IN challenge with C. 
muridarum following SL immunisation.  
Each mouse was weighed prior to infection to establish a starting weight and daily 
following infection to determine weight change. Percentage weight change was for each 
animal was calculated by comparing the pre-infection body weight to daily p.i body 
weights. This figure depicts the effect each vaccination strategy has on weight change 
following an IN infection. Both CT/CpG- and CTA1-DD-based vaccines delivered via 
the SL route are grouped together to show the effect each adjuvant has on protection. 
Antigen, unimmunised (primary infection), live infection (secondary infection) and no 
infection controls are also included. Adjuvant controls were excluded from graphed data 
for simplicity (Appendix 3). Results are presented as the mean ± SD. Significant 
differences were determined using a one-way ANOVA with Tukey’s post-test by 
comparing the weight changes between groups at the same point in time. One P value, 
the most significant, is given for groups showing a significant change. Significance was 
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set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and 
<0.001 (***). 
The immunity elicited by each vaccine following the TC immunisation was similar 
to the protection obtained following SL immunisation. Transcutaneous immunisation 
with the CT/CpG-containing vaccine provided robust protection against weight loss 
when compared to the unimmunised and antigen alone controls (P <0.01). Minimal 
protection against weight loss was elicited by the CTA1-DD adjuvanted vaccine 
given by the TC route and was not statistically significant from unimmunised or 
antigen alone controls (Figure 5.5). 
Figure 5.5: Percentage weight change of animals following IN challenge with C. 
muridarum following TC immunisation.  
Each mouse was weighed prior to infection to establish a starting weight and daily 
following infection to determine weight change. Percentage weight change was for each 
animal was calculated by comparing the pre-infection body weight to daily p.i body 
weights. This figure depicts the effect each vaccination strategy has on weight change 
following an IN infection. Both CT/CpG- and CTA1-DD-based vaccines delivered via 
the TC route are grouped together to show the effect each adjuvant has on protection. 
Antigen, unimmunised (primary infection), live infection (secondary infection) and no 
infection controls are also included. Adjuvant controls were excluded from graphed data 
for simplicity (Appendix 3). Results are presented as the mean ± SD. Significant 
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differences were determined using a one-way ANOVA with Tukey’s post-test by 
comparing the weight changes between groups at the same point in time. One P value, 
the most significant, is given for groups showing a significant change. Significance was 
set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and 
<0.001 (***). 
Percentage weight change represented in the form of a line graph displays 
differences at the various time intervals. However, the net area under the curve 
analysis is a better depiction of the overall magnitude of cachexia over the duration 
of the infection. Unimmunised animals displayed a net negative weight change over 
the course of infection, indicating the development of severe pneumonia (Figure 5.6). 
Live infection control animals also had a net negative weight change, but this was 
significantly less than the naive unimmunised animals (P <0.01), which indicates a 
more mild cachexia. No infection control animals had a net positive weight change, 
significantly different from infected controls (P <0.001), indicative of a steadily 
increasing body mass. Both IN delivered vaccines were unable to reduce the overall 
magnitude of the cachexia that developed following infection when compared to the 
unimmunised control animals. Sublingual and TC immunisation with the CT/CpG 
adjuvanted vaccine significantly protected mice from cachexia when compared to the 
unimmunised controls (P <0.05-0.01). Sublingual immunisation with the CT/CpG-
based vaccines elicited a significantly greater level of protection against cachexia 
than the live infection control group (P <0.05).  
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Figure 5.6: Net area under the curve of percentage weight change following IN 
challenge.  
The area under the curve is a calculation of the region between the line of the percentage 
weight change and the x-axis (Appendix 3). This figure depicts the net total area, both 
negative and positive peaks, of body weight change over the 10 day course of infection 
in arbitrary units. Each vaccine was grouped with their respective route of immunisation, 
IN (    ), SL (    ) and TC (    ). Results are presented as the mean ± SD. Significant 
differences were determined using a one-way ANOVA with Tukey’s post-test. 
Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-
0.01 (**) and <0.001 (***). 
Infectious burden 
Preventing or even reducing the level of infection is crucial to control the 
transmission of infection. The peak of infection was assessed by quantifying the 
infectious burden in lungs on day 10 p.i at the height of a pulmonary infection in 
mice (Horvat et al., 2007). This was used not only to measure the effect each vaccine 
had on the amount of recoverable Chlamydia, but also to validate cachexia results. 
Following infection, 100% of unimmunised animals were PCR positive for C. 
muridarum (Figure 5.7), with bacterial loads in excess of 4 x 10
4
 copies/µg of genomic 
(g)DNA. All animals from the live infection control group were completely negative for 
chlamydial DNA at day 10 p.i. This abrogated course of infection in the live infection 
control group supports the strong resistance to re-infection indicated by the weight loss 
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data. The vaccines that were protective against cachexia also greatly reduced the 
bacterial burden in the lungs at the peak of infection. The CT/CpG-based vaccine 
significantly reduced levels of recoverable bacteria when compared to the 
unimmunised controls regardless of the immunisation route (P <0.05), whereas the 
CTA1-DD-containing vaccine was only protective following IN administration (P 
<0.05). Transcutaneous and SL immunisation with CTA1-DD adjuvanted vaccine, 
which failed to prevent the development of cachexia, also induced no significant 
reduction in total bacterial burden. The protection against bacterial burden elicited 
following IN immunisation with the MOMP antigen was similar, with or without an 
adjuvant, which verifies the weight loss data. No chlamydial DNA could be detected in 
the uninfected control group. 
Figure 5.7: Chlamydial burden in lung tissue at day 10 p.i determined by ompA 
PCR.  
Genomic DNA was extracted from lung tissues taken from all groups at day 10 p.i. 
Chlamydial DNA was quantified from lung gDNA by ompA-specific qRT-PCR using a 
standard curve. The copies of C. muridarum DNA per µg of host gDNA for each 
vaccine were grouped with their respective route of immunisation, IN (    ), SL (    ) and 
TC (   ). Results are presented as the mean ± SD. Significant differences were 
determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P 
< 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 
(***). 
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The effectiveness of each vaccine to protect against the pathology that occurs 
following live C. muridarum IN challenge 
While reducing the level of infection is important to minimise disease severity and 
transmission, a vaccine must also prevent the pathological changes associated with 
the exacerbation of certain chronic lung diseases. C. muridarum can reproduce many 
chronic inflammatory and autoimmune diseases in the mouse, associated with a C. 
pneumoniae infection in humans, although these often require the use of 
immunologically impaired mice (IFNγ-/-) or unnatural route of infection (Hough and 
Rank, 1988; Rank et al., 1988b; Fan et al., 1999; Du et al., 2002). We therefore 
determined whether each vaccine was capable of preventing the fibrotic scarring 
associated with an active chlamydial pulmonary infection (He et al., 2010) and 
exacerbation of respiratory diseases like asthma and COPD (Postma and Timens, 
2006). Pulmonary fibrosis, characterised by excessive growth of fibroblasts and 
extracellular matrix deposition (eg. collagen), is the main component of many lung 
diseases (Luzina et al., 2008). Lung tissues taken from infected, unimmunised 
animals showed significant collagen deposition and lung consolidation, 
characteristics of a severe lung disease (Figure 5.8). The live infection control group, 
strongly resistant to re-infection, showed a similar level of fibrosis in the lungs to the 
naive unimmunised animals, as a result of the primary infection. The no infection 
control group displayed no evidence of fibrotic scarring when compared to the 
infection controls (unimmunised and live infection control) (P <0.001). Animals 
immunised with CT/CpG-based vaccines via the TC and SL routes that provided 
protection against cachexia and the bacterial burden, were also significantly 
protected against pathology when compared to the unimmunised controls. The 
greatest protection against fibrotic scarring however was seen in animals immunised 
by the TC route with the CTA1-DD adjuvanted vaccine, where the pathology score 
was equivalent to that in uninfected animals. Interestingly, these animals were not 
significantly protected against weight loss or bacterial burden. Neither vaccine 
delivered IN protected against pathology; in fact, both vaccines appeared to 
exacerbate fibrosis, despite reducing weight loss and bacterial burden.  
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A. 
 
B. 
Figure 5.8: Fibrotic scarring and lung consolidation following IN infection with C. 
muridarum.  
Lung tissues taken from each mouse at day 10 p.i were paraffin embedded, sectioned 
and stained for fibrosis using Masson’s trichrome. (A) The pathology score scale used to 
compare the development of disease following infection. Representative histological 
images for each pathology scores are depicted. “0” signifies healthy, undamaged lung 
tissue. Scores of “1” through to “3” depict worsening degrees of collagen deposition 
(blue) and the beginnings of obstruction and consolidation of the lungs (yellow arrows). 
Pathology can also be seen on a macroscopic level, when comparing healthy (left) and 
unhealthy (right) lobes of the lungs. (B) Average pathology scores, assigned by three 
separate individuals blinded to groups and experimental design. Results are presented as 
the mean ± SD. Each vaccine is grouped with their respective route of immunisation, IN 
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(    ), SL (    ) and TC (    ). Significant differences were determined using a one-way 
ANOVA with Tukey’s post-test. Significance was set at P < 0.05 for all tests. P >0.05 
(not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
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DISCUSSION  
In this chapter, we assessed the level of protective immunity against a chlamydial 
respiratory tract infection and the associated disease generated following 
immunisation with two different vaccines, by a variety of needle-free routes. 
Immunisation of animals with the MOMP plus CT/CpG via the TC and SL routes 
significantly reduced infection-induced weight loss and the amount of recoverable 
Chlamydia from the lungs at day 10 p.i. This protection was similar to the immunity 
acquired after a natural infection, with the addition of near complete protection from 
pathology as determined by fibrosis and lung consolidation. Where the CT/CpG-based 
vaccine prevented progressive weight loss and bacterial burden regardless of 
administration route, CTA1-DD was only effective against a pulmonary infection 
following IN administration. Induction of strong serum IgG and splenic antigen-
specific cellular responses were associated with the protection against infection, 
while local pro-inflammatory cells in the lymph nodes draining the lungs determined 
whether pathology was prevented (Chapter 4). Interestingly, the protection against 
infection elicited by both IN delivered vaccines (reduced weight loss and bacterial 
load) did not however, provide protection against pulmonary fibrosis. Moreover, TC 
immunisation with the CTA1-DD-based vaccine prevented pathology despite having 
no significant influence on chlamydial burden and only a minimal effect on weight 
loss. Therefore, this study not only identified a vaccine that protects against both 
infection and pathology, but also infection or pathology individually. This illustrates 
the challenges involved when developing a vaccine against Chlamydia: should the 
primary aim be to prevent infection (sterilising immunity) or prevent disease-
associated pathology, as preventing/reducing infection does not necessarily protect 
against pathology and vice versa, at least in this mouse model. 
Protection against chlamydial respiratory tract infection was associated with the 
induction of antibody and cell-mediated responses. Chlamydia has a unique biphasic 
lifecycle, consisting of the intracellular replicating RBs and the extracellular and 
infectious EBs. Effective protection against acute chlamydial infection elicited by 
MOMP-based vaccines requires the combination of Th1 cellular and Th2-driven 
antibody responses, targeting the RB and EB forms, respectively (Farris et al., 2010). 
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The vaccines that induced a significant amount of protection against a respiratory 
tract infection, determined by weight loss and bacterial burden (Figure 5.7), 
generated the highest titres of MOMP-specific serum antibodies (Figure 4.9). In the 
absence of B cells and hence antibodies, mice resolve a primary and secondary 
genital tract infection similar to WT mice, however, these same mice are 
significantly more susceptible to re-infection (Su et al., 1997). Similarly, B cell-
deficient mice are more susceptible to re-infection following an IN chlamydial 
challenge, but also have higher mortality rates and develop more severe cachexia 
compared to WT mice (Williams et al., 1997; Yang and Brunham, 1998). This 
suggests that antibodies prevent the establishment of an infection and control 
infection severity in the respiratory tract model. Although serum antibodies have 
been shown to neutralise Chlamydia in vitro and in vivo (Zhang et al., 1987; Zhang 
et al., 1989; Peterson et al., 1993; Peterson et al., 1997; Peterson et al., 1998; Pal et 
al., 1999), their contribution towards immunity against infection is not without 
contradiction. Many of the inconsistencies regarding the effect of serum antibodies in 
eradicating a chlamydial infection come from studies on the genital tract model of 
infection (Rank et al., 1979; Ramsey et al., 1988; Ramsey et al., 1989; Buzoni-Gatel 
et al., 1990; Cotter et al., 1995; Morrison and Morrison, 2005), which is commonly 
reported to be more dependent on mucosal antibodies for protection. Conversely, 
systemic and mucosal transfer of convalescent serum confers protection against a 
subsequent Chlamydia respiratory challenge (Williams et al., 1982; Williams et al., 
1984; Kaukoranta-Tolvanen et al., 1995; Pal et al., 2008). This difference between 
the responses required to elicit protection in the respiratory tract verses the genital 
tract is clear when we look at the protective effect of parenterally administered 
vaccines. Systemic immunisation with the MOMP and the adjuvant Alum, designed 
to elicit high serum antibody titres, confers a significant degree of protection against 
a respiratory tract infection but not following a genital tract challenge (Cheng et al., 
2011b; Yu et al., 2012). This indicates that the induction of systemic antibodies can 
confer partial protection against a Chlamydia respiratory tract infection (Williams et 
al., 1982; Williams et al., 1984; Cheng et al., 2009).  
Titres of IgG and not IgA were a better associate of protection against a respiratory 
infection in vivo. The adoptive transfer of MOMP-specific IgG and IgA-producing 
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backpack hybridomas had a marginal affect on the clearance of a genital tract 
infection, yet IgG was significantly more protective against infection than IgA 
(Cotter et al., 1995). Immunoglobulin A has also been shown to have no effect on the 
resolution of a primary respiratory tract infection or the incidence of mortality 
following passive immunisation (Williams et al., 1984; Murthy et al., 2004). This 
suggests that serum IgG may play a more dominant role than systemic IgA against a 
Chlamydia infection, supportive of our findings. However, the lack of protection 
induced by serum IgA in vivo may reflect an inability to elicit its primary function, 
which is direct neutralisation and prevention of microbial attachment to the mucosal 
surface (Janeway et al., 2005; Cunningham et al., 2008). Although the MOMP-
specific IgA generated in the serum following vaccination significantly improved the 
neutralisation of Chlamydia in vitro, it may not have possessed the necessary 
secretory component required for receptor-mediated transport across the mucosal 
epithelium to allow IgA to neutralise the infection in vivo (Su et al., 1995; 
Cunningham et al., 2008). This hypothesis can be supported by the detection of low 
levels of IgA in the BAL (Figure 4.10), which did not induce a significant increase in 
neutralisation in vitro or coincide with protection against infection in vivo (Figure 5.2 
– 5.7). Alternatively, IgG is able to passively transfuse from the serum into the 
highly vascularised lung mucosal tissues and potentially promote the Fc-mediated 
control of infection (Caldwell and Perry, 1982; Moore et al., 2002). Therefore, IgA 
was ineffective at mediating protection against infection in vivo, possibly due to the 
induction of insufficient levels of IgA in the mucosal secretions needed to inhibit 
chlamydial attachment (Williams et al., 1984). Induction of IgG antibodies was 
associated with protection from infectious challenge. The inability of IgG to 
neutralise Chlamydia infectivity in vitro, suggests that IgG may mediate protection in 
vivo through Fc-dependent mechanisms as opposed to direct neutralisation (Caldwell 
and Perry, 1982; Moore et al., 2002).  
Despite the positive influence high serum IgG titres had on protection against 
infection, the quantity, quality nor class of antibodies in the serum or mucosal 
secretions (Figure 4.9, 4.10) were associated with protection from pathology (Figure 
5.8). Both IgG and IgA anti-MOMP antibodies can prevent the development of upper 
reproductive tract pathology following a genital tract infection (Cotter et al., 1995). 
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Furthermore, IgA-deficient mice display exaggerated lung histopathology following 
an IN infection, even in the presence of a compensatory over-production of other 
serum antibodies (IgM, IgG, IgG2a, IgG1 and IgG2b) (Murthy et al., 2004). This 
suggests that IgG is ineffective at preventing pathology, while IgA plays a role in 
regulating pulmonary inflammation and mucosal homeostasis following a primary 
chlamydial respiratory infection. The low levels of MOMP-specific IgA generated in 
the BAL following vaccination, which failed to neutralise the infection in vitro and 
elicit protection against infection in vivo, may have also been unable to prevent 
pathology. Moreover, suboptimal doses of IgG have even been associated with 
enhancement pathology (Peterson et al., 1993; Su et al., 1995; Peterson et al., 1997; 
Cunningham et al., 2011). The induction of MOMP-specific antibodies following 
vaccination was therefore unable to prevent the development of pathology after an 
IN challenge, despite their positive influence on infection. 
The vaccines that elicited a significant level of protection against weight loss and 
infectious burden following an IN infection (Figure 5.2 – 5.7), induced secretion of 
the pro-inflammatory cytokine TNFα and T cell-related cytokines (IL-17 and IFNγ) 
by splenocytes following in vitro re-stimulation with the MOMP (Figure 4.4). These 
same vaccines also elicited low level secretions of the anti-inflammatory cytokines 
IL-4 and IL-10 by splenocytes (Figure 4.4). As the induction of pro-inflammatory 
cytokines (IFNγ, TNFα and IL-17) by T cells is known to enhance the resolution of 
infection (Williams et al., 1993; Williams et al., 1997; Lu and Zhong, 1999; Yang et 
al., 1999; Jupelli et al., 2008; Bai et al., 2009; Zhang et al., 2009; Jupelli et al., 2010) 
and anti-inflammatory cytokines (IL-4 and IL-10) inhibit the clearance of a 
chlamydial respiratory tract infection (Williams et al., 1997; Yang et al., 1999), these 
vaccines primed the ideal response necessary to eradicate an active infection.   
Pro-inflammatory cytokines have been shown to act individually or synergistically to 
improve inhibition of chlamydial growth. Regardless of its cellular source 
(Rothfuchs et al., 2004), IFNγ is consistently shown to be crucial in the resolution of 
an active chlamydial infection. Although it is still to be determined whether IFNγ has 
a direct bacteriostatic or bactericidal effect on C. muridarum by inducing IRGs 
(Nelson et al., 2005b; Coers et al., 2011) or if protection is mediated by stimulating a 
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unique T cell population (Cotter et al., 1997b). The Th17 cytokine IL-17 also confers 
protection against intracellular bacteria including Chlamydia, predominantly through 
the regulation of the Th1 response and neutrophil recruitment (Bai et al., 2009). 
TNFα also positively influences the rate of bacterial clearance in the lungs (Williams 
et al., 1990), through the recruitment and activation of numerous innate an adaptive 
populations. However, IFNγ-mediated inhibition of Chlamydia growth in vitro is 
enhanced 2-fold with the inclusion of TNFα (Summersgill et al., 1995). The cytokine 
TNFα can increase expression of IFNγR and other transcriptional activators of IFNγ, 
thereby promoting IFNγ-mediated host defences (Robinson et al., 2003). It has been 
suggested that the synergism between IFNγ and TNFα could be heightened further in 
vivo, as TNFα-mediated inhibition of chlamydial growth is indirect and requires the 
recruitment of additional cell populations (Perry et al., 1999b). The cytokine TNFα 
also facilitates the release of IFNγ-induced NO by macrophages (Chen et al., 1996; 
Igietseme, 1996; Fichorova and Anderson, 1999; Robinson et al., 2003; Miljkovic 
and Trajkovic, 2004; Gabr et al., 2011), which is important for infection resolution in 
the lungs (Qiu et al., 2008). Together, TNFα and IFNγ increase expression of MHCII 
molecules and synergise with IL-17 to up-regulate ICAM-1 (Fichorova and 
Anderson, 1999; Gabr et al., 2011), associated with immune cell recruitment, 
activation of Th1 cells and the normal resolution of a genital tract infection 
(Igietseme et al., 1996; Igietseme et al., 1999). Although we did not screen the type 
of cells secreting cytokines or assess for multi-functional phenotypes, emphasis has 
recently been placed on the contribution of CD4
+
 T cells secreting a combination of 
cytokines (IFNγ+TNFα+ and IL-17+IFNγ+ double positives, specifically) towards 
protection against a genital tract infection (Igietseme et al., 1993; Olsen et al., 2010; 
Yu et al., 2010; Yu et al., 2011; Yu et al., 2012). This is because multi-functional T 
cells secrete larger amounts of cytokines and provide better co-stimulation for both T 
and B cells than single cytokine producing cell types (Kannanganat et al., 2007). 
Infection with live EBs opposed to immunisation with dead EBs is known to induce 
stronger protection against re-infection, due in part to the generation of higher 
percentages of multi-functional T cells (Yu et al., 2011). T cells co-producing 
multiple cytokines have been generated following vaccination and shown to confer a 
considerable amount of protection against a Chlamydia, Mycobacterium tuberculosis 
and Leishmania major (Darrah et al., 2007; Forbes et al., 2008; Kamath et al., 2009; 
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Olsen et al., 2010; Yu et al., 2010; Yu et al., 2012). Therefore, the induction of IFNγ, 
TNFα and IL-17 following immunisation coincided with strong protection against 
infection, potentially due to a synergistic interaction between multiple pro-
inflammatory cytokines. To the best of our knowledge this is the first evidence of 
this combination cytokine response, first mentioned by Igiesteme et al., (1993) and 
Yu et al., (2010), conferring protection against Chlamydia in the respiratory tract 
infection model. We cannot definitively say whether CD4
+
 T cells were co-
producing these cytokines upon re-stimulation with the MOMP. However, the 
quality of T cells and the development of a multi-functional phenotype can be 
influenced by the adjuvant (Darrah et al., 2007; Yu et al., 2010; Yu et al., 2012), 
duration of antigen exposure (Iezzi et al., 1998; Jelley-Gibbs et al., 2005), the type of 
APCs targeted (Reis e Sousa, 2004; Steinman and Hemmi, 2006) and the innate 
cytokine milieu at the site of immunisation (O'Garra, 1998) 
Unexpectedly, we were unable to detect an IFNγ response in the spleen (Figure 4.4) 
or MdLN (Figure 4.6) following SL immunisation with the MOMP plus CT/CpG, 
even though this group of animals was significantly protected against infection. 
Interferon-γ was secreted by MOMP-stimulated lymphocytes isolated from the 
MiLN (Figure 4.8), but it is unlikely that these cells would have been activated 
rapidly following a pulmonary infection. It is possible that IFNγ-secreting MOMP-
specific cells were present, but may have adopted a more effector phenotype 
migrating to other non-lymphoid tissues (Zhao et al., 2003) or simply, the 
lymphocytes produced IFNγ following antigenic stimulation at a point in time not 
chosen for cytokine analysis (Han et al., 2011). 
Our data indicated that protection against infection was associated with a strong pro-
inflammatory response in the spleen. Although TNFα and IFNγ are potent inhibitors 
of fibrosis in vitro and in vivo (Atamas and White, 2003; Pochetuhen et al., 2007), 
the production of these cytokine by splenocytes could not be linked with protection 
against pathology. However, when a significant level of local antigen-specific 
proliferation and cytokine production was detected in the MdLN draining the 
respiratory tract (Figure 4.6), protection against infection (Figure 5.2 – 5.7) increased 
significantly and extended to include the prevention of pathology (Figure 5.8). 
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Activation of T cells occurs exclusively in the lymph nodes draining the lungs in the 
first few days following a pulmonary infection with a number of different viral and 
bacterial pathogens (Chackerian et al., 2002; Lawrence and Braciale, 2004). Once 
activated, these T cells have been shown to undergo multiple rounds of proliferation 
and recruitment to the infected lungs, all of which can occur before an antigen-
specific response can be detected in the spleen (Lawrence and Braciale, 2004). 
Furthermore, lymphotoxin-α-/- (LTα) mice, which are completely deficient in lymph 
nodes and have altered splenic architecture, have an effective but delayed clearance 
of murine gammaherpes 68 virus and influenza virus infections, due to a decreased 
ability to initiate an immune response (Lee et al., 2000; Lund et al., 2002). This 
indicates the importance of lymph nodes when orchestrating rapid accumulation of T 
cells to the site of infection.  
The enhancement of protection against infection and pathology seen in these groups 
may reflect the ability of antigen-specific cells residing in the lymph nodes draining 
the site of infection to respond more rapidly than the spleen-resident cells. Support 
for this hypothesis is provided by our findings that animals that mounted a local 
response in the lymph nodes draining the site of infection following vaccination (TC 
or SL delivered CT/CpG-based vaccine), were more resistant to weight change 
during the course of infection compared to animals that only mounted a systemic 
response when the same vaccine was delivered by the IN route. This has also been 
found to be the case for M. tuberculosis, where induction of T cells in the airways 
and not the spleen dictated protection from infection (Santosuosso et al., 2005; 
Forbes et al., 2008). In the context of protection against pathology, a reduction in the 
severity of lung histopathology following a Burkholderia pseudomallei infection has 
been associated with the early recruitment of inflammatory immune cells into the 
lungs (Judy et al., 2012). Therefore, rapid activation and recruitment of a pro-
inflammatory response to the lung mucosa may prevent adverse pathology, whereas 
a systemic response may be initiated following the recruitment of damaging innate 
populations to the lungs and the onset of pathology. Protection against pathology 
following an IN challenge with Chlamydia may rely on a vaccine priming and 
positioning antigen-specific cells in the regional lymph nodes, that can respond early 
during an infection and limit the involvement of the innate response in eradicating 
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the infection. To our knowledge this is the first evidence of the importance of 
generating a response in the lymph nodes following vaccination for protection 
against a chlamydial respiratory tract infection. 
Interestingly, there appeared to be a significant disconnection between infection and 
pathology in some vaccine groups, where a reduction in bacterial burden did not 
necessarily coincide with protection against inflammatory disease and vice versa. 
Both IN delivered vaccines elicited protection from infection (Figure 5.2 – 5.7), yet 
seemed to exacerbate pathology compared to that of a normal course of infection 
(Figure 5.8). Intranasal immunisation elicited the strongest pro-inflammatory 
cytokine response that may have caused an imbalance between the control of 
infection and prevention of disease, resulting in excessive immunopathology (Lu et 
al., 2011). Alternatively, it is conceivable that trace amounts of the vaccine may have 
drained into the lungs (Visweswaraiah et al., 2002) and caused local inflammation 
and fibrosis, interpreted as infection-induced pathology.  
This does not appear to be the case for the TC delivered CTA1-DD-adjuvanted 
vaccine group, which was solidly protected from pathology (Figure 5.8) despite 
having no significant reduction in the infectious burden (Figure 5.2 – 5.7). This 
disconnection between infection and pathology has two possible explanations; either 
(1) the development of pathology was merely postponed (Fraga et al., 2012) or (2) 
the disease process has been circumvented in some way, independent of reducing the 
bacterial load. Defence against a pathogen has been proposed to occur via two 
mechanisms, either by limiting the pathogen burden (resistance) or the disease 
severity (tolerance) (Raberg et al., 2007). The immunity induced by this particular 
vaccine appears to be one of tolerance against disease, as by definition, resistance has 
an effect on pathogen burden where tolerance does not (Raberg et al., 2007). 
Tolerance to disease is not to be confused with immunological tolerance, which 
involves the suppression of antigen-specific responses, but instead describes a 
decreased susceptibility to immune- or pathogen-induced damage (Medzhitov et al., 
2012). However, tolerance to disease in some regards may refer to immunological 
tolerance. This concept of tolerance towards infection-induced disease was first 
described in animals by Råberg et al., (2007), where genetic differences were found 
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to influence tolerance to malaria, independent of parasitic load. Infection with 
Plasmodium chabaudi chabaudi causes haemolysis of red blood cells and results in a 
lethal form of hepatic failure. Expression of haeme oxygenase-1 (HO-1) catalyses the 
circulating free haeme, produced during haemolysis, preventing TNFα/ROS-
mediated apoptosis by hepatocytes and hence liver failure (Seixas et al., 2009). Mice 
expressing sickle haemoglobin are remarkably resistant to severe malaria, 
irrespective of the parasite load, as sickle haemoglobin not only prevents the 
expansion of pathogenic CD8
+
 T cells but also induces expression of HO-1 in 
hematopoietic cells and prevents the cytotoxic effects of free haeme (Ferreira et al., 
2011). Even though this particular example is of a genetic predisposition driving 
tolerance against disease manifestation, it has been suggested that similar inducible 
protective pathways could exist for other types of infection, including Chlamydia 
(Miyairi et al., 2012). Identifying and understanding these pathways may form the 
basis for new treatment strategies (Medzhitov et al., 2012), that could include 
vaccines.  
The type of immune response induced or the vaccine constituents may provide clues 
to what mechanism(s) may be involved in the development of tolerance against 
pulmonary fibrosis. Notably, this vaccine induced a strong IL-17 response in the 
spleen and MdLN following in vitro re-stimulation with the MOMP (Figure 4.4, 4.6), 
indicative of an elevated Th17 cell response. T cells can influence the fibrotic 
process in a number of ways, but are thought to function primarily in regulation of 
the healing process (Luzina et al., 2008). The IL-17 cytokine has no direct effect on 
fibroblast proliferation or fibrosis (Molet et al., 2001), but is a strong inducer of the 
anti-fibrotic Th1 response (Bai et al., 2009). In the context of a Chlamydia 
pulmonary infection, IL-17 has been associated with the susceptibility to infection in 
C3H/HeN mice (Zhou et al., 2009), yet neutralisation of IL-17 in BALB/c mice 
increases bacterial growth, weight loss and pathological changes (Bai et al., 2009; 
Zhang et al., 2009). Although, IL-17-mediated inflammation appears to prevent 
Chlamydia-induced immunopathology in the lungs, this involves limiting the 
pathogen burden by resistance as opposed to tolerance, contrasting to our findings.  
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The CTA1-DD adjuvant has also been implicated in the generation of antigen-
specific tolerance. Fusion of the enzymatically inactive CTA1R7K-DD with H-2
q
-
restricted type II collagen peptide (amino acid 259–274), CTA1R7K-COL-DD, has 
been used to successfully treat collagen-induced arthritis in mice by inducing 
antigen-specific tolerance (Hasselberg et al., 2009). CTA1R7K-COL-DD elicited 
immunological tolerance by the suppression of antigen-specific proliferation and 
IFNγ production following in vitro re-stimulation with collagen. However, this 
tolerogenic effect was only detected in the collagen-fused mutant devoid of 
enzymatic activity (CTA1R7K-COL-DD) and not the fully functional CTA1-COL-
DD fusion. It is highly unlikely that the CTA1-DD used in the study was 
enzymatically inactive because it was fully functional and immunogenic via the IN 
route. Inactivation of the ADP-ribosyltransferase subunit of CTA1-DD by an 
interaction between the adjuvant and the permeation enhancer used to pre-treat the 
immunisation site is also improbable, as the skin was re-hydrated thoroughly prior to 
the vaccine being applied. Alternatively, other adaptive immune factors induced by 
vaccination and not assessed are limiting the fibrotic process or enhancing injury 
repair. This speculation requires further investigation that may well unveil yet 
undefined countermeasures against development of pathology.  
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CONCLUSIONS 
The aim of this chapter was to assess the level of protective immunity against a 
Chlamydia respiratory tract infection and the associated disease following 
immunisation with the MOMP plus CTA1-DD or CT/CpG via TC, IN and SL routes. 
Aspects of the immune response induced following vaccination, determined in 
Chapter 4, were then associated with the level of protection against infection and 
disease. Induction of high serum IgG and not IgA associated with protection against 
infection and this was largely mirrored in the mucosal secretions. Systemic pro-
inflammatory responses were also associated with the enhanced resolution of 
infection, possibly due to the synergistic effect of IFNγ, TNFα and IL-17 inhibiting 
chlamydial growth both directly and indirectly. Detection of an antigen-specific 
response in the MdLN draining the lungs associated with protection against 
pathology, which may reflect the time required to initiate and recruit an immune 
response to the site of the infection. However, protection against pathology 
developed in cases when the bacterial load recovered from the lung tissue was 
unaltered. This suggested that there may be other mechanisms modulating the 
development of disease following infection, which are independent of infection 
control. 
 
 144 
 
 
 
 
 
 
 
CHAPTER SIX: PROTECTION AGAINST A 
REPRODUCTIVE TRACT INFECTION AND THE 
ASSOCIATED PATHOLOGY FOLLOWING AN 
INTRAVAGINAL CHALLENGE WITH C. 
MURIDARUM 
 
 
 
 
 
 
 145 
 
INTRODUCTION 
C. trachomatis (serovars D – K) is the most common bacterial STI worldwide, with 
over 250,000 new cases each day. Population prevalence is approximately 1 – 3% 
(Howie et al., 2011; Ali et al., 2012), but for high risk groups like adolescent women 
prevalence can reach almost 30% (Burstein et al., 1998; Bunnell et al., 1999; Cook et 
al., 1999). Women also have the highest incidence of asymptomatic infection 
(between 70 – 90%) (Stamm and Holmes, 1990) and account for 80% of the total 
economic burden (Patel et al., 2008). As the current strategy of detection and 
treatment is not only ineffective at controlling the prevalence of infection (Brunham 
et al., 2005; Brunham and Rekart, 2008) and could in fact be contributing towards 
the uncontrolled spread of infection (Hadgu and Sternberg, 2009), a vaccine 
predominantly targeting females is recognised to have the greatest potential to impact 
on rates of infection and disease prevalence (Brunham et al., 2005; Gray et al., 
2009).  
Utilising an animal model that accurately reflects the many aspects of human 
infection and disease is vital for success in humans. Female mice can be infected via 
the vaginal vault with C. muridarum, the natural route of infection in humans 
(Ramsey et al., 2009). This does however require an initial pre-treatment with 
progesterone (Tuffrey and Taylor-Robinson, 1981), which can alter the 
immunological balance of the mice to favour an anti-inflammatory response (Kita et 
al., 1989). An IVag infection of mice leads to the colonisation of the vagina and a 
period of shedding of infectious chlamydial organisms. Shortly after the 
establishment of the infection in the lower reproductive tract, the infection ascends to 
colonise the upper reproductive tract (Carey et al., 2009). This is followed by the 
development of hydrosalpinx, which is an accumulation of clear serous fluid in the 
oviduct (Carey et al., 2009). Hydrosalpinx is characteristic of the scarring associated 
with tubal factor infertility in humans and the size of swelling of the oviduct is 
directly proportional to the extent of the damage (Shah et al., 2005b; Imtiaz et al., 
2006). Blockages are thought to occur by scarring and adhesion of the oviducts and 
the disruption of the oviduct contractile activity responsible for clearing oviduct 
secretions and moving sperm to the uterus (Shibahara et al., 2001; Dixon et al., 
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2010). This pathology is hypothesised to be initiated and sustained by the pro-
inflammatory cytokines/chemokines secreted by Chlamydia-infected epithelial cells, 
which in an ongoing chronic infection promote, cellular proliferation, tissue 
remodelling and scarring. Local production of IL-1β has been shown in an ex vivo 
model of Fallopian tubes infected with C. trachomatis to be a key initiator of direct 
tissue destruction, even in the absence of leukocytes (Hvid et al., 2007). Similarly, 
IL-1β has also been implicated as a major driver of upper tract pathology in mice 
(Cheng et al., 2008; Prantner et al., 2009; Nagarajan et al., 2012). However, these 
pathological effects of infection are also likely to be further exacerbated following 
the recruitment and infiltration of tissue-damaging innate and adaptive immune cell 
populations (Lee et al., 2010b; Lu et al., 2011).  
In addition to replicating human disease, the ideal model for predicting a vaccine’s 
efficacy will also imitate the reliance on different immune populations for protection. 
Humans and mice elicit Chlamydia-specific T and B cells are detectable in humans 
and mice following a genital tract infection (Mittal et al., 1996; Morrison and 
Caldwell, 2002; Agrawal et al., 2007). Antibodies contribute to immunity against re-
infection in mice (Morrison and Morrison, 2005), although the role mucosal and 
systemic antibodies play in the resolution of a chlamydial genital tract infection in 
humans is unclear (Mittal et al., 1996). Interferon γ-secreting CD4+ Th1 cells can be 
detected in the female reproductive tract and in PBMC following a natural infection 
in humans (Mittal et al., 1996; Agrawal et al., 2007) and as with mice (Morrison and 
Caldwell, 2002), these were associated with protection against infection and disease 
in humans (Debattista et al., 2002; Kinnunen et al., 2002). Therefore, the mouse 
model accurately replicates the many facets of disease associated with a C. 
trachomatis infection in humans and shares a similar dependence on the different 
arms of the adaptive immune response required in humans to eradicate an infection 
and prevent pathology. 
Protection against a chlamydial genital tract infection relies on the generation of Th1 
cell-mediated response and to a lesser extent Th2-driven antibody response. As a 
result, the majority of chlamydial vaccines incorporate Th1 polarising adjuvants. 
Utilisation of the adjuvants CAF01, DDA-MPL, DDA-TDB, CpG-1826, CpG-
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1826/IL-12, in conjunction with a multitude of different antigens, induced high levels 
of IFNγ-secreting Th1 cells (Li et al., 2007; Yu et al., 2010; Murthy et al., 2011b; 
Yu et al., 2012). This response confers partial protection against the vaginal shedding 
(Li et al., 2007; Yu et al., 2010; Murthy et al., 2011b; Yu et al., 2012) and oviduct 
pathology (Li et al., 2007; Murthy et al., 2011b). Induction of optimal protective 
immunity by MOMP-based vaccines however requires the contribution of both CD4
+
 
T cells and antibodies to prevent the establishment of infection (Farris et al., 2010). 
The combination of the MOMP with Th2 as well as Th1 polarising adjuvants CT and 
CpG improves the induction of IFNγ-expressing T cells and mucosal antibodies, 
which associates with enhanced clearance of a chlamydial genital tract infection 
(Berry et al., 2004). Furthermore, the use of mucosal and cutaneous routes of 
immunisation is known to improve the homing of antigen-specific responses to the 
genital tract via the CMIS (Czerkinsky and Holmgren, 2010a; Czerkinsky and 
Holmgren, 2010b). To utilise these routes however requires a potent adjuvant to 
overcome tolerance, which is commonly elicited towards an antigen when it is 
applied to the epithelium. Intranasal immunisation with the MOMP together with 
potent mucosal adjuvants CT and CpG, significantly reduced that amount of 
recoverable Chlamydia following a genital tract infection (Barker et al., 2008). 
However, the toxicity of CT and CpG following IN administration precludes their 
use in human prophylactic vaccines. (Fujihashi et al., 2002; Couch, 2004; 
Heikenwalder et al., 2004; Kiyono and Fukuyama, 2004; Mutsch et al., 2004; 
Klinman et al., 2007; DeFrancesco, 2008). These adjuvants can also generate 
mucosal immunity by routes other than IN and confer a considerable amount of 
protection against a genital tract infection (Berry et al., 2004; Huang et al., 2008; 
Cuburu et al., 2009). Most importantly, these routes limit the toxic side effects 
commonly affiliated with nasal delivery of potent mucosal adjuvants. 
Utilisation of the IN route to elicit protection against mucosal pathogens is still 
highly desirable due to a strong ability to induce immunity in the genital tract 
(Brandtzaeg, 2009). Therefore, the demand for safe yet effective adjuvants that can 
be administered via the IN route is greater than ever. As CTA1-DD does not 
accumulate in the CNS (Eriksson et al., 2004), it has been shown to be a non-toxic 
yet potent mucosal adjuvant (Sundling et al., 2008). The CTA1-DD adjuvant 
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combined with the HIV-1 envelope glycoprotein (Env) induced a significantly 
greater amount of mucosal IgA when compared to the same vaccine given 
parenterally (Sundling et al., 2008). Animals immunised IN with the chlamydial 
MOMP, adjuvanted with CTA1-DD, produce strong systemic and mucosal 
Chlamydia-neutralising antibodies, which enhanced the resolution of a Chlamydia 
genital tract infection (Cunningham et al., 2009). However, it is unclear whether 
CTA1-DD can be used in conjunction with the MOMP by alternative immunisation 
routes, perhaps more capable of stimulating greater mucosal immunity against a 
genital tract infection and the associated disease. 
Chapter 4 compared and quantified the systemic and mucosal immune responses of 
two vaccines delivered by multiple routes. In this chapter the ability of each 
vaccination strategy to induce protection against a live C. muridarum genital tract 
infection was assessed. Protection was determined by the ability of each vaccination 
strategy to reduce infection and pathological damage.  
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MATERIALS AND METHODS 
Timeline 
Figure 6.1: Experimental timeline for assessment of protection against a genital 
tract infection and pathology.  
Mice were immunised on days 0, 7, 14 and 28 and progesterone treated 7 days prior to 
being infected intravaginally. Mice were sacrificed on day 48, 6 days p.i, to collected 
cervix/vagina, uterine horn and oviducts for assessment of bacterial burden and gene 
expression. A second group of identical animals was also culled on day 91, 49 days p.i, 
for analysis of oviduct upper reproductive tract disease. Vaginal swab were taken for 
both groups every 3 to 7 days following the IVag challenge. 
Intravaginal C. muridarum challenge 
Intravaginal challenge was conducted as previously described (Carey et al., 2009). 
Each animal received a SC injection with 2.5mg of medroxyprogesterone (Depo 
Provera), 7 days prior to challenge with C. muridarum. Anesthetised mice were 
given 5 x 10
2 
IFU of C. muridarum into the vaginal vault in 20µL of SPG. The 
genital region was swabbed after infection with 70%v/v ethanol to remove any 
Chlamydia from the exterior. Progesterone primed, uninfected animals (no infection 
control) in addition to those recovering from a primary C. muridarum genital 
infection (live infection control), strongly resistant to re-infection, were also included 
as controls. 
Monitoring clearance of infection and burden 
Vaginal swabs were taken by swabbing the vagina five times clockwise and anti-
clockwise using a sterile nasopharyngeal Calgiswab (Modular Medical Products, 
Alice Springs, Australia) moistened with ice-cold SPG. Collection of vaginal swabs 
occurred every 3 days until day 21 p.i, from then every 7 days until sacrifice (day 49 
p.i). Swabs were submerged in 500µL of SPG containing two sterile glass beads, and 
vortexed for 20 sec before storing at -80°C. Swabs were vortexed again after thawing 
0 7 14 28 35 42 48
Sacrifice
• Cervix/Vagina
• Uterine horns
• Oviducts
91
Sacrifice •Hydrosalpinx
Vaginal swab
Days
Immunisation
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and before analysis. Cervico-vagina, uterine horn and oviduct tissues were excised 
and placed in 300µL of ice-cold SPG. Before storing at -80°C, tissues from the 
reproductive tract were homogenised (OMNI TH tissue homogeniser) at 5,000rpm 
until tissues were completely dispersed. Tissue homogenates were centrifuged at 
500xg for 5 min at 4°C before storing and culturing. Infection was quantified using 
the tissue homogenate to infect a confluent monolayer and stained using the method 
previously (Chapter 3). Animals were deemed to have a productive infection at level 
≥300IFU per swab (Carey et al., 2009).  
Assessment of oviduct pathology 
Presence of hydrosalpinx was noted for gross pathology. Although the formation of 
hydrosalpinx is not a definitively representative of oviduct occlusion (Shah et al., 
2005b), its presence does suggest tubule damage and potential fertility 
complications. Hydrosalpinx was measured post mortem at day 49 p.i. 
Presence/absence of hydrosalpinx indicated the incidence of oviduct occlusion and 
the oviduct diameter reflected the severity of the blockage.  
Ribonucleic acid (RNA) extraction and gene expression analysis 
Oviducts were excised on day 6 p.i and stored in RNAlater (QIAGEN) at -80°C. 
Oviducts were separated from the ovary and uterine horns using a stereomicroscope 
(Leica-Microsysems, North Ryde, Australia). Total RNA was extracted from pooled 
oviduct homogenate using the RNeasy Fibrous Tissue mini kit (Cat No. 74704, 
QIAGEN) and treated with RNase-free DNase (QIAGEN) as per the manufacturer’s 
instructions. The purity of RNA was assessed by the 260/280nm ratio using the 
nanodrop spectrophotometer (ThermoScientific). Complimentary DNA (cDNA) was 
synthesised from 1µg of total RNA using RT
2
 First Strand synthesis kit (Cat No. 
330401, QIAGEN) as per the manufacturer’s instructions. cDNA samples were 
mixed with RT
2
 SYBR ROX qPCR mastermix, aliquoted into the RT
2
 Profiler 
Mouse Th17 and Autoimmunity PCR Array (Cat No. PAMM-073A SABioscience-
QIAGEN), amplified and analysed on a 7900HT FAST ABI system (Applied 
Biosystems, Mulgrave, Australia). Expression was normalised using multiple 
reference genes (Glucuronidase-β – gusB, hypoanthine guanine phosphoribosyl – 
HPRT, HSP90ab1, Glyceraldehyde-3-phosphate dehydrogenase – GAPDH, β actin – 
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actB). Fold-changes were calculated using PCR Array Data Analysis Software 3.0 
(QIAGEN) based on the 
ΔΔ
Ct method of relative quantification. Expression was 
further normalised against progesterone treated uninfected animals. 
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RESULTS 
The effectiveness of each vaccine to protect against infection following live C. 
muridarum IVag challenge 
A vaccine with the potential to reduce both the peak bacterial load as well as the 
duration of chlamydial shedding in the lower genital tract, could significantly reduce 
infection transmission (Gray et al., 2009). We therefore determined the degree of 
protection induced by each vaccine by quantifying the amount of bacteria shed into 
the vagina following an IVag challenge with C. muridarum (Figure 6.2). The 
infection in the naive unimmunised group peaked at day 6 p.i and animals continued 
to shed Chlamydia into the vagina for a period of 35 days (Table 6.1). The live 
infection control mice, recovering from a primary infection, were strongly resistant 
to re-infection and were not found to have a productive infection (>300IFU) in the 
vagina. Although no vaccine was able to elicit an equivalent level of protection to the 
live infection control, against the establishment of an infection, IN immunisation 
with either vaccine significantly reduced the peak bacterial load in the vaginal 
shedding when compared to the unimmunised controls at day 6 p.i (P<0.01). Both 
vaccines administered via the SL route significantly decrease the bacterial load shed 
into the vagina (P<0.05), whereas only the CTA1-DD-based vaccine delivered by the 
TC route effectively reduced shedding at day 6 p.i (P<0.05). 
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Figure 6.2: The C. muridarum burden in the vagina and collected by the vaginal 
swab at day 6 p.i. 
Following an IVag challenge with C. muridarum, vaginal swabs were collected over the 
entire duration of an infection and stored in SPG. The amount of C. muridarum collected 
by each swab (IFU/swab) was quantified in vitro from the SPG. Cut-off level for a 
productive infection was set at ≥300IFU/swab. Results are presented as the mean ± SD. 
Each vaccine is grouped with their respective route of immunisation, IN (    ), SL (    ) 
and TC (    ). Significant differences were determined using a one-way ANOVA with 
Tukey’s post-test. Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 
0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
The duration of vaginal shedding was significantly decreased following SL and TC 
immunisation with CT/CpG-based vaccines (P<0.01) (Table 6.1). All of these 
vaccinated animals had ceased shedding by day 18 p.i compared to day 35 p.i for 
unimmunised animals, reducing the duration of infection in the lower genital tract by 
50%. Intranasal immunisation with the CT/CpG containing vaccine also reduced the 
duration of shedding, although this was not significant from the adjuvant control 
group. Immunisation with the CTA1-DD adjuvanted vaccine failed to shorten the 
infection duration, regardless of the immunisation route. 
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Table 6.1: Number of animals with a detectable vaginal C. muridarum infection 
collected by vaginal swabbing.  
 
Following an IVag challenge with C. muridarum, vaginal swabs were collected over the 
entire duration of an infection and stored in SPG. The amount of C. muridarum collected 
by each swab was quantified in vitro from the SPG. Animals were deemed to have 
productive infection at ≥300IFU/swab. Results are presented as number of animals with 
a productive infection as the numerator, over the total number of animals in each group 
as the denominator. The heat map represents 100% of animals infected in black, grey as 
animals begin to clear the infection and white when 100% of animals had no detectable 
infection. Significant differences were determined using a Kaplan-Meier survival curve 
and the log rank post-test. Significance was set at P < 0.05 for all tests. P >0.05 (not 
shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
The net area under the curve analysis of the course of vaginal shedding is a better 
depiction of the overall magnitude of the infection measured in the lower 
reproductive tract. Sublingual and TC immunisation with CT/CpG adjuvanted 
vaccine significantly reduced the overall magnitude of the infection in the vagina 
when compared to the unimmunised naive control group (Figure 6.3). Immunisation 
with the CTA1-DD containing vaccine was unable to significantly decrease the 
overall bacterial magnitude measured in the lower genital tract. 
Days
Group 3 6 9 12 15 18 21 28 35
IN. MOMP + CTA1-DD 5/5 5/5 5/5 5/5 5/5 4/5 1/5 0/5 0/5
IN. MOMP + CT/CpG 4/4 4/4 4/4 4/4 3/4 3/4 2/4 0/4 0/4
IN. MOMP 5/5 5/5 5/5 5/5 5/5 4/5 1/5 0/5 0/5
IN. CTA1-DD 5/5 5/5 5/5 5/5 5/5 4/5 1/5 0/5 0/5
IN. CT/CpG 5/5 5/5 5/5 5/5 5/5 4/5 0/5 0/5 0/5
SL. MOMP + CTA1-DD 5/5 5/5 5/5 5/5 4/5 3/5 2/5 0/5 0/5
SL. MOMP + CT/CpG 5/5 5/5 5/5 4/5 2/5 0/5 0/5 0/5 0/5 ***
SL. MOMP 5/5 5/5 5/5 5/5 4/5 3/5 1/5 0/5 0/5
SL. CTA1-DD 5/5 5/5 5/5 5/5 4/5 3/5 1/5 0/5 0/5
SL. CT/CpG 5/5 5/5 5/5 5/5 5/5 5/5 2/5 0/5 0/5
TC. MOMP + CTA1-DD 5/5 5/5 5/5 5/5 5/5 5/5 1/5 0/5 0/5
TC. MOMP + CT/CpG 5/5 5/5 5/5 5/5 1/5 0/5 0/5 0/5 0/5 ***
TC. MOMP 5/5 5/5 5/5 5/5 5/5 5/5 4/5 0/5 0/5
TC. CTA1-DD 5/5 5/5 5/5 5/5 5/5 5/5 4/5 1/5 0/5
TC. CT/CpG 5/5 5/5 5/5 5/5 5/5 5/5 2/5 0/5 0/5
Unimmunised 15/15 15/15 15/15 15/15 15/15 14/15 11/15 1/15 0/15
Live infection control 0/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15 ***
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Figure 6.3: Infection magnitude determined by the net area under the curve of 
vaginal shedding.  
The area under the curve is a calculation of the region between the line drawn for vaginal 
shedding (IFU/swab) and the x-axis (Appendix 4). This figure depicts the net total area 
of the vaginal shedding for each group over the entire course of infection in arbitrary 
units. Results are presented as the mean ± SD. Each vaccine is grouped with their 
respective route of immunisation, IN (    ), SL (    ) and TC (    ). Significant differences 
were determined using a one-way ANOVA with Tukey’s post-test. Significance was set 
at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 
(***). 
Preventing the ascension of the infection from the vagina into the upper reproductive 
tract can prevent the development of pathology (Cotter et al., 1995). We therefore 
determined the ability of each vaccine to prevent infection ascension and 
colonisation of the upper reproductive tract tissues at the peak of infection on day 6 
p.i (Carey et al., 2009). In the unimmunised naive animals, the greatest quantity of 
Chlamydia was detected in the cervico-vagina, collected by the vaginal swab (Figure 
6.4). Proportionally, the oviducts contained the highest bacterial load of all tissues in 
unimmunised animals, followed by the cervico-vagina then the uterine horns. Low 
levels of infection were detected in the tissues of the live infection control group, 
which verifies the strong protection against re-infection indicated by the vaginal 
shedding data. Intranasal immunisation with the CT/CpG adjuvanted vaccine was the 
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only vaccine to significantly decrease the infectious burden in the upper reproductive 
tract at the peak of infection when compared to the unimmunised controls (P<0.01). 
In animals immunised with CT/CpG adjuvanted vaccine via the IN route, the 
infection either failed to ascend beyond the uterine horns or was eradicated from the 
upper reproductive tract by day 6 p.i. The protection against infection of the upper 
reproductive tract conferred by this vaccine matched with a decrease in the 
chlamydial shedding peak burden and duration measured in the lower reproductive 
tract (Figure 6.2; Table 6.1). Sublingual and TC immunisation with the CT/CpG-
based vaccine, which significantly reduced the peak and duration of vaginal 
shedding, were however unable to prevent the colonisation of the upper reproductive 
tract. The CTA1-DD adjuvanted vaccine failed to prevent the ascension of the 
infection, regardless of the route of administration. 
Figure 6.4: Total infectious load detected in the vaginal swab, cervico/vagina, 
uterine horns and oviducts at day 6 p.i 
Cervico-vagina, uterine horn and oviduct tissues were taken from all groups at day 6 p.i 
and homogenised in SPG. The amount of C. muridarum in the vaginal swab and each 
tissue was quantified in vitro from the SPG. The chlamydial IFU was determined per 
swab or per mg of host tissue. Results are presented as the mean only for simplicity. 
Significant differences were determined for the total; bacterial burden on the entire 
reproductive tract using a one-way ANOVA with Tukey’s post-test. Significance was set 
at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 
(***). 
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The effectiveness each vaccine to protect against the pathology that occurs 
following live C. muridarum vaginal challenge 
Staining for collagen and hence fibrosis was found to be a poor indicator of 
pathology as there was often no clear pathological distinction between tissue taken 
from infected and uninfected groups (Appendix 5). We therefore assessed the 
incidence and severity of hydrosalpinx on day 49 p.i, as this is a commonly used 
marker of upper reproductive tract pathology and infertility in the mouse model 
(Shah et al., 2005b). Following infection, all unimmunised naive animals developed 
severe uni/bilateral hydrosalpinx, indicated by the significant increase in oviduct 
diameter when compared to the uninfected control (P<0.001) (Figure 6.5). The 
incidence and severity of hydrosalpinx was similar between the live infection control 
group and the unimmunised animals. The no infection control group displayed a 
normal oviduct diameter and no evidence of oviduct pathology. The CT/CpG-
containing vaccine delivered via the TC and SL routes, significantly reduced the 
severity of hydrosalpinx when compared to unimmunised controls (P<0.01). 
Moreover, the incidence of gross pathology was also reduced in contrast to the 
unimmunised controls by 50%. These animals immunised with the CT/CpG-based 
vaccine by the SL and TC route, also displayed a reduce peak of infectious burden 
and shorter durations of infection (Figure 6.2; Table 6.1). Interestingly, IN 
immunisation with the CT/CpG-containing vaccine appeared to prevent the 
ascension of infection into the upper reproductive tract (Figure 6.4), however, 75% 
of animals still displayed evidence of oviduct pathology. The CTA1-DD containing 
vaccine delivered via the IN route also reduced both the severity and incidence of 
hydrosalpinx, but this was not found to be significant. The greatest protection against 
the incidence and severity of hydrosalpinx however was observed following SL 
immunisation with the CTA1-DD containing vaccine. The severity of hydrosalpinx 
was reduced significantly by vaccination (P<0.01) and 9/10 oviducts were of normal 
diameter, compared to 2/10 mice in the unimmunised controls (70% reduction). 
Interestingly, SL application of CTA1-DD-based vaccine, shown to offer the greatest 
protection from oviduct pathology, did not significantly alter the total burden in 
tissues at day 6 p.i or infection duration measured in the lower genital tract. This 
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suggests that the protection against hydrosalpinx conferred by this vaccine was 
mediated via mechanisms unrelated to bacterial burden. 
A. 
 
B. 
Figure 6.5: Upper reproductive tract pathology determined by hydrosalpinx 
formation.  
Following an IVag challenge with C. muridarum, each group of animals was assessed 
for the development of oviduct pathology post-mortem at day 49 p.i. (A) Shows the 
appearance of normal (unaffected) uterine horn (UH), oviduct (Ovi) and ovary (O) (left), 
compared to the gross upper reproductive pathology and oviduct swelling following an 
IVag infection with Chlamydia (right). (B) The severity of pathology was measured by 
oviduct swelling. The incidence of pathology was represented as a fraction atop of each 
bar, indicating the number of normal sized oviducts as the numerator, over the total 
number of oviducts measured as the denominator. Results are presented as the mean ± 
SD. Each vaccine is grouped with their respective route of immunisation, IN (    ), SL  
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(    ) and TC (    ). Significant differences were determined using a one-way ANOVA 
with Tukey’s post-test. Significance was set at P < 0.05 for all tests. P >0.05 (not 
shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
Gene expression analysis of oviduct tissues  
The development of oviduct pathology in some instances did not reflect the bacterial 
load cultured from the oviduct tissues, indicating a disconnection between the 
infection level and disease. We therefore analysed the expression of key factors 
mediating immunity and immunopathology in the oviduct tissue at day 6 p.i. The day 
6 p.i point in time was chosen as it represents the peak of bacterial burden on the 
oviduct tissue in naive animals (Carey et al., 2009). In addition, treatment of infected 
animals with antibiotics up to day 7 p.i, eliminates the development of hydrosalpinx 
(Su et al., 1999), which suggests that the onset of irreversible oviduct pathology 
begins during or shortly after the peak of infectious burden at day 6 p.i. The oviducts 
are also where infection-induced inflammation results in tubal blockage and 
infertility in the mouse. Figure 6.6 depicts the gene expression profiles during a 
normal course of infection and pathology development (unimmunised), pathology 
protected (SL delivered MOMP plus CTA1-DD) and the infection protected (IN 
delivered the MOMP plus CT/CpG), all normalised against the no infection control. 
In the unimmunised group there was a strong induction of pro-inflammatory 
cytokines IL-1β (63-fold increase), IL-18 (2-fold increase), TNFα (49-fold increase) 
and IL-6 (19-fold increase). When this gene expression profile was compared to that 
of an animal protected from infection exclusively (IN delivered MOMP plus 
CT/CpG), the infection protected animals displayed a significant down-regulation of 
pro-inflammatory cytokines IL-1β (62-fold reduction), IL-18 (6-fold reduction), 
TNFα (48-fold reduction) and IL-6 (13-fold reduction) and up-regulation of Th17-
related factors IL-17A (218-fold increase), IL-17C (118-fold increase), IL-17D (11-
fold increase), IL-17F (864-fold increase), IL-17RC (4-fold increase), IL-17RD (8-
fold increase) and IL-17RE (4-fold increase). Conversely, when a normal course of 
infection was compared to that of an animal protected from pathology exclusively 
(SL delivered MOMP plus CTA1-DD), the pathology protected animals displayed a 
significant up-regulation of Th17-related cytokines IL-17A (165-fold increase), IL-
17C (121-fold increase), IL-17D (8-fold increase) and pro-inflammatory cytokines 
TNFα (5-fold increase) and IL-6 (20-fold increase). In addition, these mice displayed 
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an increased expression of Th2 and Treg-associated cytokines IL-13 (25-fold 
increase) and IL-10 (7-fold increase) and the extracellular matrix hydrolysing 
MMP13 (7-fold increase). These animals also showed a down-regulation of the pro-
inflammatory cytokines IL-1β (61-fold reduction) and IL-18 (34-fold reduction), and 
IL-17 receptors IL-17RD (13-fold reduction) and IL-17RE (136-fold reduction). 
Noteworthy similarities between both vaccinated groups, was the overwhelming 
down-regulation of pro-inflammatory cytokines and over-expression of IL-17 
cytokines when compared to a normal course of infection. Differences between the 
vaccines included an increase in IL-13, IL-10, and MMP13 and a decrease in IL-17 
receptor expression in the pathology protected group compared to infection 
protected. 
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Figure 6.6: Gene expression of key mediators of inflammation and immunity in the 
oviducts at day 6 p.i. 
The RNA was extracted from pooled oviducts from the SL. MOMP + CTA1-DD 
(pathology – protected; infection – unprotected; MOMP response – weak), IN. MOMP + 
CT/CpG pathology – unprotected; infection – protected; MOMP response – strong), 
unimmunised pathology – unprotected; infection – unprotected; MOMP response – n/a) 
and no infection control groups at day 6 p.i. The difference in expression of T cell 
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surface receptors, suppressor of cytokine signalling (SOCS), pro-inflammatory 
cytokines, Th1/Th2/Th17/Treg differentiation factors and MMPs are shown between 
pathology protected animals, infection protected animals and unimmunised. Expression 
for all groups were normalised against the no infection control group. Results are 
presented as the mean fold-change for five mice. Significance was set at >10-fold 
change. Between 10 – 100-fold-change (*), 100 – 500-fold-change (**) and >500-fold-
change (***). 
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DISCUSSION  
The ideal vaccine should elicit immunity against infection as well as pathology. In 
this chapter, we assessed the level of protection conferred against a chlamydial 
genital tract infection and the associated disease following immunisation with two 
different vaccines by three needle-free routes. The CT/CpG adjuvanted vaccine 
delivered via the SL and TC routes significantly reduced the incidence and severity 
of pathology, in addition to the duration of infection measured in the lower genital 
tract. The protection elicited by this vaccine was associated with the induction of 
antigen-specific secretion of IFNγ and TNFα in the lymph nodes draining the site of 
infection (Chapter 4), previously shown to elicit protection from infection (Igietseme 
et al., 1993; Olsen et al., 2010; Yu et al., 2010; Yu et al., 2011; Yu et al., 2012). 
Despite the induction of antigen-specific antibodies, these appeared to play a minor 
role in protection against infection and pathology. Interestingly, we also identified 
two contrasting vaccines capable of enhancing infection resolution or preventing 
pathology exclusively. The IN delivered CT/CpG-based vaccine prevented the 
ascension of infection into the oviducts by day 6 p.i, yet the incidence of pathology 
was unaffected (infection protected). Conversely, the SL delivered CTA1-DD 
adjuvanted vaccine prevented the development of pathology without significantly 
altering the bacterial burden in the oviducts (pathology protected). This demonstrated 
a disconnection between bacterial burden and tissue damage, which presented a 
unique opportunity to investigate how immunity against infection and pathology can 
develop independently from one another. In the oviduct tissue, both vaccines 
suppressed the expression of the IL-1β (implicated in pathology), but displayed 
opposing effects on the IL-17 signalling pathway. While both vaccines expressed 
high levels of IL-17 cytokines, the infertility-protected group displayed significantly 
reduced expression of corresponding IL-17 receptors. This study showed that the 
degree of protection against infection and tissue damage generated following 
vaccination is defined by the balance of IL-17-mediated responses. 
Immunity against Chlamydia genital tract infection is predominantly dependent on 
the Th1 cell-mediated response, with a minor role for antibodies (Farris and 
Morrison, 2011). Similarly, the immunity induced by MOMP-based vaccines relies 
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on the presence of both T cells and antibodies (Farris et al., 2010). B cell-deficient 
mice are more susceptible to re-infection and shed greater amounts of Chlamydia in 
cervico-vagina secretions between days 5 – 8 p.i following a secondary infection (Su 
et al., 1997). This suggests that antibodies mediate immunity against the 
establishment of a genital tract infection and control bacterial burden in the early 
stages of re-infection. The induction of MOMP-specific antibodies following 
vaccination did not prevent the establishment of an infection, although there was 
some minor correlation between serum IgG antibody titres (Figure 4.9) and the 
control of bacterial burden in the lower genital tract (Figure 6.2, 6.3; Table 6.1). The 
systemic transfer of MOMP-specific serum or monoclonal antibodies prior to 
challenge has been shown previously to significantly enhance the resolution of a 
genital tract infection (Pal et al., 1997b; Farris et al., 2010), contrasting to our 
findings. However, both of these studies used large and repeated doses of antigen-
specific antibodies to confer such strong protection. Furthermore, neither study 
reported the quantity of antigen-specific antibody reaching the genital tract and 
whether this amount is physiologically achievable or relevant.  
Similar to the respiratory tract model, IgA also played a subordinate role in 
protection against a genital tract infection. This was likely due to the low levels of 
IgA detected in the lower genital tract secretions (Cotter et al., 1995), which were 
similar across all MOMP-immunised groups (Figure 4.11). Therefore, IgA was 
ineffective at mediating protection against a genital tract infection in vivo, possibly 
due to the induction of insufficient levels of IgA in the mucosal secretions needed to 
inhibit chlamydial attachment (as shown in vitro) (Figure 4.11). 
There also appeared to be minimal correlation between the induction of systemic and 
mucosal IgG titres (Figure 4.9, 4.11, 4.12) and the prevention of oviduct pathology 
(Figure 6.5). Adoptive transfer of IgG and to a lesser extent IgA, using a backpack 
hybridoma system reduced the incidence and severity of hydrosalpinx following a 
genital tract infection (Cotter et al., 1995). The authors suggested that high serum 
IgG antibody levels together with the highly vascularised upper female reproductive 
tract lead to a considerable level of antibody transudation from the serum, which 
contributed to the lower incidence of hydrosalpinx (Cotter et al., 1995). However, 
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this antibody-mediated protection against upper tract pathology also reduced the 
chlamydial burden in the oviduct tissues, contrasting to our findings that showed no 
consistent correlation between antibodies and a reduction in bacterial load in the 
upper reproductive tract. The overall involvement of antibodies in host defence 
remains poorly relatable to clearance of a genital tract infection (Johansson et al., 
1997) and the role of antibodies in preventing pathology is perhaps even more 
complex. Similarly, the contribution of antibodies to protection against infection and 
pathology following a genital tract infection in our study appears minimal. 
Sublingual and TC immunisation with the CT/CpG-based vaccine elicited a 
significant level of protection against the duration of infectious vaginal shedding 
(Table 6.1) and oviduct pathology (Figure 6.5) following a genital tract challenge. 
This vaccine induced secretion of the type 1 pro-inflammatory cytokines TNFα and 
IFNγ by lymphocytes isolated from the MiLN, following in vitro stimulation with the 
MOMP (Figure 4.6). These same stimulated cells also secreted low levels of the 
inhibitory anti-inflammatory cytokine IL-4. Generating a strong Th1 cell-mediated 
response is major objective of vaccine design (Yu et al., 2010; Yu et al., 2011; Yu et 
al., 2012), as CD4
+
 cells are the dominant contributor toward the resolution of an 
active infection, immunity against re-infection and protection against upper 
reproductive tract pathology (Landers et al., 1991; Morrison et al., 1995; Su and 
Caldwell, 1995; Morrison et al., 2000; Morrison and Morrison, 2001). Induction of 
IFNγ signalling through the IFNγR is vital for the resolution of a genital tract 
infection, potentially through both T cell-dependent and independent mechanisms 
(Cotter et al., 1997b; Perry et al., 1997; Ito and Lyons, 1999; Perry et al., 1999b; 
Nelson et al., 2005b). The role that TNFα plays is less clear (Darville et al., 2000), 
but may contribute toward infection resolution as well as pathology (Perry et al., 
1999b; Murthy et al., 2011a). Synergism between IFNγ and TNFα has also been 
reported to enhance the rate of infection clearance more so than either cytokine 
produced alone (Igietseme et al., 1993; Kannanganat et al., 2007; Olsen et al., 2010; 
Yu et al., 2010; Yu et al., 2011; Yu et al., 2012). This may occur by increasing 
cytokine production, antigen-presentation and recruitment of T cells into the genital 
tract (Perry et al., 1998; Fichorova and Anderson, 1999; Gabr et al., 2011). 
Therefore, the induction of IFNγ and TNFα following immunisation coincided with 
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strong protection against a genital tract infection, potentially due to a synergistic 
interaction between multiple pro-inflammatory cytokines. To our knowledge, this is 
the first evidence of this combination cytokine response conferring protection against 
oviduct pathology following a genital tract challenge. 
Furthermore, it was essential that these antigen-specific and pro-inflammatory cells 
were positioned in the local lymph nodes draining the genital tract (MiLN) to 
enhance protection. This is an identical finding to that in the respiratory tract 
infection model (Chapter 5), where the induction of pro-inflammatory cytokine 
responses in MdLN and not the spleen, predicted protection against infection and 
disease. Proliferation of antigen-specific T cells, the acquisition of effector function 
and migratory properties can be detected in the regional lymph node draining the site 
of a HSV infection up to 2 days prior to any response in the spleen (Coles et al., 
2002). Similarly, Roan et al., (2006) showed the importance of MiLN-resident 
Chlamydia-specific T cells for the induction of protective immunity in mice against 
an intrauterine challenge with the human C. trachomatis serovar L2. Following the 
adoptive transfer of Chlamydia-specific T cell antigen 1 (Cta1) NR1 CD4
+
 T cell 
clones; these cells were found to proliferate extensively in the MiLN 3 – 4 days 
following the infection. These T cells were found to express higher levels of 
activation markers (CD69 and CD44) and low levels of CD62L, indicative of tissue-
homing effector memory phenotype. Seven days following the infection, NR1 cells 
were detected in the genital tract tissues, expressing the same activation and effector 
memory phenotype identified on NR1 cells proliferating in the MiLN. This response 
conferred an equivalent amount of protection against chlamydial burden to that seen 
in the strongly resistant live infection control group. Importantly, the same level of 
proliferation and activation of NR1 cells could not be detected in non-draining lymph 
nodes (Roan et al., 2006), which may indicate that the antigen-specific cells localised 
in the MiLN and not other peripheral lymphoid tissues are major drivers of 
protection against a Chlamydia genital tract infection in mice. Therefore, protection 
against the magnitude of infection and the development of oviduct pathology 
following a chlamydial genital tract infection relies heavily on priming and 
positioning type 1 cytokine-secreting cells in the regional lymph nodes draining the 
site of infection, potentially for the initiation of a rapid response to infection. 
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Immunisation with the CT/CpG-adjuvanted vaccines via the SL and TC routes may 
have promoted the expression of homing receptors on activated lymphocytes and 
enhanced their recruitment to distant mucosal effector sites via the CMIS. 
Oviduct pathology however (Figure 6.5), was not always directly linked with the 
bacterial burden in the upper reproductive tract (Figure 6.4). The infection protective 
vaccine (IN. MOMP plus CT/CpG) appeared to prevent the ascension of infection 
into the oviducts, but not the development of pathology when compared to the 
unimmunised naive mice. Conversely, the pathology protective vaccine (SL. MOMP 
plus CTA1-DD) reduced the incidence of oviduct pathology to near that seen in 
uninfected mice without significantly altering the bacterial burden in the oviducts. 
This disconnection between bacterial burden and the development of pathology was 
also seen in the respiratory tract model of infection (Chapter 5) and has been reported 
elsewhere in the literature (Maxion et al., 2004; Carey et al., 2009; Wang et al., 
2009). Increasing the inoculation doses of C. muridarum modulates the innate and 
adaptive response; however the level of gross oviduct pathology that develops is not 
significantly different between animals given 5 x 10
2
 verses 1 x 10
7
 IFU 
intravaginally (Maxion et al., 2004; Carey et al., 2009). This has also been shown in 
the context of a vaccine, where IM immunisation with T3SS protein Tarp together 
with IFA/CpG provided almost no protection against the infection measured in the 
lower genital tract, but significantly reduced the incidence of hydrosalpinx (Wang et 
al., 2009). We therefore decided to investigate the cause of this anomaly in more 
detail, by analysing the gene expression in the oviduct tissues, directly involved in 
pathogenesis, between the infection- and pathology protected groups. Although 
analysis at multiple points in time would have been desirable, we chose day 6 p.i for 
analysis as it represents the peak bacterial burden in the oviducts and corresponds to 
a period in which the onset of irreversible pathology begins in naive animals (Su et 
al., 1999; Carey et al., 2009). The most notable difference in gene expression 
following infection between vaccinated and unvaccinated animals was an up-
regulation of pro-inflammatory cytokines IL-1β and IL-18 in the unimmunised 
group. Macrophages and neutrophils are the major source of IL-1β and IL-18, but 
these cytokines are also produced by Chlamydia-infected epithelial cells (Munder et 
al., 1998; Lu et al., 2000a; Hook et al., 2005; Prantner et al., 2009). This is 
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consistent with the finding that the immune cells recruited into the oviduct around 
day 6 following a primary infection of naive mice are predominantly innate 
(macrophages and neutrophils), as opposed to adaptive (T and B cells) (Kelly and 
Rank, 1997; Kelly et al., 2000). Therefore, the immune response of an unimmunised 
animal to a chlamydial infection in the upper reproductive tract, at a point in time 
consistent with the development of irreversible pathology, was predominantly driven 
by innate immunity.  
Both IL-1β and IL-18 were significantly up-regulated in the infected unimmunised 
group by comparison to vaccinated groups (Figure 6.6). Interestingly, caspase-1 
cleaves pro-IL-1β and pro-IL-18 to the mature and biologically active forms 
(Thornberry et al., 1992), which may indicate the involvement of the inflammasome 
in the development of pathology in naive animals. Capase-1
-/- 
mice exhibit a normal 
primary and secondary course of infection, yet these animals develop significantly 
less pathology than WT mice (Cheng et al., 2008), suggesting that caspase activity is 
in part responsible for the development of pathology in naive mice. The cytokine IL-
18 is yet to be investigated in the genital tract model of infection, although IL-18-
deficiency has been shown to have minimal effect on the clearance of infection and 
pathological damage following a lung infection (Lu et al., 2000b). Interleukin-1β on 
the other hand has been extensively implicated in the development of pathology 
following a genital tract chlamydial infection (Cheng et al., 2008; Prantner et al., 
2009; Nagarajan et al., 2012), even in the absence of infiltrating leukocytes (Hvid et 
al., 2007). Infected unvaccinated animals displayed over a 60-fold up-regulation of 
IL-1β compared to both vaccinated groups, at a point in time corresponding with the 
commencement of irreversible pathology (Su et al., 1999). Consistent with the 
literature (Cheng et al., 2008), IL-1β appears to play a dominant role in oviduct 
pathogenesis in naive animals during a primary infection, which may be due to a 
greater reliance on innate immunity (neutrophils and macrophages) for the clearance 
of infection (Figure 6.7).  
Both vaccinated groups however showed a stronger down-regulation of IL-1β when 
compared to the unvaccinated group, which may indicate a shift in these animals to 
utilise the adaptive immune response generated following vaccination opposed to the 
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damaging innate response. However, the infection protected vaccine group 
developed pathology, despite the reduction in IL-1β expression. This suggests that 
there are mechanisms in addition to IL-1β/caspase-1, contributing towards pathology 
in mice that may involve an immunopathological adaptive element.  
The most notable difference in gene expression between the infection protected and 
unvaccinated groups regarding aspects of the adaptive immune response was the 
increased expression of Th17-realated constituents. The infection protected vaccine 
group displayed enhanced expression of IL-17 cytokines (IL-17A, C, D and F) and 
their associated receptors (IL-17RC, D and E) compared to the unimmunised group, 
indicating a potential increase in IL-17-mediated signalling. The cytokine IL-17A 
(also known as IL-17) is crucial for host defence against numerous intracellular 
pathogens (Khader et al., 2009), including Chlamydia (Bai et al., 2009). Interleukin-
17 and IL-17F are produced primarily by the CD4
+
 Th17 subset of T cells (Dong, 
2008) and influence the recruitment of neutrophils and development of Th1 
immunity (Bai et al., 2009; Watanabe et al., 2009; Scurlock et al., 2010). 
Furthermore, Yu et al., (2010) recently described a correlation between IFNγ+IL-17+ 
CD4
+
 T cells and enhanced resolution of chlamydial genital tract infection. The 
infection protected group, shown to have elevated expression of IL-17 cytokines and 
their associated receptors in the oviducts, cleared the infection in the upper 
reproductive tract significantly faster than unimmunised animals that displayed 
almost no expression of Th17-related factors. Our data therefore supports a 
protective role for IL-17-mediated defence against a Chlamydia genital tract 
infection, at least in relation to infectious burden.  
However, IFNγ+IL-17+ CD4+ T cells, deemed protective against chlamydial infection 
(Yu et al., 2010; Yu et al., 2011; Yu et al., 2012), are also enriched in tissue affected 
in Crohn’s disease and experimental autoimmune encephalomyelitis (EAE) (Neurath 
et al., 2002; Bettelli et al., 2004), suggestive of a link between Th17 and 
autoimmunity. Lu et al., (2011) also recently found that protection from a chlamydial 
infection following vaccination associated with high levels of IFNγ, yet a reduction 
in pathology required decreased levels of IL-17. As IL-17-mediated responses have 
been implicated in both immunopathology and host defence against pathogens 
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(Peters et al., 2011), this may explain why the infection protected group was unable 
to prevent oviduct pathology despite preventing the infection ascension. Supportive 
of this theory of vaccine-induced IL-17-mediated protection and immunopathology, 
the pathology protected vaccine group displayed decreased expression of IL-17 
cytokines and IL-17 receptors, signifying a potential inhibition of IL-17-mediated 
signalling that may have prevented the development of oviduct pathology and the 
rapid clearance of infection. 
The precise mechanism(s) behind IL-17-mediated immunity and immunopathology 
in regards to a chlamydial infection are unknown. Interleukin-17 cytokines can act 
upon epithelial cells as the mucosa highly expresses IL-17 receptors (Li et al., 2006; 
Ramirez-Carrozzi et al., 2011). The cytokine IL-17 does not have a direct anti-
chlamydial effect at least in vitro (Zhang et al., 2009) and may instead confer 
immunity by recruiting and activating of other adaptive immune populations (Bai et 
al., 2009). Alternatively, stimulation of epithelial cells with IL-17 induces the release 
of pro-inflammatory cytokines, chemokines and various colony-stimulating factors 
that encourage the recruitment of tissue-damaging neutrophils (Fossiez et al., 1996). 
Interleukin-17 cytokines further synergises with pro-inflammatory cytokines like IL-
1β and TNFα produced by the epithelia cells (Jovanovic et al., 1998; Yamaguchi et 
al., 2007; Gaffen, 2009; Onishi et al., 2010; Chiricozzi et al., 2011) to support the 
longevity of the pro-inflammatory immune response. This response may recruit and 
activate additional macrophages and neutrophils, producing NO and MMPs (Prause 
et al., 2004) that have been shown to be damaging during a chlamydial genital tract 
infection (Dixon et al., 2010; Lee et al., 2010b; Frazer et al., 2011). Moreover, IL-1β 
and TNFα can stimulate a further release of IL-17 cytokines and expression of IL-17 
receptors (Chang et al., 2011; Ramirez-Carrozzi et al., 2011). Therefore, the 
induction of IL-17-mediated responses following vaccination may create a positive 
feedback loop, potentially initiated by the adaptive response and sustained by the 
host cell epithelium (Figure 6.7), not unlike the cellular hypothesis of chlamydial 
pathogenesis (Stephens, 2003).  
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A. 
 
B. 
 
C. 
 
Figure 6.7: Hypothesised mechanisms of infection clearance and development of 
pathology in the oviducts in vaccinated and unvaccinated animals.  
(A) Infection of naive animals leads to a significant induction of pro-inflammatory 
cytokines, mainly tissue damaging IL-1β. This could lead to an influx of neutrophils and 
M1 macrophages (SOCS1<SOCS3), which are the major producers of IL-1β. Over-
production of IL-1β leads to direct tissue damage. (B) Infection of the infection protected 
group (IN. MOMP plus CT/CpG) leads to a significant up-regulation of IL-17-mediated 
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defences, which rapidly resolves the infection. Prolonged IL-17 signalling may however 
lead to the recruitment of neutrophils and secretion of pro-inflammatory cytokines by 
epithelial cells. Pro-inflammatory cytokines recruit M1 macrophages (SOCS1<SOCS3) 
and increase IL-17-mediated defences, which causes tissue damage. (C) Infection of the 
pathology protected group leads to a significant up-regulation of IL-17 cytokines, but not 
the receptors required for optimal signal transduction or eradication of the infection. IL-
13 is also expressed which activates anti-inflammatory M2 type macrophages 
(SOCS1>SOCS3). M2 macrophages secrete IL-10 and MMP13 involved in inhibiting 
pro-inflammatory cytokine secretion and enhancing tissue repair, respectively. 
The role of IL-17 signalling was recently assessed in the context of a primary 
Chlamydia genital tract infection (Scurlock et al., 2010). The IL-17RA is an essential 
co-receptor to the majority of IL-17 receptors, necessary for optimal signal 
transduction of IL-17A, C, D and F (Kuestner et al., 2007; Rong et al., 2009; Hu et 
al., 2010; Chang et al., 2011; Ramirez-Carrozzi et al., 2011). Mice deficient in IL-
17RA therefore largely portray the involvement IL-17 signalling plays in host 
defence and disease. The IL-17RA
-/-
 mice were found to resolve a primary infection 
and develop pathology similar to WT animals (Scurlock et al., 2010). For the most 
part, this study recognised IL-17-mediated responses as redundant in the 
development of oviduct pathology following a primary infection. However, 
pathology mediated by IL-17 signalling reported in our study was due to the presence 
of an adaptive response generated following vaccination and not present during a 
primary infection. Therefore, we expand on the findings by Lu et al., (2011) 
implicating IL-17 signalling, driven by the adaptive immune response, as playing a 
causative role in upper reproductive tract pathology following a chlamydial genital 
tract infection.   
How each vaccine was able to differentially regulate IL-17-mediated responses is 
unclear, however, the route of immunisation (Zygmunt et al., 2009) and adjuvants 
(McNeal et al., 2007; Hasselberg et al., 2009; Meza-Sanchez et al., 2011; Xu et al., 
2012) utilised may have contributed. The infection protective vaccine contained both 
CT and CpG that elicit high levels of TGF-β, IL-6 and IL-17 (Meza-Sanchez et al., 
2011; Xu et al., 2012), which can facilitate the development of Th17 immunity. 
These adjuvants however also promote Th1 and Th2 immune responses, which are 
known suppressors of Th17 responses (Weaver et al., 2006). The IN route utilised by 
the infection protective vaccine may also have been a contributing factor. Zygmunt et 
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al., (2009) described a predisposition for immunisation via the IN route to promote 
Th17 immune responses due to an adjuvant-independent over production of IL-6 by 
DC localised in the NALT. Alternatively, the SL mucosa targeted by the pathology 
protective vaccine, which displayed reduced IL-17 responses, may elicit a more 
tolerogenic phenotype. The human oral mucosa, displaying similar cellular 
distribution to BALB/c mice (Mascarell et al., 2009), expresses high levels TGF-β 
and FoxP3 and low levels of Th17 differentiation factors IL-6 and RORγt and 
associated cytokines IL-17A, IL-17F, IL-22 and IL-26 (Allam et al., 2011). CTA1-
DD also elicits a high level of IFNγ with relatively low levels of IL-17 (McNeal et 
al., 2007), identical to the type of response that is responsible for the protection 
against pathology (Lu et al., 2011). In this study, the oviduct tissues of animals 
immunised with the CTA1-DD adjuvanted vaccine via the SL route displayed a 
higher expression of IFNγ and IL-10 compared to the infection protected group, 
cytokines previously shown to negatively regulate Th17 immunity (Harrington et al., 
2005; Cruz et al., 2006; Chaudhry et al., 2011; Huber et al., 2011; Lazarevic et al., 
2011). The IL-10 cytokine has also been shown in vitro to inhibit the production of 
potentially damaging pro-inflammatory cytokines by epithelial cells and 
macrophages (Yilma et al., 2012), which may be important in controlling the 
development of pathology in the upper reproductive tract tissues. Although 
speculative, the IL-17-mediated bias induced within animals protected from 
infection, may have been the result of utilising the IN route and CT/CpG adjuvant 
combination. Conversely, the SL route, the CTA1-DD adjuvant and increased 
expression of IFNγ and IL-10 in the oviduct tissue, may have suppressed the 
induction of IL-17-mediated defence in pathology protected animals. 
In addition to the potential suppression of IL-17-mediated signalling, the phenotype 
of the pathology protected group could also be explained by the activation of M2 
macrophages that inhibit inflammation and mediate wound repair. Activated by IL-4 
and IL-13 secreted by CD4
+
 Th cells (Loke et al., 2007), M2 macrophages are a 
major source of IL-10 and MMP13. Interestingly, IL-13, IL-10 and MMP13 are 
significantly up-regulated in oviducts of the pathology protected group when 
compared to the infection protected vaccine group. Alternatively activated 
macrophages (M2) differ from classical macrophages (M1) by the synthesis of 
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arginase, which inhibits NO production used by M1 macrophages to kill intracellular 
bacteria (Briken and Mosser, 2011). As NO production has both protective and 
pathological roles during a Chlamydia infection (Ramsey et al., 2001a; Ramsey et 
al., 2001b; Jayarapu et al., 2010), this may also explain the phenotype of the 
pathology protected vaccine, protected from the development of oviduct disease but 
not the infection. In mice, the ratio of SOCS1 and SOCS3 can be used to identify the 
induction of M1 and M2 macrophages, where the SOCS1:SOCS3 ratio is high in M2 
macrophages but low in M1 macrophages (Dickensheets et al., 2007; Whyte et al., 
2011). In the present study, the SOCS1:SOCS3 ratio favoured the M2 phenotype in 
the oviducts of the pathology protected animals (3:2), but polarised towards the M1 
type for both the unvaccinated (2:3) and infection protected vaccine group (1:2). This 
was also found to be the case during a N. brasiliensis lung infection, where M2 
macrophages facilitated rapid resolution of tissue damage (Chen et al., 2012). 
Therefore, the over-expression of M2-related cytokines and MMPs, in addition to a 
SOCS’s ratio that favours the development of arginase-expressing M2 macrophages, 
may implicate M2 macrophages mediating inflammation and wound repair in the 
pathology protected vaccine group.  
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CONCLUSIONS 
The aim of this chapter was to assess the level of protective immunity against a 
Chlamydia genital tract infection and the associated disease following immunisation 
with the MOMP plus CTA1-DD or CT/CpG via TC, IN and SL routes. The MOMP 
plus CT/CpG vaccine was most protective against a reproductive tract infection and 
associated pathology when delivered by the SL and TC routes. Intranasal 
immunisation with the MOMP plus CTA1-DD was partially protective against 
infection, yet SL administration with the same vaccine provided near complete 
protection against pathology. The immune responses induced following 
immunisation, determined in Chapter 4, were then compared with the level of 
protection against infection and disease. Although there appeared to be a minor 
correlation between the induction of serum IgG and protection, antigen-specific 
production of TNFα and IFNγ in the lymph nodes draining the site of infection 
(MiLN) were found to have the strongest connection with early infection resolution 
and pathology prevention. This study also indicated that the IL-17-mediated 
responses generated following vaccination can determine the balance between 
infection control and tissue damage. An over-expression of IL-17 signalling may 
facilitate the early eradication of infection but also exacerbate pathology, potentially 
through the induction of a cyclical pro-inflammatory response. Therefore, the 
induction of IL-17-mediated responses should be avoided for an effective vaccine 
against a Chlamydia genital tract infection, by careful selection of adjuvants and 
immunisation routes. We also provided the first, albeit circumstantial evidence, of 
the involvement of M2 type macrophages potentially modulating protection against 
Chlamydia-induced oviduct pathology. 
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CHAPTER SEVEN: GENERAL DISCUSSION AND 
FUTURE DIRECTIONS 
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Chlamydia is rife in the community and infections are responsible for a wide range 
of diseases with enormous global economic and health burden. To date, screening 
and treatment strategies employed by many countries have failed to stem the rise in 
prevalence long-term and as a result the development of an effective vaccine is the 
only viable alternative. Chlamydia is a pathogen that infects through mucosal 
surfaces, therefore protection is reliant on generating mucosal immunity. Effective 
induction of mucosal immunity occurs best when targeting vaccination to the 
epithelium, which stimulates APCs present in the mucosal tissues that are specialised 
in initiating responses to mucosal pathogens. The success of vaccines targeting the 
mucosal epithelium is reliant on a potent adjuvant to elicit robust activation and 
maturation of APCs present at the site of immunisation, necessary to overcome the 
induction of tolerance. A major obstacle to the development of an effective vaccine 
for Chlamydia is the lack of proven strong adjuvants that induce good protection at 
mucosal surfaces, without harmful side effects. We addressed this gap in two ways, 
by investigating a novel non-toxic mucosal adjuvant (CTA1-DD) and by utilising 
different immunisation routes (IN, SL and TC) to limit the toxicity of adjuvants 
precluded from human use (CT and CpG), while still harnessing their 
immunogenicity.  
The CTA1-DD adjuvant was safe and immunogenic via the IN route 
Currently, there is only one commercially available vaccine that targets a mucosal 
surface other than the gut. FluMist® is a trivalent live-attenuated influenza vaccine 
delivered intranasally, which elicits a greater level of local immunity in the lungs 
than the more commonly used inactivated influenza vaccine delivered parenterally 
(Brokstad et al., 2002). The live attenuated nature of this vaccine means it is self-
replicating and -adjuvanting and does not require the addition of a potent mucosal 
adjuvant to elicit protective immunity. Nasalflu® however, containing the 
inactivated flu virosome, required the addition of the powerful enterotoxic LT 
adjuvant to elicit a protective response following IN delivery. As a direct result of the 
adjuvant, some patients developed CNS complications following IN vaccination 
(Fujihashi et al., 2002; Couch, 2004; Kiyono and Fukuyama, 2004; Mutsch et al., 
2004). This side effect was substantiated by an additional clinical trial using two 
different IN subunit vaccines which also contained the LT adjuvant (Lewis et al., 
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2009). The IN route is of particular interest for human vaccine design against 
mucosal pathogens as it targets the Waldeyer’s tonsillar ring, which contain unique 
mucosal inductive sites, specialised in promoting trafficking of mucosal immunity to 
distant effector sites like the reproductive and respiratory tracts (Kiyono and 
Fukuyama, 2004; Brandtzaeg, 2009). As most subunit vaccines targeted to the 
epithelium require a potent adjuvant to generate a protective response at the mucosal 
surface, there is a need for more effective adjuvants that are safe when delivered by 
the IN route. In the present study, CTA1-DD was found to be both immunogenic and 
safe by the IN route in mice. The emergence and success of novel non-toxic 
adjuvants like CTA1-DD make the nasal route safer to target for vaccination, which 
has profound implications for human vaccines developed against mucosal pathogens.  
The CT/CpG adjuvant was safe and immunogenic via needle-free routes of 
immunisation other than IN 
Cholera toxin and CpG have historically been the “gold standard” mucosal adjuvants 
for use in animal studies, as these prevent mucosal tolerance and elicit strong 
immune responses following vaccination. The inherent toxicity of both CT and CpG 
has restricted their use in humans, particularly via certain routes of immunisation like 
IN (Fujihashi et al., 2002; Couch, 2004; Heikenwalder et al., 2004; Kiyono and 
Fukuyama, 2004; Mutsch et al., 2004; Klinman et al., 2007; DeFrancesco, 2008). 
Utilising different immunisation routes can however limit the toxicity of certain 
adjuvants in both animals and humans, while still harnessing their immunogenicity 
(Skelding et al., 2006; McKenzie et al., 2007; Frech et al., 2008). In the present 
study, CT/CpG was both safe and immunogenic by the SL and TC routes in mice. 
This has significant implications for human vaccine development for a number of 
reasons. Needle-free immunisation targeting the epithelium is preferred to injections 
as it is safer and more cost-effective (if the threat of blood-borne diseases is 
considered), does not require trained personnel, facilitates rapid immunisation of 
large populations and enhances the population compliance critical for herd immunity 
(Giudice and Campbell, 2006). Overall, adjuvants initially thought to be too toxic for 
human use, may be administered via SL or TC route and still maintain effectiveness 
needed for the development of needle-free vaccines capable of inducing mucosal 
immunity. 
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The protection elicited by SL and TC immunisation with the CT/CpG-based 
vaccine could have a real benefit to the community, if resistance can be replicated 
in humans 
Induction of complete sterilising immunity against Chlamydia is most desirable, but 
may be difficult or impossible to achieve (Beagley et al., 2009b). Altering the course 
of infection may be a more realistic measure of controlling infection and reducing 
disease. Gray et al., (2009) recently mathematically modelled the potential impact of 
vaccines with different efficacies against C. trachomatis, using behavioural, 
biological and clinical data. It was suggested that implementing a vaccine that 
elicited even moderate gender-specific protection i.e. reduced chlamydial shedding 
or infection duration, predominantly targeting females, has the potential to 
completely eradicate all infection and Chlamydia-related sequelae from the human 
population (Gray et al., 2009). The acquired immunity generated following SL and 
TC immunisation with CT/CpG in conjunction with the MOMP, was protective 
against both genital and respiratory tract Chlamydia challenges, reducing both the 
peak and duration of infection. According to the models used by Gray et al., (2009), 
this vaccine could have a positive influence on infection and disease prevalence if the 
results can be replicated in humans.  
Vaccination by the SL and TC routes with the CT/CpG-based vaccine also reduced 
the subsequent development of oviduct pathology in female mice by 50%. It is 
estimated that the Australian health systems spends between $90 – 160 million each 
year on C. trachomatis-related illness, with disease in women accounting for 80% of 
the total outlay (Patel et al., 2008). In addition to reducing reproductive tract 
pathology, the CT/CpG-based vaccine delivered via SL and TC routes also reduced 
the fibrotic scarring and lung consolidation associated with the exacerbation of 
COPD and asthma. Chronic lower respiratory tract disease like COPD and asthma 
were the underlying cause of 6,122 deaths in 2010 (ABS, 2010), with the total annual 
economic cost of over $100 billion in Australia (NAC, 1992; ALF, 2010). A 
chlamydial vaccine that provides simultaneous protection against infection and 
pathology at both mucosal surfaces has enormous implications for global health, if 
protection can be translated from mice to humans. 
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Mouse models of infection are an essential first step for pre-clinical development and 
testing of vaccines. However, a number of key differences exist between rodents and 
humans, in the context of the vaccination strategy used in this study, which will 
require further investigation in animal models more akin to human anatomy and 
physiology. Rodent skin, targeted by TC immunisation, is considerably more 
permeable with more hair follicles than human skin. These differences in the 
epithelia architecture may influence crucial passage of the vaccine into the 
epithelium and hence immunogenicity. Alternatively, the oral cavity of rodents, 
targeted by SL immunisation, is more keratinised compared to humans (Song et al., 
2009). This could affect dosing by the rate or amount of absorption through the 
buccal mucosa. Saliva contains various levels of esterases, carbohydrases and 
phosphatases, which could also prove to reduce a vaccine’s immunogenicity due to 
normal digestive processes (Sohi et al., 2009). A long-acting sedative like ketamine, 
used in animals to facilitate SL immunisation and prevent swallowing, reduces 
salivary secretions and potentially dampens any affect saliva has on a vaccines 
efficacy (Moench et al., 2003). Saliva production and composition also varies based 
on the animal model, disease state and the nature of the vaccine, and as a result a 
saliva reducing agent may be needed to accompany any vaccine delivered SL to 
prevent enzymatic interference (Siegel, 1984). Sublingual vaccines have been used 
successfully to target allergy in humans, although the activity loss attributed to saliva 
needed to be considered when determining the appropriate dose (Igea et al., 1994). 
Mice are also considerably less susceptible to the gastrointestinal effects of CT 
compared to humans, who develop overt diarrhoea when exposed to as 5µg of CT 
(Levine et al., 1984). It is probable that topical immunisation with CT will be non-
toxic in humans (McKenzie et al., 2007; Frech et al., 2008). However, administration 
of CT to the oral cavity, during SL immunisation, has the potential to enter the gut 
and cause diarrhoea in humans, toxicity that would not have been observed in the 
resistant rodent model. Furthermore, CpG could be less immunogenic in humans 
compared to mice, if a vaccine is to be targeted to the epithelium. TLR9, the target of 
CpG, is expressed by the majority of mDCs and other innate cell types present at 
each immunisation site in mouse. The TLR9 molecule in humans however is only 
expressed by B cells and pDCs that are not routinely found in the epithelium (Krieg, 
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1995; Klinman, 2004). The CpG adjuvant applied to the epithelium of humans may 
therefore be less immunogenic than in mice, due to the differential expression of 
TLR9 by APCs. Although the effectiveness of both the adjuvants (CT/CpG) and 
routes (SL and TC) reported in the present study using the rodent model is not 
directly applicable to humans, the success of these vaccination strategies justifies 
further examination in an animal more comparable to humans. 
The non-human primate is the best pre-clinical model to evaluate vaccines, although 
a single animal can cost upwards of $100,000(USD) to care for over its life-time 
(Nath et al., 2000). Alternatively, pigs share approximately 78% homology with 
human genes regulating immunity and inflammation (Dawson, 2012). Swine also 
have comparable skin and oral cavity architecture (Sullivan et al., 2001; Sohi et al., 
2009) and distribution of immune cells in the epidermis to humans (Fritz et al., 1990; 
Bos, 2005), making the porcine model appropriate for assessing the potential efficacy 
of both the SL and TC routes of immunisation in humans. The porcine model of 
human C. trachomatis genital tract infection has also recently been developed 
(Schautteet and Vanrompay, 2011), which would enable a live challenge with a 
human serovar of C. trachomatis to determine the level of protective vaccine-
induced immunity against infection in vivo. While the pig model would provide a 
more human-like model for the testing the efficacy of each route of immunisation, it 
may not accurately reflect the safety and immunogenicity of the CT/CpG adjuvant 
combination to that in humans. Swine share the same resistance to the 
enterotoxogenic effects of CT and expression of TLR9 as rodents (Foss and 
Murtaugh, 1999; Balmelli et al., 2010). Therefore, any successful trial in pigs would 
require further optimisation in the non-human primate model. In the primate model, 
the use of the CT adjuvant via the SL route may require the development of a 
controlled release device, similar to those used in pharmakinetics studies (Senel et 
al., 2012), to minimise the risk of the enterotoxin entering the gastrointestinal tract. 
Due to the likely reduced ability of the CpG adjuvant to elicit an immune response 
from APC residing in the epithelium of primates, an alternate Th1-polarising 
adjuvant may need to be implemented before a human vaccine can be developed. 
Progress towards a needle-free human chlamydial vaccine utilising the SL or TC 
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route will require controlled delivery and adjuvant selection in order to maintain the 
vaccine’s safety and immunogenicity.  
Another limitation of most animal models is the live Chlamydia challenge and how it 
reflects protection against infection transmission in the human population. The 
MOMP-based vaccines may elicit some cross protection against other serovars 
(Zhang et al., 1987; Zhang et al., 1989), although the MOMP usually generates 
serovar-specific immunity that is primarily directed towards four highly variable 
surface exposed domains (Ramsey et al., 2009). This means that immunisation with 
the MOMP commonly confers protection only against a homologous strain of 
Chlamydia expressing an identical MOMP antigen. This is also the case in the 
present study, where the MOMP administered during vaccination and the MOMP 
expressed by the strain of C. muridarum used to challenge share an identical amino 
acid sequence encoded by a matching ompA gene. As multiple C. trachomatis 
serovars circulate within the human population, many with diverse ompA genotypes 
containing nonsynonomous mutations, the current mouse model cannot assess 
protection against heterologous challenges due to the limited number of mouse-
specific pathogens. Future studies in pigs or primates could allow for heterologous 
challenge experiments with a number of different human serovars. There are 
however two potential solutions to counteract the induction of serovar-specific 
immunity in the human population, a polyvalent or multi-subunit vaccine approach. 
The polyvalent pneumococcal vaccine Pneumovax 23® utilises 23 variants of the 
same antigen to provide maximum population coverage against Streptococcus 
pneumoniae serotypes common in the geographical region. A polyvalent vaccine 
containing MOMP antigens derived from serovars E, F and G could protect against 
90% of C. trachomatis infection in Australia (Mossman et al., 2008). Alternatively, a 
multi-subunit approach incorporating a number of chlamydial antigens particularly 
those highly conserved among Chlamydiales could protect against multiple serovars 
(Stagg, 1998; Li et al., 2007). With the availability of both C. trachomatis and C. 
pneumoniae genomes, identification of such novel vaccine candidates is occurring on 
a much larger scale. Although the current mouse model cannot simulate the problem 
of serovar-specific immunity following vaccination, there are strategies that can be 
employed to prevent this occurring in humans.  
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The longevity of immunity induced following vaccination is also critically important 
for population-based protection against Chlamydia (Gray et al., 2009). Most 
prophylactic vaccines require repeated booster immunisations to maintain immunity 
against infection. This would also likely be the case for any human Chlamydia 
vaccine, particularly if the vaccine was comprised of subunits. Induction of long-
lasting immunity has been reported for both the adjuvants (CT and CpG) and routes 
(SL and TC) (Naito et al., 2007; Klinman et al., 2010; Negri et al., 2010), although 
this was not investigated in the present study. Future experiments will need to 
monitor the persistence of antigen-specific responses and immunity to infection after 
extended periods following vaccination. Despite the inherent limitations present 
when choosing any animal model, the successful induction of protective immunity 
by the MOMP plus CT/CpG vaccine in mice justifies a trial in other animal models 
more comparable with humans.  
Induction of a strong pro-inflammatory cell-mediated response in lymph nodes 
regional to the site of infection was the best associate of protection against 
Chlamydia 
The frequency and/or magnitude of lymphocytes producing IFNγ is commonly used 
as the major indicator of protective immunity against Chlamydia. However, the 
induction of multi-functional TNFα+IFNγ+CD4+ Th cells following vaccination was 
shown to be a better associate of protection than single cytokine-producing cell types 
(Olsen et al., 2010; Yu et al., 2010; Yu et al., 2012). In the present study, we 
consistently detected MOMP-specific production of TNFα and IFNγ by cells isolated 
from the lymph nodes draining the reproductive and respiratory tracts in 
experimental groups strongly protected from both infectious challenges. Secretion of 
TNFα by CD8+ T cells has however been found by others to exacerbate pathology 
(Murthy et al., 2011a). Therefore, it is vital that future studies assess the cytokine 
secretion profiles of individual CD4
+
 and CD8
+
 T cells following vaccination. This 
may provide better predictors of protective immunity and enable the design of future 
vaccines capable of inducing multi-functional T cell phenotypes.  
Priming and positioning antigen-specific cells in the lymph nodes draining the sites 
of infection and not the spleen, was vital for optimal protective immunity against 
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pathology following both genital and respiratory tract challenges. The importance of 
generating an immune response in the regional lymph nodes as opposed to the spleen 
following vaccination in order to elicit protection against infection has not previously 
been reported in the context of a Chlamydia infection. This has significant 
ramifications for chlamydial vaccine design as most research focuses on splenic 
responses, which may prove to be a poor indicator of immunity particularly against 
mucosal pathogens (Kundig et al., 1996; Bachmann et al., 1997; Bachmann et al., 
2005; Santosuosso et al., 2005; Roan et al., 2006; Forbes et al., 2008; Judy et al., 
2012; Mackay et al., 2012). It is unclear whether the protection conveyed by antigen-
specific lymphocytes residing in the lymph nodes is a consequence of earlier 
initiation and recall of immunity or if a distinct memory population is present with a 
superior ability to home to the mucosal tissues following activation. Many studies 
have shown that surgical or genetic deletion of lymph nodes impairs the development 
of immunity against infection and disease (Rayhane et al., 1999; Lee et al., 2000; 
Kumaraguru et al., 2001; Lund et al., 2002; Vonk et al., 2002; Kallal et al., 2010). 
However, protection against some pathogens can be increased in the absence of 
lymph nodes (Magez et al., 2002). Therefore, future studies may utilise LTα-/- or 
lymphadenectomised mice to assess the importance of secondary lymphoid tissues in 
initiating infection resolution and protection against pathology following a primary 
Chlamydia infection.  
Phenotyping and adoptive transfer studies of spleen verses lymph nodes could also 
be used to determine if these cells home faster and have mucosal/central 
memory/effector memory characteristics. Congenic mice could be used to assess 
immune recall. Thy1.1/1.2 or Ly5.1/5.2 congenic mice, express a unique T cell allele 
that can be detected with an antibody to differentiate host and donor lymphocytes. 
Isolation of T cells from the lymph nodes or spleens of Thy1.1 congenic mice 
recovering from a chlamydial infection could be adoptively transferred into separate 
naive Thy1.2 mice. A subsequent infection of the recipient Thy1.2 mice may be used 
to determine the recruitment time of spleen- verses lymph nodes-derived 
lymphocytes based on the appearance of the Thy1.1 antigen at the site of infection. 
This future direction may reaffirm the idea that circulating memory T cells possess a 
limited ability to localise and control infection in peripheral tissues (Kundig et al., 
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1996; Bachmann et al., 1997; Bachmann et al., 2005). Further work may also 
analyse the expression of activation and homing molecules on antigen-specific cells 
in the draining lymph nodes verses the spleen following vaccination. Identification of 
a unique homing phenotype could enable a vaccination strategy to be tailored to 
recruit antigen-specific responses into the lymph nodes as well as the mucosal 
tissues, ideal for protection against Chlamydia. 
A reduction in the bacterial load does not always associate with protection against 
pathology. 
Protection against a Chlamydia infection requires the induction of a robust pro-
inflammatory cytokine response. However, it is believed that the tissue damage 
associated with a chlamydial infection is not a direct effect of bacterial colonisation 
or bacterial load, but an indirect consequence of a pathological pro-inflammatory 
immune response vital to eradicate the infection (immunopathology). The present 
study identified a disconnection between bacterial burden and development of 
disease following both genital and respiratory tract challenges, which supports the 
theory that the magnitude of inflammation following infection and not the bacterial 
load is mediating the severity of disease. We investigated this finding in more detail 
in the genital tract model of infection. The production of pro-inflammatory 
cytokines, mainly IL-1β, was associated with development of disease in 
unvaccinated animals. However, the balance of IL-17-mediated defence appeared to 
determine the level of protection against pathology in vaccinated animals. This 
suggested that there may be at least two mechanisms driving disease following a 
Chlamydia genital tract infection, one driven by the innate response through IL-
1β/caspase-1 and the other by the Th17 adaptive immunity generated following 
vaccination. This has profound implications for future chlamydial vaccines, as 
currently many vaccines are designed to maximise the pro-inflammatory response 
(including Th17 responses) to improve infection clearance, with minimal 
consideration given to protection against pathology. This finding has identified a 
potential problem with the current focus of chlamydial vaccine design, particularly if 
the ultimate goal is to reduce the incidence of disease. Therefore, identifying the 
contribution of the Th17 response towards protection and immunopathology is 
crucial for the development of more efficacious vaccines. 
 186 
 
The role the Th17 response plays during a chlamydial infection is only just starting 
to be unravelled. There is evidence in the literature to suggest that IL-17 signalling 
plays no role in immunity or disease following a primary infection (Scurlock et al., 
2010). High levels of Th17 responses generated during vaccination however have 
been implicated in both infection resolution and immunopathology following a 
genital tract infection (Yu et al., 2010; Lu et al., 2011). A similar dual role of IL-17 
signalling was also found in the present study, where over-expression of IL-17 
cytokines and their associated receptors in the upper reproductive tract of vaccinated 
animals were linked with the enhancement of infection resolution and adverse 
oviduct pathology following an IVag challenge. The mechanism behind IL-17-
mediated protection and immunopathology was speculated to be attributed to a later 
recruitment of damaging neutrophils and macrophages. However, gene expression 
and immunohistochemical analysis of the oviducts at different points in time are 
needed to validate our hypotheses and further investigate the role of IL-17-mediated 
responses. Future studies may also expand on the work by Scurlock et al., (2010) by 
adoptively transferring CD4
+
 T cells from immune WT mice into IL-17RA
-/-
 mice to 
examine the role IL-17 signalling plays during a secondary genital tract infection. 
Alternatively, immunisation with the Th17-polarising adjuvant β-glucan curdlan 
(LeibundGut-Landmann et al., 2007) together with the MOMP prior to challenge 
could also be used to assess whether Th17-driven immunity exacerbates pathology. 
As the Th17 response is known to have different roles following both genital and 
respiratory tract challenges (Bai et al., 2009; Zhang et al., 2009; Yu et al., 2010; Lu 
et al., 2011), the proposed future studies will also need to be repeated using the 
respiratory tract model. These studies may clarify the protective and pathological 
roles of the Th17 response during a Chlamydia infection and whether it should be 
avoided following vaccination. 
Alternately activated macrophages (M2) were also implicated in mediating tissue 
repair and reducing the incidence of hydrosalpinx following a genital tract challenge 
in the present study. This was demonstrated by the overexpression of IL-13, IL-10, 
MMP13 and SOCS1>SOCS3 ratio. M2 type macrophages are thought to be inducers 
of tolerance as opposed to immunopathology (Gordon, 2003). Mice with 
dysfunctional M2 type macrophage have been shown in other models to display 
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delayed wound healing and excessive fibrosis (Wilson and Wynn, 2009). Evidence 
for the presence of M2 type macrophages suggests the existence of a Th2-driven 
anti-inflammatory response (Loke et al., 2007). T helper type 2 cells are widely 
believed to be non-protective (Perry et al., 1997; Wang et al., 1999; Yang, 2001; 
Hawkins et al., 2002) and contribute to pathology following a primary infection by 
inhibiting the development Th1 immunity (Yang et al., 1996; Perry et al., 1997; 
Wang et al., 1999; Kaiko et al., 2008; Chen et al., 2010; Asquith et al., 2011). 
However, in the presence of strong Th1 immunity generated following a primary 
infection, Th2 cells may serve to minimise the potential inflammatory damage 
inherent with Th1 over-expression (Buendia et al., 2002), potentially by activating 
M2 type macrophages. Future studies may search for further evidence of M2 
macrophages during a natural infection by staining for arginase. In addition, the 
adoptive transfer of SOCS1
-/-
 (M1) or SOCS3
-/-
 (M2) monocytes into diphtheria 
toxin (DT) treated CD11bDTR mice (depleted of macrophages), may also unveil a 
regulatory function of macrophages following a genital tract challenge. The 
involvement of M2 type macrophages has not been reported previously and presents 
an exciting new avenue to study chlamydial pathogenesis. 
In conclusion, an efficacious vaccine against Chlamydia may require the stimulation 
of mucosal immunity. Of importance is the development of potent yet safe delivery 
systems or mucosal adjuvants capable of overcoming tolerance and eliciting long-
lived immunity against infection. Our hypothesis was that utilising different 
immunisation routes and novel non-toxic mucosal adjuvants will elicit simultaneous 
protection against Chlamydia genital and respiratory tract infections, without any 
harmful side effects. In the present study, we have shown that the non-toxic mucosal 
adjuvant CTA1-DD is safe and immunogenic via the IN route. Although too 
dangerous for use in a human in prophylactic vaccine delivered intranasally, CT/CpG 
was also found to be both safe and immunogenic if alternate routes of administration 
(SL and TC) were utilised. Moreover, the MOMP adjuvanted with CT/CpG also 
possesses the potential to have an enormous impact on C. trachomatis- and C. 
pneumoniae-related burden, if protection can be successfully translated into the 
human population. Furthermore, our study identified a disconnection between 
bacterial load and disease severity, challenging the current premise that pathology 
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can be prevented by simply reducing the level of infection. Investigation of this 
anomaly shed light on novel mechanisms of chlamydial pathogenesis, driven by the 
adaptive immune response generated following vaccination. This study illustrates the 
challenges involved when developing a vaccine against Chlamydia and forces us to 
rethink how we design future vaccines. 
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APPENDIX ONE 
A. B. 
  
Figure A1: Antigen-specific proliferation and serum IgG antibody titres following different skin pre-treatments prior to TC 
immunisation. 
The skin of each group of animals was pre-treated with a combination of permeation enhancers (acetone or DPC, IPM, MPR) and permeation 
enhancers (GM-CSF or CXCL13) prior to being immunized with the MOMP plus CTA1-DD via the TC route. (A) The spleens were excised 
from vaccinated animals, pooled and homogenised to create a single-cell suspension. Splenocytes were stimulated with the MOMP or media 
for 72 hr and then incubated with thymidine for an additional 14 hr. Cell proliferation was determined by incorporation of thymidine into 
newly synthesised DNA. The cpm value (ionising radiation) of the MOMP stimulated cells was divided by the cpm value obtained from the 
media stimulated cells to give a stimulation index. (B) The induction of MOMP-specific serum IgG following vaccination was quantified by 
ELISA. Endpoint titres were calculated for all samples using background absorbance of PBST plus two SD. Results are presented as the mean 
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± SD. Significant differences were determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P < 0.05 for all tests. 
P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
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APPENDIX TWO 
A. B. 
  
Figure A2: Antigen-specific proliferation and serum IgG antibody titres following SL immunisation with 50, 100 and 200µg of the 
MOMP. 
The optimal antigen dose following SL immunisation was determined by administering 50, 100 and 200µg of the MOMP together with 
CTA1-DD to the buccal mucosa. (A) The spleens were excised from vaccinated animals, pooled and homogenised to create a single-cell 
suspension. Splenocytes were stimulated with the MOMP or media for 72 hr and then incubated with thymidine for an additional 14 hr. Cell 
proliferation was determined by incorporation of thymidine into newly synthesised DNA. The cpm value (ionising radiation) of the MOMP 
stimulated cells was divided by the cpm value obtained from the media stimulated cells to give a stimulation index. (B) The induction of 
MOMP-specific serum IgG following vaccination was quantified by ELISA. Endpoint titres were calculated for all samples using background 
absorbance of PBST plus two SD. Results are presented as the mean ± SD. Significant differences were determined using a one-way ANOVA 
with Tukey’s post-test. Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
g
0
g
50
g
10
0
g
20
0
0
1
2
3
4
5
S
ti
m
u
la
ti
o
n
 i
n
d
e
x
ns*
ns ns
g
50
g
10
0
g
20
0
0
2000
4000
6000
8000
10000
E
n
d
p
o
in
t 
T
it
re
 242 
 
APPENDIX THREE 
A.  
 
B. 
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C.  
 
Figure A3: Percentage weight change of all groups animals following IN challenge 
with C. muridarum. 
Each mouse was weighed prior to infection to establish a starting weight and daily 
following infection to determine weight change. Percentage weight change was for each 
animal was calculated by comparing the pre-infection body weight to daily p.i body 
weights. This figure depicts the effect each vaccination strategy has on weight change 
following an IN infection. Both CT/CpG- and CTA1-DD-based vaccines delivered via 
the (A) IN, (B) SL and (C) TC route are grouped together to show the effect each 
adjuvant has on protection. Antigen, adjuvants, unimmunised (primary infection), live 
infection (secondary infection) and no infection controls are also included. Results are 
presented as the mean ± SD. Significant differences were determined using a one-way 
ANOVA with Tukey’s post-test by comparing the weight changes between groups at the 
same point in time. One P value, the most significant, is given for groups showing a 
significant change. Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 
0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
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APPENDIX FOUR 
A. 
Figure A4: Chlamydial shedding into the vagina collected by the vaginal swab of all 
groups animals following IVag challenge with C. muridarum. 
Following an IVag challenge with C. muridarum, vaginal swabs were collected over the 
entire duration of an infection and stored in SPG. The amount of C. muridarum collected 
by each swab was quantified in vitro from the SPG. Animals were deemed to have 
productive infection at ≥300IFU/swab. Cut-off level for a productive infection was set at 
≥300IFU/swab. Results are presented as the mean ± SD. Significant differences were 
determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P < 
0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 
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APPENDIX FIVE 
A. 
 
B. 
Figure A5: Fibrotic scarring of the uterine horns and oviducts following IVag 
infection with C. muridarum. 
Uterine horn and oviduct tissues taken from each mouse at day 49 p.i were paraffin 
embedded, sectioned and stained for fibrosis using Masson’s trichrome. (A) The 
pathology score scale used to compare the development of disease following infection. 
Representative histological images of the oviducts (top panel) and uterine horns (bottom 
panel) for each pathology scores are depicted. “0” signifies healthy, undamaged tissue. 
Scores of “1” through to “4” depict worsening degrees of collagen deposition (blue) and 
the beginnings of obstruction (yellow arrows). (B) Combined pathology score from 
uterine horns and oviducts was assigned by three separate individuals blinded to groups 
and experimental design. Results are presented as the mean ± SD. Each vaccine is 
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grouped with their respective route of immunisation, IN (    ), SL (    ) and TC (    ). 
Significant differences were determined using a one-way ANOVA with Tukey’s post-
test. Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 
0.001-0.01 (**) and <0.001 (***). 
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APPENDIX SIX 
Accession No. Symbol 
Fold-change 
IN. MOMP  
+ CT/CpG 
SL. MOMP  
+ CTA1-DD 
Unimmunised 
NM_009786 Cacybp 1.12 1.12 -1.11 
NM_011329 Ccl1 1.09 3.64 1.82 
NM_011333 Ccl2 13.23 113.21 92.25 
NM_016960 Ccl20 2.73 41.28 12.45 
NM_009137 Ccl22 1.14 -1.38 1.60 
NM_013654 Ccl7 6.31 34.68 25.02 
NM_013486 Cd2 -1.03 4.39 2.73 
NM_031162 Cd247 1.01 -2.04 -3.59 
NM_007642 Cd28 -1.89 2.77 1.06 
NM_133654 Cd34 -1.40 -1.83 -1.91 
NM_013487 Cd3d 1.67 10.84 5.02 
NM_007648 Cd3e 1.48 8.07 2.05 
NM_009850 Cd3g 2.36 4.50 2.23 
NM_013488 Cd4 1.00 3.29 2.68 
NM_011616 Cd40lg 3.05 5.58 2.44 
NM_001081110 Cd8a 3.40 25.87 11.34 
NM_009883 Cebpb 1.54 3.02 2.47 
NM_020008 Clec7a 3.10 10.54 5.91 
NM_009969 Csf2 1.60 2.83 2.33 
NM_009971 Csf3 2.11 5.06 3.10 
NM_009142 Cx3cl1 1.36 2.28 1.77 
NM_008176 Cxcl1 13.17 188.55 85.73 
NM_021704 Cxcl12 1.11 -1.06 1.08 
NM_009140 Cxcl2 5.34 307.75 199.65 
NM_009141 Cxcl5 17.84 208.16 232.74 
NM_080729 Il25 3.20 -1.60 1.10 
NM_007901 S1pr1 -1.49 -1.55 -1.29 
NM_054039 Foxp3 1.40 2.70 14.40 
NM_008091 Gata3 -3.04 -2.39 1.89 
NM_010493 Icam1 -1.02 7.09 6.18 
NM_017480 Icos 1.32 10.82 8.03 
NM_008337 Ifng 3.20 120.37 80.01 
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NM_010548 Il10 1.52 12.65 5.33 
NM_008352 Il12b 3.13 44.22 12.52 
NM_008353 Il12rb1 2.40 21.89 5.34 
NM_008354 Il12rb2 2.21 19.64 8.89 
NM_008355 Il13 3.64 28.52 3.16 
NM_008357 Il15 -57.34 -24.14 3.06 
NM_010552 Il17a 220.62 167.74 2.65 
NM_145834 Il17c 121.08 123.85 3.03 
NM_145837 Il17d 14.06 5.32 -2.71 
NM_145856 Il17f 865.95 7.43 2.07 
NM_008359 Il17ra 1.54 1.70 1.75 
NM_019583 Il17rb -1.10 -2.79 -2.15 
NM_134159 Il17rc 2.55 -2.26 -2.25 
NM_134437 Il17rd 9.36 -14.45 -1.29 
NM_145826 Il17re 2.00 -138.27 -2.06 
NM_008360 Il18 -7.87 -32.19 2.06 
NM_008361 Il1b 1.18 1.92 63.25 
NM_008366 Il2 1.29 3.13 2.06 
NM_021782 Il21 2.27 3.93 2.56 
NM_016971 Il22 5.32 2.24 2.08 
NM_031252 Il23a 1.74 2.82 1.09 
NM_144548 Il23r 2.28 1.58 1.45 
NM_145636 Il27 4.56 33.66 31.35 
NM_010556 Il3 3.59 1.32 1.72 
NM_021283 Il4 1.11 -1.62 -2.31 
NM_010558 Il5 3.54 1.68 6.54 
NM_031168 Il6 5.43 39.13 18.89 
NM_010559 Il6ra 1.28 1.84 1.29 
NM_008372 Il7r 1.03 4.07 1.92 
NM_020583 Isg20 1.77 3.09 2.35 
NM_146145 Jak1 -1.05 1.05 -1.34 
NM_008413 Jak2 2.22 3.54 1.51 
NM_008607 Mmp13 4.85 10.39 3.48 
NM_010809 Mmp3 1.53 1.13 1.07 
NM_013599 Mmp9 1.06 1.43 2.04 
NM_010851 Myd88 3.16 8.30 3.82 
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NM_010899 Nfatc2 1.48 1.54 1.15 
NM_008689 Nfkb1 1.14 1.48 1.43 
NM_011281 Rorc 1.04 -1.33 -1.20 
NM_009896 Socs1 2.18 18.72 5.23 
NM_007707 Socs3 4.20 21.84 8.18 
NM_011486 Stat3 2.06 2.82 2.10 
NM_011487 Stat4 7.24 -5.60 1.44 
NM_011488 Stat5a 1.03 -1.04 -1.54 
NM_009284 Stat6 -1.28 -1.12 -1.56 
NM_011518 Sykb 1.21 3.81 3.22 
NM_019507 Tbx21 3.50 22.93 14.15 
NM_011577 Tgfb1 2.47 2.25 1.74 
NM_054096 Tirap 1.05 2.00 -1.27 
NM_021297 Tlr4 1.36 1.19 -1.00 
NM_013693 Tnf 1.74 53.83 49.26 
NM_009424 Traf6 1.67 1.26 1.93 
NM_009537 Yy1 1.12 -1.23 -1.29 
NM_010368 Gusb -1.32 -1.47 -1.01 
NM_013556 Hprt 1.50 1.22 1.19 
NM_008302 Hsp90ab1 -1.31 -1.31 -1.32 
NM_008084 Gapdh 1.26 1.36 -1.09 
NM_007393 Actb -1.09 1.16 1.23 
 
Figure A6: Complete list of genes, accession numbers and fold-changes of genes 
regulating inflammation and immunity. 
RNA was extracted from pooled oviducts from the SL. MOMP + CTA1-DD (pathology 
– protected; infection – unprotected; MOMP response – weak), IN. MOMP + CT/CpG 
pathology – unprotected; infection – protected; MOMP response – strong), unimmunised 
pathology – unprotected; infection – unprotected; MOMP response – n/a) and no 
infection control groups at day 6 p.i. Expression for all groups were normalised against 
the no infection control group. Results are presented as the mean fold-change for five 
mice.  
